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ABSTRACT 
 
The goal of this study was to develop drugs that exclusively affect pathogenic 
dihydrofolate reductase (DHFR) without causing harm to the human counterpart. To 
achieve that goal, a well-known dihydrofolate reductase (DHFR) inhibitors, 
trimethoprim (TMP), methotrexate (MTX) and trimetrexate (TMQ), were modified, 
tested, and crystallized on Mycobacterium tuberculosis (Mtb) dihydrofolate reductase 
(DHFR), wild type and quadruple mutant Plasmodium falciparum (Pf) DHFR-
thymidylate synthase (TS), Staphylococcus aureus DHFR, and human DHFR. We 
focused on the drug design to utilize the structural differences between the pathogenic 
DHFRs and the human DHFR; specifically, we focused on a pocket near the substrate 
binding site where Asp27 and Gln28 of Mtb DHFR, and Asp54 and Met55 of Pf DHFR-
TS are located. The same site is closely packed in human DHFR. From the initial 
screening and designing process, C-8 benzyl-2,4-diaminoquinazoline TMQ analogs were 
found to have outstanding selectivity against Mtb and Pf DHFR. Co-crystal structures of 
C-8 benzyl TMQ analogs with Mtb and Pf DHFR showed that the flexibility of Gln28 in 
Mtb DHFR, and Met55 in Pf DHFR contributes to extra space and interaction with C-8 
benzyl moiety. This flexibility, which is not available in the human DHFR, enables the 
TMQ analogs to bind exclusively to the pathogenic DHFRs. Our novel C-8 benzyl-2,4-
diaminoquinazoline TMQ analogs exhibited great potency and selectivity toward 
pathogenic DHFRs. In addition, these C-8 benzyl-2,4-diaminoquinazoline TMQ analogs 
were potent on Staphylococcus aureus DHFR as well and we hypothesize based on our 
 iii 
 
findings that our C-8 benzyl-2,4-diaminoquinazoline TMQ analogs have potential for 
selective, broad spectrum antimicrobials against whose DHFR share the common 
structural feature with Mtb or Pf DHFR, an acid residue and a flexible residue next to it. 
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NOMENCLATURE 
 
ASN Asparagine 
ASP Aspartate 
CYS Cysteine 
DHF Dihydrofolic Acid (Dihydrofolate) 
DHFR Dihydrofolate Reductase 
DHPS Dihydropteroate Synthase 
DM                             Double Mutant 
EC50 Half Maximal Effective Concentration 
IC50 Half Maximal Inhibitory Concentration 
ILE Isoleucine 
GLN Glutamine 
GLU Glutamate 
MDR Multi Drug Resistance 
MET Methionine 
MRSA Methicillin-Resistant Staphylococcus Aureus 
MTB Mycobacterium Tuberculosis 
MTX Methotrexate 
NADP Nicotinamide Adenine Dinucleotide Phosphate 
NADPH Nicotinamide Adenine Dinucleotide Phosphate Reduced 
PF Plasmodium Falciparum 
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PHE Phenylalanine 
PTX Pyritrexim 
PYR Pyrimethamine 
QM                             Quadruple Mutant 
SA Staphylococcu Aureus 
SHMT Serine Hydroxymethyltransferase 
SMX Sulfamethoxazole 
TB Tuberculosis 
THF Tetrahydrofolic acid (Tetrahydrofolate) 
THR Threonine 
TMP Trimethoprim 
TMQ Trimetrexate 
TRP Tryptophan 
TS Thymidylate Synthase 
WHO World Health Organization 
WT                              Wild Type 
XDR Extensively Drug Resistance 
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CHAPTER I 
 
INTRODUCTION 
 
Antimicrobials are becoming less effective throughout most species, if not all, due 
to the development of various resistance (Boucher, Talbot et al. 2009). This problem is 
further propagated by multi-drug resistant (MDR) strains developing various resistances, 
which give rise to extensively drug resistant diseases. This illustrates the need for the 
development of novel, potent and selective drugs for pathogens such as tuberculosis 
(TB), and malaria (Velayati, Masjedi et al. 2009, Das, Chakraborty et al. 2013). 
Tuberculosis has been a serious health threat to the human race since long before 
the cause of the disease was even identified (1986, Bloom and Murray 1992). The 
complex combination of drugs and a long duration of treatment make it harder to 
eradicate this bug (Ditiu 2011) compared to other pathogenic diseases. Furthermore, the 
cost of treatment is expensive and this resulted in incomplete compliance with the 
treatment course, which led to the emergence of mutated TBs (Mitchison 2012, Pina, 
Clotet et al. 2012). For these reasons it is urgently required to put more effort to find a 
clue to develop a novel, selective, and fast-acting drug (World Health Organization. 
Regional Office for Europe., Dara et al. 2012). There are some drug targets that 
exclusively exist in tuberculosis, such as malate synthase and not found in human. 
However, many other drug targets exist in human and sometimes those two enzymes 
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have structural similarity, and dihydrofolate reductase is one of them. This is why we 
need to search for selective and potent inhibitors. 
Malaria is also a serious health threat, and the deadliest form of malaria is caused 
by Plasmodium falciparum, which is a protozoan (Bjorkman and Bhattarai 2005). The 
malaria problem has also been exacerbated by resistance to practically all available drugs 
(World Health Organization. 2011). The combination of pyrimethamine (PYR, DHFR 
inhibitor) and sulfadoxine (SMX, dihydropteroate synthase (DHPS) inhibitor) has long 
been used as first line treatment for malaria (Wernsdorfer and Payne 1991). However, 
this combination has led to increased drug resistance, and the quadruple mutant of Pf 
DHFR-TS ((N51I/C59R/ S108N/I164L) is known to be most problematic to treat 
(Terlouw, Nahlen et al. 2003, Mbugi, Mutayoba et al. 2006). Even though WHO 
released a new 1st line malaria drug in 2010, artemisinin and its derivatives, and tried to 
minimize the chance of acquiring resistance by controlling the use of artemisinin family, 
resistance to these new drugs was already been reported (World Health Organization. 
Director-General's Office. Communications Office. 2006, White 2010). 
In clinical and community-based environment, infections are of great concern 
especially in the United States, and it is still being further aggravated by the resistant 
strains in which most of the available drugs have already been compromised. 
Staphylococcus aureus is one of the well-known pathogens that cause a lot of infections 
in both clinical environment and community-based environment, and the methicillin-
resistance Staphylococcus aureus (MRSA) has been a specific concern due to its tenacity 
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and difficulty for treatment. Since it was found in 1961, MRSA has become resistance to 
many of the available antibiotics such as methicillin, amoxicillin, and penicillin.  
Dihydrofolate reductase (DHFR) is an enzyme that catalyzes the conversion of 
dihydrofolate (DHF) into tetrahydrofolate (THF) in the thymidylate cycle (Figure 1-1), 
which comprises serine hydroxymethyltransferase (SHMT), thymidylate synthase (TS), 
and DHFR (Douglas 1987).  
 
 
 
 
Figure 1-1. DHFR catalyzed conversion of DHF into THF. The reaction shows that a hydride 
is transferred from NADPH to the C-6 position of DHF to produce THF. 
 
 
 
Tetrahydrofolate and dTMP, products of DHFR and TS respectively, are required 
for DNA and amino acid synthesis, making DHFR an attractive target for drug 
development in various species for a long time (Hitchings and Smith 1980). DHFR 
 4 
 
inhibitors have been used against a number of different diseases from rheumatoid 
arthritis to psoriasis to cancer (Cody 1985, Zink, Lanig et al. 2004).  
 
 
 
 
Figure 1-2. Sequence alignments of M. tuberculosis, wild type P. falciparum, and human 
DHFRs. Most of the important residues are well conserved such as Asp27, Phe31, 
or Tyr100 in Mtb DHFR. 
 
 
 
DHFRs from various species show little sequence identity between them, 
especially between Mtb and human DHFR which is just 29% as we can see in the Figure 
1-2, but exhibit surprisingly high similarity in the overall folding (Li, Sirawaraporn et al. 
2000, Yuvaniyama, Chitnumsub et al. 2003). As seen in Figure 1-3, the overall structure 
is characterized by two main clefts, one that fits the cofactor, reduced nicotinamide 
adenine dinucleotide phosphate (NADPH) and the other for the substrate, dihydrofolate 
(DHF). M. tuberculosis DHFR consists of 159 residues and a monomer under 
physiological conditions (Li, Sirawaraporn et al. 2000). The overall structure also 
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contains 8 beta strands and flanking 4 alpha helices. With different inhibitors bound 
structures exhibited slight difference from this standard structure, i.e. 5 alpha helices 
instead of 4, but the overall structure is very well conserved throughout all DHFRs in 
our study. Human DHFR is comprised 186 residues and forms a monomer under 
physiological conditions. Unlike Mtb and human DHFR, Pf DHFR forms a complex 
with thymidylate synthase (TS) as one protein, but the overall folding and the core 
residues for DHFR active site are similar to Mtb DHFR (Yuvaniyama, Chitnumsub et al. 
2003).  
 
 
 
 
Figure 1-3. Superimposed overall structure of Mtb DHFR (gray, 1DF7) and human DHFR 
(khaki, 1U72) bound with methotrexate (MTX). 
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Figure 1-4. Chemical structure of known DHFR inhibitors and DHFR substrate, 
dihydrofolate (DHF).  
 
 
 
Trimethoprim (TMP, Figure 1-4) is a well-known 1st generation DHFR inhibitor 
that shows great potency against bacteria including  E. coli in combination with sulfa 
drugs (Amyes 1982). Trimethoprim and its derivatives are based on 2,4-
diaminopyrimidine ring, and TMP has shown great potency and selectivity against many 
bacteria including E. coli. Because TMP is not potent against human DHFR, TMP has 
long been used as an antibiotic. However, trimethoprim showed only mild activity in 
Mycobacterium tuberculosis, 20 uM of IC50 (Unpublished data). Furthermore, it was 
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reported that TMP was not potent against M. tuberculosis without sulfamethoxazole 
(SMX) while SMX alone was potent enough against M. tuberculosis (Suling, Reynolds 
et al. 1998, Forgacs, Wengenack et al. 2009, Ong, Sievers et al. 2010). This TMP-SMX 
combination, along with pyrimethamine-SMX combination, caused point mutation in 
DHFR from many organisms, and in S. aureus DHFR, TMP/SMX combination is known 
to generate resistance through a major point mutation, F98Y. Low potencies have been 
observed in many of the compounds containing the pyrimidine ring instead of the 
quinazoline or the pterine ring, yet some of the pyrimidine ring-containing compounds 
have exhibited on DHFR such as WR99210. There also have been researches on the 
pyrimidine ring-containing selective inhibitors on Staphylococcus aureus DHFR and 
from other species.   
Methotrexate (MTX) is another first generation DHFR inhibitor. It is a structural 
analog of the substrate of DHFR, dihydrofolate (DHF). It has been 60 years since MTX 
was first introduced as a DHFR inhibitor, and it is still being actively used as anticancer 
agent. Leucovorin is usually used along with MTX as a rescue agent. Unlike TMP, MTX 
and its derivatives are based on 2,4-diaminoquinazoline ring which has one more ring 
than 2,4-diaminopyrimidine. MTX also has a glutamate moiety with two carboxylic 
acids, and it is practically impossible to permeate the mycobacterium cell wall by simple 
diffusion. In human, there are two known transporter for MTX, and another probable 
transport in low pH has been discovered in 2004 (Wang, Zhao et al. 2004). In our study 
on mc27000, which is a vaccine strain of M. tuberculosis, MTX displayed no activity up 
to 100 μM, while trimethoprim exhibited mild activity of 50 μM MIC. 
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Trimetrexate (TMQ/TMX) is one of the well-known 2nd generation DHFR 
inhibitors (Hoffman and Welsh 1995). As its name indicates, trimetrexate is a structural 
combination of two 1st generation DHFR inhibitors, trimethoprim (TMP) and 
methotrexate (MTX). Trimetrexate has been used to treat a wide variety of diseases 
including pneumonia and cancer (Ramanathan, Lipsitz et al. 1999, Garcia, Leichman et 
al. 2003, Senkovich, Bhatia et al. 2005, Short, Gilleece et al. 2009). It is an intriguing 
candidate for a drug against tuberculosis or malaria because it has a 2,4-
diaminoquinazoline ring, which enables the compounds to better interact with DHFR 
compared to trimethoprim (TMP), but lacks  diglutamate moiety, which could interfere 
with transport across the cell membrane without a specific carrier (Ge, Haska et al. 2007). 
TMQ has also been evaluated for anticancer agent in combination with leucovorin and 5-
fluorouracil, which is a thymidylate synthase inhibitor (Punt, Keizer et al. 2002). Most of 
the 2nd generation DHFR inhibitors, including TMQ, have the side effect problem 
because they are potent on human DHFR as well, and some of the DHFR inhibitors are 
even used for cancer treatment (Matin, Jacobs et al. 2005). To be able to use any given 
DHFR inhibitor with the 2,4-diaminoquinazoline scaffold as an antimicrobial or 
antibacterial, selectivity comes into a crucial factor to consider. Unlike the DHFR 
inhibitors with 2,4-diaminopyrimidine scaffold such as TMP, the 2,4-
diaminoquinazoline based compounds interact fairly similarly to both pathogenic DHFR 
and human DHFR. 
Either pyrimidine-based or quinazoline-based DHFR inhibitors, especially for the 
antibiotic-purpose, selectivity comes into significant factor to consider because DHFR is 
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also an essential enzyme for human. Usually pyrimidine based DHFR inhibitors are less 
toxic to human DHFR and a good example is TMP. However, some of the pyrimidine-
based DHFR inhibitors, when they have flexible linker as in WR99210, showed great 
potency on both pathogenic and human DHFRs, and there has been an attempt, on 
malarial DHFR, to develop a selective inhibitor that exclusively work against a 
pathogenic DHFR. One of the WR99210 analogs, P218, was published to be a 
successful compound that is selective against P. falciparum DHFR and it is under 
investigation for the purpose (Yuthavong, Tarnchompoo et al. 2012). Unlike the 
pyrimidine-based DHFR inhibitors, however, there has not been any report of potent and 
selective activity exclusively against pathogenic DHFRs. 
Structure-based drug design, especially using x-ray crystallography as a main tool, 
is a well-known concept/methodology to develop a novel drug (Meng, Zhang et al. 
2011). Crystal structures could give valuable information to the researchers to 
design/modify the inhibitors that effectively and exclusively work on the enzyme of 
interest, and further SAR study with enzymatic assay and/or structure elucidation help to 
proceed to the next step. Many scientists use a known inhibitor as a starting point and 
use the structure-based drug design to modify the structure to enhance the desired 
interactions with the enzyme of their study, and Krieger et al. successfully demonstrated 
how powerful and efficient this tool could be in the course of drug discovery through the 
structure-based drug designing study on the inhibitors of Mycobacterium tuberculosis 
malate synthase (Krieger, Freundlich et al. 2012). In our study, the DHFR structures 
from M. tuberculosis, P. falciparum, and S. aureus bound with different kind of analogs 
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of known DHFR inhibitors enabled us to modify the structures further to render the 
selectivity we desired to the compounds.  
Based on the crystal structures available for Mtb DHFR and Pf DHFR-TS, the 
active sites, especially the substrate binding site, were closely examined. In the 2000 
publication by Li et al. regarding the structural features of Mtb DHFR and how it 
compares to the human DHFR, a significant difference was mentioned (Li, Sirawaraporn 
et al. 2000, da Cunha, Ramalho et al. 2008). It was in the substrate binding site which is 
loosely surrounded by hydrophilic residues, while the same site is tightly crowded in 
human DHFR. One of the crucial differences in residues consisting of the pocket is 
Gln28 in Mtb DHFR, whose counterpart in human DHFR is Phe31. We discovered that 
flexibility of the residue in the pocket is more important than the hydrophilicity of the 
pocket. It was also found that the similar pocket is available in Pf DHFR substrate 
binding site. In Pf DHFR-TS, Met55 is near that pocket, which is corresponding to 
Gln28 in Mtb DHFR. 
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Figure 1-5. Surface view of Mtb DHFR:MTX. Asp27 and Gln28 (buried in the surface) are 
shown, and the glycerol molecule in the glycerol binding pocket. This glycerol binding pocket is 
the most noticeable difference between Mtb DHFR and human counterpart (1DF7). The similar 
space and a flexible residue (Met55) are available in Pf DHFR-TS.  
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Figure 1-6. Surface view of Mtb DHFR:TMP. Though no glycerol was found in the glycerol 
binding pocket, Gln28 and the space is available in the structure (1DG5). 
 
 
 
It was indeed possible to exploit this difference to get selectivity for Mtb DHFR 
and Pf DHFR-TS over human DHFR, which is crucial for development of selective 
drugs. At first, we expected that introducing only hydrophilic groups that can form 
hydrogen bonding interactions in the pocket may achieve the desired selectivity because 
it is surrounded by hydrophilic residues such as Trp22 or Gln28 (Figure 1-5, 1-6). But it 
turned out to be just partially true, and hydrophobic groups including benzyl group was 
enough to show great selectivity for Mtb DHFR and Pf DHFR-TS (Figure 1-7). 
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Figure 1-7. Surface view of WT Pf DHFR:TMQ. Asp54 and Met55 are shown and Met55 
clearly occupies the glycerol binding pocket. This space and the flexible residue are not available 
in human DHFR. 
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Figure 1-8. Surface view of human DHFR:TMQ. The space corresponding to the glycerol 
binding pocket in Mtb DHFR is occupied by bulky Phe31 and lack of flexibility of Phe31 makes 
human DHFR distinct from Mtb or Pf DHFR. 
 
 
 
Based on the distinct difference found in Mtb DHFR (or Pf DHFR-TS) and human 
counterpart (Figure 1-8), two major modifications on trimetrexate (TMQ) were done, 
3,4,5-trimethoxyaniline ring and C-8 position of quinazoline ring, and the selectivity 
gain, at least from our experiments, came mostly from C-8 quinazoline modification and 
without C-8 benzyl modification, there was no selectivity gain was observed. This result 
will be discussed in detail. 
Based on the extensive structure-activity relationship (SAR) study on Mtb DHFR 
and human DHFR, we discovered that a residue next to the acid residue, usually Asp or 
Glu, plays a crucial role for our C-8 benzyl-2,4-diaminoquinazoline TMQ analogs to fit 
in the substrate binding pocket. The two pathogenic DHFRs we studied, Mtb DHFR and 
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Pf DHFR-TS, have Gln28 (Mtb) and Met55 (Pf) that are flexible enough with more than 
two rotational axis, and they were able to allow our C-8 benzyl analogs enough room to 
fit in. However, in human DHFR the corresponding residue is Phe31 which has a bulky 
side chain and has just one rotational axis. As a result, human DHFR and its Phe31 did 
not allow our C-8 benzyl TMQ analogs to sit in the substrate binding pocket. Even 
though there are many differences between Mtb DHFR and Pf DHFR-TS, it was quite 
possible to exploit the common structural feature those two DHFRs share and develop 
selective inhibitors. Furthermore, this common ground of the structural similarity is not 
limited to Mtb DHFR and Pf DHFR-TS. All the pathogenic DHFRs that have the 
common features that were shown in Mtb DHFR or Pf DHFR-TS, which are the space 
similar to the glycerol binding pocket in Mtb DHFR and the flexible residue next to the 
acid residue. 
In this perspective, we performed a proof-of-concept validation study of our 
hypotheses that our C-8 benzyl TMQ could be used as broad spectrum selective 
antimicrobial/antibiotic using Staphylococcus aureus dihydrofolate reductase. This Sa 
DHFR is a very interesting comparison with Mtb DHFR, Pf DHFR-TS, and human 
DHFR because it is similar in size with Mtb DHFR, has the same acid residue (Asp27), 
and has Val28 instead of Gln28 compared to Mtb DHFR. Valine has much smaller side 
chain compared to Phenylalanine in human DHFR, but it has just one rotational axis just 
like Phenylalanine. Therefore, we speculated that it could tell us which factor is more 
important for our C-8 benzyl TMQ analogs binding, side chain size or rotational 
freedom. Overall folding of the Sa DHFR (wild type and F98Y single mutant) is very 
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similar to Mtb DHFR and the only noticeable difference close the active site came from 
a helix containing loop region of Ile50-Arg58.  
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CHAPTER II 
 
SAR STUDY OF TMP AND MTX ANALOGS 
 
II.1. Structure-Activity Relationship (SAR) Study of Trimethoprim (TMP) and its 
Analogs on M. tuberculosis DHFR and Human DHFR, and Methotrexate (MTX) and its 
Analogs on Mtb DHFR, P. falciparum DHFR, and Human DHFR 
 
In this chapter, we will be discussing the initial structure-activity relationship 
(SAR) study of the two well-known DHFR inhibitors, TMP and MTX, and their 
derivatives. Despite the low sequence homology between Mtb DHFR and human DHFR, 
they share common overall fold and structure. This makes it quite challenging to develop 
a potent and selective inhibitor against Mtb DHFR. However, Li et al. discovered the 
structural differences between the two DHFRs in 2000 and one of them was a pocket 
available in Mtb DHFR near the substrate binding site and a glycerol molecule from the 
crystallization condition was found in that pocket in the crystal structure they published 
(1DF7) and they named the pocket the glycerol binding pocket (Li, Sirawaraporn et al. 
2000). 
We decided to utilize that glycerol binding pocket and made TMP and MTX our 
starting point of further SAR study and analogs development. TMP is potent and 
selective against E. coli DHFR, but, unfortunately, this is not the case against 
tuberculosis. TMP exhibited only mild potency on Mtb DHFR with IC50 of 19 uM. MTX 
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also is potent inhibitor for DHFR from various species, and it is potent on human DHFR 
as well and it has been used as anti-cancer agents. The challenges on these two starting 
compounds to develop potent and selective inhibitors were exactly opposite. Gaining 
potency on Mtb DHFR was required on TMP derivatization and lowering inhibition on 
human DHFR was desired on MTX derivatization. 
Based on the crystal structures available for Mtb DHFR and human DHFR, we 
modified three well-known DHFR inhibitors, trimethoprim (TMP) and methotrexate 
(MTX). Trimethoprim (TMP) and methotrexate (MTX) are 1st generation DHFR 
inhibitors, and trimetrexate (TMQ) is the 2nd generation DHFR inhibitor. Extensive 
studies have been done on TMP and MTX analogs and we learned important clues to 
develop selective inhibitors. However, TMP and MTX both have their limitation to be a 
drug for TB. TMP exhibited low potency and MTX displayed no activity on the whole-
cell assay. 
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Figure 2-1. The conserved and important hydrogen bond interactions between TMP and 
Mtb DHFR exhibited in the crystal structure, 1DG5. Most of the interactions are 
with the 2,4-diaminopyrimidine ring, and with the 3,4,5-trimethoxybenzene ring has 
limited interaction with Mtb DHFR. Due to the smaller size of TMP, there is not 
much interaction on the 3,4,5-trimethoxybenzene ring side with Mtb DHFR. 
 
 
 
In the trimethoprim (TMP) bound crystal structure of Mtb DHFR (1DG5), there 
are conserved hydrogen bonding interactions between TMP and Mtb DHFR residues 
(Figure 2-1). Asp27 has two hydrogen bonding interactions with 2-amino group and N-1 
nitrogen with the distances of 2.81 Å and 2.67 Å, respectively. Asp27 further forms the 
hydrogen bonding network with Thr113 via a water molecule. The distance between 
Asp27 and the water molecule is 2.64 Å, and between the water molecule and Thr113 is 
2.41 Å. Thr113 has another hydrogen bonding network via a different water molecule 
 20 
 
with 2-amino group of TMP, and the distance between Thr113 and this water molecule 
is 2.73 Å and between the water molecule and the 2-amino group of TMP is 3.27 Å.  
For 4-amino group of the 2,4-diaminopyrimidine ring of TMP has three hydrogen 
bonding interactions with the main chain carbonyl group of Ile5 and with the main chain 
carbonyl group of Ile94, and with the carbonyl group of Tyr100. The distances are 2.76 
Å, 2.85 Å, and 3.27 Å, respectively.  
The 3,4,5-trimethoxy ring have less interactions compared to 2,4-
diaminopyrimidnie ring, and the closest contact comes with Ser49 and the distance is 
3.11 Å. In this structure, the m-methoxy group on the benzene ring was approximately 
5.5 Å from the glycerol binding pocket near the substrate binding site found in another 
structure, 1DF7. Even though there are glycerol molecules found in Mtb DHFR:TMP 
structure (1DG5), it is not the glycerol binding site we tried to take advantage of. It was 
speculated that the addition of a 3- or 4-carbon long aliphatic chain with some functional 
groups at the end would allow the inhibitor to fit in that pocket. The moiety, which 
interacts with the residues in the pocket, helped to get better selectivity, but not potency. 
Two different categories of functional groups were tried. One group of compounds 
has a carboxylic acid group as in the substrate, dihydrofolate (DHF). The other group of 
compounds contains relatively hydrophobic groups including benzene ring. From the 
initial design, putting propanoic acid or butanoic acid at the meta-position of the benzene 
ring of the trimethoprim seemed an optimal fit into the pocket near the substrate binding 
site. However, the carboxylic acids in both of the carboxylic acid containing TMP 
analogs, JCS-1143 and JCS-1147, were found in the different site than the pocket near 
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the substrate binding site. Instead, the derivatives containing benzene or p-methoxy 
benzene fit in the pocket near the substrate binding site.  
Trimethoprim (TMP), 2,4-diamino-5-(3',4',5'-trimethoxybenzyl)pyrimidine, is a 
well-known DHFR inhibitor. Derivatives of TMP have been synthesized to evaluate the 
possibility that greater selectivity could be achieved by taking advantage of the pocket 
near the substrate binding site in Mtb DHFR. This pocket is not available in the human 
DHFR active site. Most of the derivatives have their structural modification on the 
trimethoxybenzene ring side, although changes on pyrimidine side also appear to 
contribute significantly to the improved selectivity. 
Three methoxy groups do play a role in obtaining better potency on Mtb DHFR. 
JCS-1145, 5-(3-methoxybenzyl)pyrimidine-2,4-diamine, displayed that the degree of 
potency loss in terms of IC50 was about 30%, from 18.8 uM to 26 uM. This JCS-1145 
have just one methoxy group and its mother compound, TMP, has three. The IC50 
values for the important TMP analogs are listed in Table 2-1. 
 
 
 
 
 
 
 22 
 
 
 
ID Number 
(JCS-) 
Substitution on 
R1 
Substitution on 
R2 
IC50 on  
Mtb DHFR 
IC50 on 
Human 
DHFR 
Selectivity 
Index 
(Human/Mtb) 
Trimethoprim 
(TMP) 
3,4,5-
trimethoxybenzene 
H 19 uM 230 uM 12.1 
1114 4-methoxybenzyl H 18 uM 36 uM 2 
1135 propylbenzyl H 5.3 uM 1.6 uM 0.3 
1143 4-butanoic acid H 0.9 uM 0.9 uM 1 
1147 3-propanoic acid H 2.4 uM 7.8 uM 3.3 
1163 4-carboxybenzyl H 2.1 uM 13.2 uM 6.3 
1168 4-methoxybenzyl CH3 26 uM 
>1000 uM 
* 
>38.5 
1169 4-methoxybenzyl CH2CH3 27 uM >500 uM * >18.5 
*Higher concentrations could not be tested due to solubility. 
Table 2-1. IC50 values of the major TMP analogs on Mtb and human DHFR. The selectivity 
values (IC50 on human DHFR/IC50 on Mtb DHFR) are also shown. 
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JCS-1163 along with JCS-1168 and -1169 are the TMP analogs that were 
successfully able to take advantage of the glycerol binding pocket, and they give us an 
interesting comparison because JCS-1163 has carboxybenzyl group attached on the TMP 
scaffold, while JCS-1168 and -1169 has methoxybenzyl group attached. This seemingly 
small difference made a huge difference in terms of selectivity. JCS-1168 has about 12-
fold lower potency against Mtb DHFR compared to JCS-1163. However, the former has 
more than 5-fold higher selectivity compared to the latter.  
 
 
 
 
Figure 2-2. The conserved interactions between JCS-1163 and Mtb DHFR. 4-amino-Tyr100, 
2-amino-Asp27, N1-Asp27, Carboxylic oxygen-Arg23, Carboxylic oxygen-Gln28 are shown. 
2,4-diaminopyrimidine of JCS-1163 (gold) ring retains all the major interactions with Mtb 
DHFR. The middle benzene ring is not in a favorable position for interaction with Phe31 in the 
back. There is no significant interaction on the solvent access side of the DHFR.   
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In the crystal structure of Mtb DHFR:JCS-1163, the 2,4-diaminopyrimidine ring 
of JCS-1163 (Figure 2-2), similar to in trimethoprim (TMP) bound Mtb DHFR structure, 
has some conserved hydrogen bond interactions with Mtb DHFR. However, JCS-1163 
displayed some different mode of interactions as well. Asp27 has two hydrogen-bonding 
interactions with 2-amino group and 1-N nitrogen with the distances of 2.63 Å and 2.65 
Å, respectively. Asp27 forms another hydrogen bonding interaction with Thr113 with 
the distance of 2.56 Å. Thr113 forms hydrogen bonding network with 2-amino group of 
JCS-1163 via a water molecule, and the distance between the oxygen atom of the 
hydroxyl group of Thr113 and the water is 2.83 Å, and the distance between the water 
and 2-amino group is 3.15 Å. This water further forms another hydrogen bonding 
interaction with the main chain carbonyl group of Glu111 and the distance between the 
two is 2.99 Å.  
For 4-amino group of the 2,4-diaminopyrimidine ring of JCS-1163 has three 
hydrogen bonding interactions with the main chain carbonyl group of Ile5, with the main 
chain carbonyl group of Ile94, and with the carbonyl group of Tyr100. The distances are 
2.69 Å, 2.63 Å, and 3.37 Å, respectively.  
Unlike 2,4-diaminopyrimidine side, 3-(4-benzoate)methoxybenzene ring side does 
not have much significant interactions with Mtb DHFR. The noticeable interactions 
came with Arg23 and Gln28. The oxygen atoms of the carboxylic acid have hydrogen 
bonding interactions with Arg23 and Gln28 with the distances of 3.08 Å and 3.65 Å, 
respectively.  
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Figure 2-3. The important conserved interactions between JCS-1163 and human DHFR. 
2,4-Diaminopyrimidine ring retains the major interactions similar to Mtb DHFR:TMP or JCS-
1163. However, the 3-(4-benzoate)benzene ring side has much different orientation and mode of 
interactions compared to Mtb DHFR:JCS-1163. The bulky Phe31 keep the substituted benzene 
ring from coming into the space.  
 
 
 
In the crystal structure of human DHFR:JCS-1163, the 2,4-diaminopyrimidine 
ring of JCS-1163, similar to in trimethoprim (TMP) or JCS-1163 bound Mtb DHFR 
structure, has some conserved hydrogen bond interactions with Mtb DHFR (Figure 2-3). 
However, JCS-1163 displayed some different mode of interactions as well. Glu30, 
corresponding to Asp27 in Mtb DHFR, has two hydrogen-bonding interactions with 2-
amino group and 1-N nitrogen of JCS-1163 with the distances of 2.55 Å and 2.49 Å, 
respectively. Glu30 forms another hydrogen bonding interaction with Thr136, 
 26 
 
corresponding to Thr113 in Mtb DHFR, with the distance of 2.65 Å. Thr136 forms 
hydrogen bonding network with 2-amino group of JCS-1163, and the distance between 
Thr136 and the 2-amino group of JCS-1163 is 3.53 Å.  
For 4-amino group of the 2,4-diaminopyrimidine ring of JCS-1163 has three 
hydrogen bonding interactions with the main chain carbonyl group of Ile7, 
corresponding to Ile5 in Mtb DHFR, with the main chain carbonyl group of Val115 
(Ile94 in Mtb DHFR), and with the carbonyl group of Tyr121 (Tyr100 in Mtb DHFR). 
The distances are 2.77 Å, 3.30 Å, and 3.12 Å, respectively.  
Unlike 2,4-diaminopyrimidine side and unlike Mtb DHFR:JCS-1163, 3-(4-
benzoate)methoxybenzene ring side does not have much significant interactions with 
human DHFR, yet more interactions were found than Mtb DHFR:JCS-1163. The 
noticeable interactions came with Pro61 and Asn64. The oxygen atom of the carboxylic 
acid has hydrogen bonding interaction with the nitrogen atom of Asn64 with the 
distances of 3.70 Å. The other oxygen of the carboxylic acid is in close proximity with 
Pro61 and the distance is 3.30 Å. Two other human DHFR residues are in close 
proximity with JCS-1163. The carbon atom of Thr56 is 3.45 A away from the 5-carbon 
of the 3-methoxybenzene ring, and the 3-carbon atom of Phe31 is 2.98 A away from 2-
carbon atom of the benzoic acid ring. These two residues are not in hydrogen bond 
interaction with JCS-1163, yet they could be used as leverage for the further SAR study 
to improve potency or selectivity. 
JCS-1163 displayed successfully that substitution on the methoxybenzene ring (4-
carboxybenzene in JCS-1163’s case) could take advantage of the glycerol binding 
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pocket, yet it was not enough to gain significant selectivity over human DHFR. This 
limitation was partially resolved by the alkylation on 2-amino group of the pyrimidine 
ring. 
JCS-1168 (methyl) and JCS-1169 (ethyl) has alkyl group on 2-amino group of the 
pyrimidine ring and this helped those compounds to gain selectivity despite the loss of 
some potency on Mtb DHFR.  
 
 
 
 
Figure 2-4. The important interactions between Mtb DHFR and JCS-1168. Note that 
interactions with Asp27 are significantly altered by the methyl group on 2-amino group. 4-
methoxybenzyl group that is attached to the benzene ring is positioning near the glycerol binding 
site and Gln28 is pushed down to allow the necessary space to JCS-1168. There is no noticeable 
interaction near the solvent access site and that could be the reason of lower potency compared 
to other TMP analogs.  
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Similar to trimethoprim (TMP) bound Mtb DHFR structure, the 2,4-
diaminopyrimidine ring of JCS-1168 has some conserved hydrogen bond interactions 
with Mtb DHFR (Figure 2-4). However, due to the methyl group attached to the 2-amino 
group, JCS-1168 displayed some different mode of interactions as well. Asp27 has just 
one hydrogen-bonding interaction with 2-amino group with the distance of 2.68 Å. 
Asp27 forms another hydrogen bonding network with 1-nitrogen atom via water 
molecule. The distance between Asp27 and the water is 2.63 Å and the distance between 
the water and 1-N is 2.82 Å. Asp27 further forms the hydrogen bonding network with 
Thr113 and the distance is 2.58 Å. Thr113 has another hydrogen bonding network via a 
water molecule with the main chain carbonyl group of Glu111, and the distance between 
Thr113 and this water molecule is 3.01 Å and between the water molecule and the 
carbonyl group of Glu111 is 3.15 Å. This water molecule is in close proximity with the 
2-amino group of JCS-1168 with the distance of 3.09 Å, and if there is hydrogen bond 
available atom instead of methyl group, the potency could be enhanced. 
For 4-amino group of the 2,4-diaminopyrimidine ring of JCS-1143 has three 
hydrogen bonding interactions with the main chain carbonyl group of Ile5, with the main 
chain carbonyl group of Ile94, and with the carbonyl group of Tyr100. The distances are 
2.91 Å, 2.71 Å, and 3.22 Å, respectively. It is really interesting and somewhat puzzling 
even to see that this 4-amino group is well-retained hydrogen bonding interactions with 
the same groups as TMP or other TMP analogs that does not have methyl (or any group) 
on 2-amino group. The distances in JCS-1168 are even shorter than in Mtb DHFR:TMP. 
One possible explanation would be the binding of JCS-1168 with the methyl group on 
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the 2-amino side made some modification of the position of key residues to minimize the 
effect and loss of potency, and the in-depth follow up research could give us an answer 
for this observation. 
For the 3-(4-methoxybenzoate)benzene ring side, the 5-carbon atom of the 
benzene ring is in close proximity with Ile94 with the distance of 3.43 Å. 4-carbon atom 
of the benzene ring is in close proximity with Leu50 with the distance of 3.91 Å. The 
carbon atom of 3-methoxy group of the benzene ring is in close proximity with Leu57 
with the distance of 3.91 Å . Although these carbon atoms are not in hydrogen bonding 
interactions, they represent a potential venue for enhancing the interactions with DHFR. 
JCS-1168 and JCS-1169 have alkyl substituent on 2-amino group of pyrimidine 
ring. When there is no substituent, 2-amino group along with N-1 nitrogen has hydrogen 
bonding interaction with Asp27 of Mtb DHFR. Based on the crystal structure of Mtb 
DHFR, JCS-1168 has lost significant amount of interactions with Mtb DHFR. For the 
normal pyrimidine or quinazoline rings have two hydrogen bonds with Asp27. However, 
due to the repulsive interaction of N-2 methyl group with water, the whole molecule was 
pushed away from the optimal position. As a result, JCS-1168’s N-2 nitrogen has a 
hydrogen bond with the oxygen of Asp27 with the distance of 2.68 Å. There are three 
hydrogen bonds available for the nitrogen of N-4 amino group, Ile5, Ile94, and Tyr100. 
In Mtb DHFR:JCS-1168 structure, due to its non-optimal position, the distance between 
N-4 amino group and the main chain carboxylic acids of lle5 and Ile94, 2.91 Å and 2.72 
Å respectively, is much closer than the hydroxyl group of Tyr100. 
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Figure 2-5. The important conserved interactions between JCS-1168 and human DHFR. 
Compared to Mtb DHFR:JCS-1168 structure, the two benzene rings have drastically different 
positions, while 2,4-diaminopyrimidine ring retains most of the important hydrogen bond 
interactions with human DHFR.  
 
 
 
Similar to TMP or JCS-1168 bound Mtb DHFR structure, in the human DHFR, the 
2,4-diaminopyrimidine ring of JCS-1168 has some conserved hydrogen bond 
interactions with human DHFR (Figure 2-5). However, due to the methyl group attached 
to the 2-amino group, JCS-1168 displayed some different mode of interactions as in Mtb 
DHFR:JCS-1168. Glu30, corresponding to Asp27 in Mtb DHFR, has just one hydrogen 
bonding interaction with 2-amino group with the distance of 2.99 Å. Glu30 also forms 
another hydrogen bonding network with 1-nitrogen atom via water molecule. The 
distance between Glu30 and the water is 3.05 Å and the distance between the water and 
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1-N is 2.54 Å. Glu30 further forms the hydrogen bonding network with Thr136, 
corresponding to Thr113 in Mtb DHFR, and the distance is 2.70 Å. Thr136 has another 
hydrogen bonding network via a water molecule with the main chain carbonyl group of 
Phe134, and the distance between Thr136 and this water molecule is 2.67 Å and between 
the water molecule and the carbonyl group of Phe134 is 3.00 Å. This water molecule is 
in close proximity with the 2-amino group of JCS-1168 with the distance of 3.59 Å, and 
if there is hydrogen bond available atom instead of methyl group, the potency could be 
enhanced. 
For 4-amino group of the 2,4-diaminopyrimidine ring of JCS-1143 has three 
hydrogen bonding interactions with the main chain carbonyl group of Ile7, with the main 
chain carbonyl group of Val115, and with the carbonyl group of Tyr121. The distances 
between 4-amino group and those groups are 2.74 Å, 2.68 Å, and 3.04 Å, respectively. 
As in Mtb DHFR:JCS-1168 structure, this human DHFR:JCS-1168 displayed the same 
retention of the 4-amino group interactions with the key residues and their main chain 
carbonyl group. Considering that there is methyl group attached to the 2-amino group, 
this retention, along with Mtb DHFR:JCS-1168, is surprising.  
For the 3-(4-methoxybenzoate)benzene ring side, the carbon atom of the 4-
methoxy group of the terminal benzene ring is in close proximity with the nitrogen atom 
of Gln35 with the distance of 3.38 Å. The oxygen atom of the same methoxy group has 
potential hydrogen bond interaction with the oxygen atom of Asn64 and the distance 
between the two is 3.03 Å. 2-carbon atom of that terminal benzene ring is in close 
proximity with Pro61 with the distance of 3.50 Å. 5-carbon atom of the same benzene 
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ring is in close proximity with Phe31 with the distance of 2.98 Å, yet the orientation of 
the Phe31 is not favorable for any interaction. Although these carbon atoms are not in 
hydrogen bonding interactions, they represent a potential venue for enhancing the 
interactions with DHFR. 
 
 
 
 
Figure 2-6. Superimposed structure of Mtb DHFR:JCS-1168 (khaki) and human 
DHFR:JCS-1168 (gray). JCS-1168’s position is drastically different in each DHFR 
due to the difference between Phe31 (human) and Gln28 (Mtb). All the major 
residues, which are significantly different than each other, are shown. Human 
DHFR’s loop region containing Pro61 is much closer to the JCS-1168 compared to 
Mtb DHFR. 
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The first analog that successfully place a functional group near the pocket is JCS-
1168, 5-(3-(4-methoxybenzyloxy)benzyl)-N2-methylpyrimidine-2,4-diamine, which has 
an N-2 methyl group on pyrimidine ring and showed less potency, IC50 of 26 uM, 
compared to trimethoprim (TMP) or its parent compound JCS-1114, 5-(3-(4-
methoxybenzyloxy)benzyl)pyrimidine-2,4-diamine, whose IC50 on Mtb DHFR is 18 uM. 
However, as seen in Figure 2-6, the selectivity gain over human DHFR (IC50 = 1 mM) 
sufficiently outweighs this small potency loss with IC50 on Mtb DHFR (IC50 = 36 uM). 
The IC50 of TMP on human DHFR is 230 uM while that of JCS-1168 is well over 1 mM, 
and was limited by solubility. JCS-1168 has a para-methoxy group on the benzyl side of 
the compound and this p-methoxy group sits in the pocket near the substrate binding site 
in Mtb DHFR, when the crystal structure was superimposed with the methotrexate 
(MTX) bound Mtb DHFR structure, 1DF7. The 4-methoxybenzene substituent on the 
benzene ring side of JCS-1168 fits in the pocket near the substrate binding site in Mtb 
DHFR:JCS-1168 structure. Gln28 in the Mtb DHFR and its flexibility enable 4-
methoxybenzene group to position in the pocket. On the other hands, in the human 
DHFR:JCS-1168 structure, the residue at the same position is Phe31, and it has 
drastically less rotational freedom compared to Glutamine. As a result, instead of sitting 
in the pocket near the substrate binding site, the same 4-methoxybenzene ring stretches 
toward the surface interacting with Asn64 with the distance of 3.03 Å.  
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Figure 2-7. Superimposed structure of human DHFR:JCS-1143 (plum) and human 
DHFR:JCS-1168 (gray). It is clearly seen that JCS-1168 induces position change 
of Phe31. The bulky benzene ring on both JCS-1168 and human DHFR caused 
unfavorable positions for both Phe31 and the terminal benzene ring of JCS-1168. 
On the other hand, relatively flexible glutamic acid moiety of JCS-1143 does not 
force Phe31 to flip away from its original position. 
 
 
 
When comparing human DHFR:JCS-1143 co-crystal structure with human 
DHFR:JCS-1168 co-crystal structure, in human DHFR:JCS-1168 structure, JCS-1168’s 
benzene ring part stretches toward the loop region so that it could avoid an unfavorable 
contact with Phe31 (Figure 2-7). Because of this non-optimal position of JCS-1168 in 
human DHFR, interactions with Phe31/Phe34 are not available and it makes poor 
hydrogen bonding interaction with Glu30. It is worth mentioning that the only difference 
between JCS-1114 and JCS-1168 is one methyl group on the N-2 position of the 
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pyrimidine ring. This seemingly small difference has made a huge change in selectivity 
of the compounds between Mtb and human DHFR. Still the selectivity comes mainly 
from the loss of potency on human DHFR. 
 
 
 
 
Figure 2-8. Superimposed structure of Mtb DHFR:JCS-1169 (blue) and human 
DHFR:JCS-1169 (gray). As in JCS-1168 bound structures, JCS-1169 has different 
position in Mtb and human DHFR, and bulky Phe31 (human) has kept JCS-1169 
from entering the pocket. 
 
 
 
The other compound that comes into glycerol binding pocket is JCS-1169, N2-
ethyl-5-(3-(4-methoxybenzyloxy)benzyl)pyrimidine-2,4-diamine (Figure 2-8). This 
compound has N-2 ethyl group on the pyrimidine ring, and shows poorer potency (IC50 = 
28uM), and less selectivity compared to JCS-1168. One extra carbon and the steric 
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hindrance caused by it kept the pyrimidine ring from staying its regular position where it 
facilitates the maximum interaction with Asp27, Ile5, Ile94, and Tyr100. JCS-1168 also 
showed some degree of loss of position, but the ethyl group in JCS-1169 rather than the 
methyl group present in JCS-1168 aggravates this.  
Superposition of the structures revealed the opportunity that could offer us a 
glimpse of the possible interactions in human DHFR (Figure 2-8). The same site where 
the glycerol binding pocket is located in Mtb DHFR is crowded by relatively 
hydrophobic residues like Leu22 or Pro26 in human DHFR. In the case of JCS-1168 or -
1169, the bulk p-methoxybenzene group on the compound could have some degree of 
rotational freedom and they ended up positioning totally different than in Mtb DHFR 
avoiding the close contact with Phe31 in human DHFR, yet the position for JCS-1168 or 
-1169 to interact with DHFR is not the optimal. Also as we could see in human 
DHFR:JCS-1168 structure, Phe31 and its restricted rotational freedom makes it 
unfavorable for JCS-1168 and -1169 to bind to human DHFR. 
The carboxylic acid moiety containing TMP analogs, such as JCS-1143 or JCS-
1147, are more potent on Mtb DHFR, compared with the methoxybenzene containing 
analogs, including JCS-1168. From the crystal structure of Mtb DHFR:JCS-1143, it is 
clear that, due to lack of N-2 alkyl substitution, the pyrimidine ring can fit better in the 
substrate binding site, and better interactions were enabled. As a result, JCS-1143 has 
about 3 fold better IC50, 0.9 uM, compared to JCS-1168, whose IC50 is 26 uM. 
The effect of the glutamic acid group on the potency and selectivity has also been 
investigated. JCS-1143, 4-(3-((2,4-diaminopyrimidin-5-yl)methyl)phenyl)butanoic acid, 
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which has a carboxylic acid moiety mimicking the substrate, dihydrofolate (DHF), and a 
well-known DHFR inhibitor, methotrexate. Initially, this carboxylic acid group was 
thought to reside within the pocket near the substrate binding site. However, this 
carboxyl acid group stretches far away from the pocket to interact with two arginine 
residues, Arg32 and Arg60 at distances of 2.67 Å and 2.42 Å, respectively. The same 
phenomenon was witnessed with JCS-1147, a derivative that was shorter by one carbon, 
3-(3-((2,4-diaminopyrimidin-5-yl)methyl)phenyl)propanoic acid 
Similar to trimethoprim (TMP) bound Mtb DHFR structure, the 2,4-
diaminopyrimidine ring of JCS-1143 has well-conserved hydrogen bond interactions 
with Mtb DHFR (Figure 2-9). 
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Figure 2-9. The conserved important hydrogen bond interactions between Mtb DHFR and 
JCS-1143. 2,4-diamionpyrimidine ring has pretty similar interactions with Mtb 
DHFR:TMP structure. The 3-pentanoic acid moiety has similar interactions with 
Mtb DHFR:MTX structure. Other than the two arginine residues (50 and 57), not 
much interactions are available between JCS-1143 and the Mtb DHFR. 
 
 
 
Asp27 has two hydrogen bonding interactions with 2-amino group and N-1 
nitrogen with the distances of 2.72 Å and 2.72 Å, respectively. Asp27 further forms the 
hydrogen bonding network with Thr113 and the distance is 2.84 Å. Thr113 has another 
hydrogen bonding network via a water molecule with 2-amino group of the 2,4-
diaminopyrimidine ring of JCS-1143, and the distance between Thr113 and this water 
molecule is 3.35 Å and between the water molecule and the 2-amino group of TMQ is 
3.15 Å. This water molecule further forms additional hydrogen bond interactions with 
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the main chain carbonyl group of Glu111 and the nitrogen of His30 with the distances of 
2.87 Å and 3.55 Å, respectively.  
For 4-amino group of the 2,4-diaminopyrimidine ring of JCS-1143 has three 
hydrogen bonding interactions with the main chain carbonyl group of Ile5, with the main 
chain carbonyl group of Ile94, and with the carbonyl group of Tyr100. The distances are 
2.80 Å, 2.66 Å, and 3.44 Å, respectively.  
For the 3-(4-butanoate)benzene ring side, the carboxylic acid moiety has two 
hydrogen bonding interactions with Arg32 and Arg60 with the distances of 3.14 Å and 
2.42 Å, respectively. The 5-carbon atom of the benzene ring is in close proximity with 
Ile94 with the distance of 3.43 Å. 4-carbon atom of the benzene ring is in close 
proximity with Leu50 with the distance of 3.91 Å. The carbon atom of 3-methoxy group 
of the benzene ring is in close proximity with Leu57 with the distance of 3.91 Å . 
Although these carbon atoms are not in hydrogen bonding interactions, they represent a 
potential venue for enhancing the interactions with DHFR. 
When Mtb DHFR:JCS-1143 structure is compared with 1DG8, Mtb 
DHFR:NADPH, the RMSD is 1.04 Å over 156 residues with 100% sequence identity. 
The sequence difference came from the N-terminal extra residues found in our Mtb 
DHFR:JCS-1143 structure. The largest deviations came from Asp48-Val54 loop region 
where benzene ring side of the compounds are in close contact, and Gly80-Pro89 loop 
which is away from the active site. When comparing human DHFR:JCS-1143 and 
human DHFR:folate, the RMSD is 0.60 Å over 184 residues  with 100% sequence 
identity. 
 40 
 
 
Figure 2-10. The conserved important hydrogen bond interactions between human DHFR 
and JCS-1143. 2,4-Diamionpyrimidine ring has very similar interactions with Mtb 
DHFR:TMP structure. The 3-pentanoic acid moiety has similar interactions with 
Mtb DHFR:JCS-1143 structure. The carboxylic acid moiety has similar 
interactions with Mtb DHFR:JCS-1143, but more interactions are available in the 
human DHFR.  
 
 
 
Similar to trimethoprim (TMP) bound Mtb DHFR structure, the 2,4-
diaminopyrimidine ring of JCS-1143 has well-conserved hydrogen bond interactions 
with human DHFR as well (Figure 2-10). Glu30, which is corresponding to Asp27 in 
Mtb DHFR, has two hydrogen bonding interactions with 2-amino group and N-1 
nitrogen with the distances of 2.76 Å and 2.59 Å, respectively. Glu30 further forms the 
hydrogen bonding network with Thr136 and the distance is 2.44 Å. Thr136 has another 
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hydrogen bonding network via a water molecule with 2-amino group of the 2,4-
diaminopyrimidine ring of JCS-1143, and the distance between Thr136 and this water 
molecule is 2.76 Å and the distance between the water molecule and the 2-amino group 
of TMQ is 3.39 Å. This water molecule further forms additional hydrogen bond 
interactions with the main chain carbonyl group of Phe134 with the distance of 2.76 Å .  
For 4-amino group of the 2,4-diaminopyrimidine ring of JCS-1143 has three 
hydrogen bonding interactions with the main chain carbonyl group of Ile7, with the main 
chain carbonyl group of Val115, and with the carbonyl group of Tyr121. The distances 
of those interactions are 3.02 Å, 3.19 Å, and 3.19 Å, respectively.  
For the 3-(4-butanoate)benzene ring side, the carboxylic acid moiety has two 
hydrogen bonding interactions with the two nitrogen atoms of Arg70 with the distances 
of 2.93 Å and 2.92 Å, respectively. One of the oxygens of the carboxylic acid further 
forms additional hydrogen bonding network with Lys68 and the oxygen of Gln35 that 
looks like a triad. The distance between the carboxylic acid and Lys68 is 3.26 Å, and 
between the Lys68 and the oxygen of Gln35 is 2.82 Å, and between the oxygen of Gln35 
and the carboxylic acid is 3.10 Å. Additionally, the 3-carbon atom of the benzene ring is 
in close proximity with the carbon atom of Thr56 with the distance of 3.59 Å. Although 
this carbon atom is not engaged in any kind of hydrogen bonding interaction, this 
proximity could be taken into account for the further SAR study of the TMP analogs. 
The last carboxylic acid containing molecule is JCS-1163, 4-((3-((2,4-
diaminopyrimidin-5-yl)methyl)phenoxy)methyl)benzoic acid, whose IC50s against Mtb 
and human DHFRs are 2.1 μM and 13.2 μM, respectively. This benzoic acid moiety 
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inserts into the pocket near the substrate binding pocket according to the crystal structure 
of Mtb DHFR:JCS-1163. 2-amino group and N-1 nitrogen of 2,4-diaminopyrimidine 
ring have hydrogen bonding interactions with Asp27 with the distances of 2.63 Å and 
2.65 Å. 4-Amino group has hydrogen bonding interactions with main chain carbonyls of 
Ile5 and Ile94 and the distances are 2.69 Å and 2.63 Å, respectively. The carboxylic acid 
at the benzene ring side of the compound has close contact with Gln28 and the distance 
is 3.65 Å. JCS-1163 also has a hydrogen bonding interaction with Arg23 with the 
distance of 3.08 Å.  
The different types of compounds have shown strikingly different results in the 
whole-cell assay as well. All of the carboxylic acid containing compounds, including 
benzoic acid moiety, exhibited no activity up to 100 uM on mc27000, although they are 
more potent in the in-vitro enzyme assay. However, all of the compounds containing 
hydrophobic group showed moderate activity, ranging from 25 uM to 50 uM.  
The last two compounds that approach the pocket are JCS-1135, 5-(3-
pheneethylbenzyl)pyrimidine-2,4-diamine, and JCS-1163, 4-((3-((2,4-diaminopyrimin-
5-yl)methyl)phenoxy)methyl)benzoic acid. The latter has a carboxylic acid group, and 
will be discussed along with other carboxyl acid containing compounds. From the 
perspective of drug design, JCS-1135 was a control that could give us a clue for figuring 
out what kind of group should be attached to benzopyrimidine. It is unexpected that this 
purely hydrophobic group leans toward the hydrophilic environment of the glycerol 
binding pocket. This second benzene ring in the compound could be a guide to the 
entrance of the pocket. Superposition of crystal structure of Mtb DHFR with JCS-1135 
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on the previously known structure of Mtb DHFR with methotrexate, 1DF7, revealed that 
the ethylbenzyl group sits right in the edge of glycerol binding pocket so that any 
interaction with hydrophilic groups such as Asp27 or main-chain carbonyls could be 
avoided. It was an important clue for selectivity that all 4 compounds we have that went 
close or enter the pocket near the substrate binding site contain the benzyl moiety.  
It is intriguing to see the results that no TMP analogs, without an aromatic ring on 
the 3,4,5-trimethoxybenzene ring, was able to reach the glycerol binding pocket of Mtb 
DHFR. For example, JCS-1143 and JCS-1147, which have just aliphatic carboxylic acid 
on the 3,4,5-trimethoxybenzene ring, exhibited fairly decent potency against Mtb DHFR 
with no selectivity. On the other hand, most of the aromatic ring on 3,4,5-
trimethoxybenzene ring containing analogs were able to reach the glycerol binding 
pocket and displayed selectivity with the degree ranging from mild to more than 30 fold 
of selectivity. This finding led us to try more aromatic ring containing analogs on TMQ 
rather than just aliphatic groups later on. 
Though creating derivatives of TMP provided compounds with good selectivity 
over human DHFR, the challenge remained to make compounds with sufficiently high 
potency against Mtb DHFR. The low potency might be due to lack of second aromatic 
ring of the compounds, i.e. pyrimidine instead of quinazoline, and our subsequent study 
have shown that this second ring is crucial for interaction with Phe31 of Mtb DHFR and 
for the improved potency. 
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ID (JCS-) R 
IC50 on 
Mtb DHFR 
(nM) 
IC50 on 
human DHFR 
(nM) 
Selectivity 
MIC on 
H37Rv (μM) 
MTX H 6 6 1 > 100  
1183 -CH2CH3 30 25 0.8 1.6 
1187 -CH3 50 40 0.8 0.4 
Table 2-2. IC50 and MIC values of MTX and its analogs against Mtb DHFR and human 
DHFR. Selectivity values and MIC values are shown as well. 
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Figure 2-11. The conserved hydrogen bond interactions between MTX and Mtb DHFR. 
Similar to TMP, most of the interactions are on 2,4-diaminoquinazoline ring, and there are 
additional interactions available with the glutamic acid moiety of MTX not shown in the picture 
(1DF7). 
 
 
 
Methotrexate (MTX) is a well-known 1st generation DHFR inhibitor. The key 
analogs and their activities are listed in Table 2-2. MTX exhibited excellent potency on 
Mtb DHFR in-vitro enzyme assay (IC50 = 5 nM), and Mtb DHFR crystal structure with 
MTX bound was solved in 2000 by Li et al.(Li, Sirawaraporn et al. 2000). This Mtb 
DHFR structure bound with MTX displayed the well-conserved hydrogen bonding 
interactions between Mtb DHFR and MTX similar to TMP bound structure (Figure 2-11). 
Asp27 has two hydrogen bonding interactions with 2-amino group and N-1 nitrogen 
with the distances of 2.88 Å and 2.64 Å, respectively. Asp27 further forms the hydrogen 
bonding network with Thr113 and the distance is 2.68 Å. Thr113 has another hydrogen 
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bonding network via a water molecule with 2-amino group of the quinazoline ring of 
MTX, and the distance between Thr113 and this water molecule is 2.75 Å and between 
the water molecule and the 2-amino group of MTX is 3.02 Å.  
For 4-amino group of the 2,4-diaminoquinzaoline ring of MTX has three hydrogen 
bonding interactions with the main chain carbonyl group of Ile5, with the main chain 
carbonyl group of Ile94, and with the carbonyl group of Tyr100. The distances are 2.82 
Å, 2.92 Å, and 3.22 Å, respectively.  
The glutamic acid moieties have less interactions compared to 2,4-
diaminopyrimidnie ring, and the closest contacts come with Gln28 and the distances are 
3.47 Å and 3.64 A. There are additional interactions, available from another glutamic 
acid moiety, not shown in the picture, and those interactions will be discussed later. 
When comparing Mtb DHFR:MTX (PDB ID:1DF7) with human DHFR:MTX, the 
overall protein folding and active site structure is very similar. Both DHFRs have clefts 
for the substrate (DHF) and the cofactor (NADPH) in the same site, and the overall 
secondary structures are well overlapped (Figure 2-12).  
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Figure 2-12. Superimposed structure of Mtb DHFR:MTX (blue) and human DHFR:MTX. 
Note that the overall folding, and active sites (substrate and cofactor binding sites) structure are 
pretty similar. MTX and cofactor (NADPH) are labeled. 
 
 
 
The important residues in Mtb DHFR that interact with MTX are similar to TMP 
as well. The distances between 2,4-diaminoquinazoline ring and Asp27 (Mtb) are 2.88 Å 
and 2.64 Å. The corresponding distances in human DHFR are 2.64 Å and 2.60 Å, 
respectively. In Mtb DHFR, Arg60 has a close contact with one of the glutamic acids 
with the distances of 2.79 Å and 2.66 Å. The corresponding residue in human DHFR is 
Arg70 (Figure 2-13), and Arg70 has an interaction with carbonyl oxygen with a distance 
of 2.13 Å. The remaining carboxylate and another carbonyl group right next to the 
aniline ring have interactions with Asn64 with distances of 3.45 Å and 2.94 Å. Arg32 in 
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Mtb DHFR has interaction with MTX and the distance is 3.00 Å. The corresponding 
residue in human DHFR is Gln35, and the distance between MTX and Gln35 is 3.04 Å.   
 
 
 
 
Figure 2-13. Superimposed structure of Mtb DHFR:MTX (blue) and human DHFR:MTX 
in the active site. Di-glutamic acids in MTX have similar interactions in both 
DHFRs. It is clearly seen that the space near C-8 position of the MTX is very tight 
in human DHFR due to the presence of a bulky phenylalanine. 
 
 
 
In spite of its excellent potency on many DHFRs from different species, MTX did 
not exhibit great potency on TB whole cell assays, either mc27000 vaccine strain or 
H37Rv. This is due to the di-glutamic acid moiety that MTX has and this hydrophilic 
moiety hinders MTX to pass through TB cell wall without proper transporter. To 
overcome this challenge, we tried alkylation on MTX’s di-glutamic acid moiety. JCS-
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1183 (ethyl) and JF-1187 (methyl) showed slightly reduced potency on both Mtb and 
human DHFR. However, they exhibited great potency on the whole cell assay on H37Rv. 
These ester-containing MTX derivatives clearly increased the permeability of the MTX 
through TB cell wall and cell membrane. There should be more in-depth study on 
whether the esters are hydrolyzed inside the cell before acting on the target or the intact 
esters are potent enough to exhibit the observed potency on H37Rv. 
 
 
 
 
Figure 2-14. The important conserved interactions between WT Pf DHFR and JCS-1187. 
The 2,4-diaminoquinazoline ring retains all the major interactions with Pf DHFR just as in Mtb 
DHFR:MTX structure. There are some differences in interactions in the esterified glutamic acid 
moiety such as the additional interaction from Arg122 or Cys59.  
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The crystallization trials to obtain crystal structures of Mtb DHFR:JCS-1187 or 
JCS-1183 were not successful. Instead, we elucidated the crystal structure from WT Pf 
DHFR. There should be some differences between Mtb DHFR and Pf DHFR, yet this 
WT Pf DHFR:JCS-1187 structure could allow us to understand the ideas regarding the 
interactions between DHFR and JCS-1187 and other MTX analogs (Figure 2-14).  
This WT Pf DHFR structure bound with JCS-1187 displayed the well-conserved 
hydrogen bonding interactions between WT Pf DHFR and JCS-1187 similar to MTX 
bound Mtb DHFR structure. Asp54, corresponding to Asp27 in Mtb DHFR, has two 
hydrogen bonding interactions with 2-amino group and N-1 nitrogen with the distances 
of 2.64 Å and 2.81 Å, respectively. Asp54 further forms the hydrogen bonding network 
with Thr185 and the distance is 3.02 Å. Thr185 has another hydrogen bonding network 
via a water molecule with 2-amino group of the quinazoline ring of JCS-1187, and the 
distance between Thr185 and this water molecule is 2.81 Å and between the water 
molecule and the 2-amino group of JCS-1187 is 3.35 Å. This water molecule further 
forms an additional hydrogen bonding interaction with the main chain carbonyl group of 
Tyr183 with the distance of 3.12 Å.  
For 4-amino group of the 2,4-diaminoquinzaoline ring of JCS-1187 has three 
hydrogen bonding interactions with the main chain carbonyl group of Ile14, 
corresponding to Ile5 in Mtb DHFR, with the main chain carbonyl group of Ile164 (Ile94 
in Mtb DHFR), and with the carbonyl group of Tyr170 (Tyr100 in Mtb DHFR). The 
distances are 2.71 Å, 3.03 Å, and 2.99 Å, respectively.  
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The esterified glutamic acid moieties have less interactions compared to 2,4-
diaminopyrimidnie ring, and the closest contacts came with Arg122 and Cys56. The 
methoxy oxygen of one of the methyl ester has a hydrogen bond interaction with the 
nitrogen of Arg122 with the distance of 2.74 Å. The carbonyl group of the same methyl 
ester has a hydrogen bonding interaction with the thiol group of Cys56 with the distance 
of 3.37 Å. This carbonyl group forms further hydrogen bonding interaction with the 
oxygen atom of the other methyl ester and the distance between the two is 2.59 Å.  
 
 
 
 
Figure 2-15. The important conserved interactions between human DHFR and JCS-1187. 
2,4-Diaminoquinazoline ring retains all the major interactions as in WT Pf DHFR:JCS-1187 and 
other structures. The methyl ester of the glutamic acid has more diverse interactions compared to 
WT Pf DHFR:JCS-1187 with human DHFR including Gln35 or Asn64. 
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On the other hand, human DHFR structure bound with JCS-1187 displayed the 
well-conserved hydrogen bonding interactions between human DHFR and JCS-1187 
similar to MTX bound Mtb DHFR structure or WT Pf DHFR:JCS-1187 structure (Figure 
2-15). Glu30, corresponding to Asp27 in Mtb DHFR, has two hydrogen bonding 
interactions with 2-amino group and N-1 nitrogen with the distances of 2.71 Å and 2.82 
Å, respectively. Glu30 further forms the hydrogen bonding network with Thr136 and the 
distance is 2.84 Å. Thr136 has another hydrogen bonding network via a water molecule 
with 2-amino group of the 2,4-diaminoquinazoline ring of JCS-1187, and the distance 
between Thr136 and this water molecule is 2.71 Å and the distance between the water 
molecule and the 2-amino group of JCS-1187 is 3.13 Å. This water molecule further 
forms an additional hydrogen bonding interaction with the main chain carbonyl group of 
Phe134 with the distance of 2.78 Å.  
For 4-amino group of the 2,4-diaminoquinzaoline ring of JCS-1187 has three 
hydrogen bonding interactions with the main chain carbonyl group of Ile7, 
corresponding to Ile5 in Mtb DHFR, with the main chain carbonyl group of Val115 
(Ile94 in Mtb DHFR), and with the carbonyl group of Tyr121 (Tyr100 in Mtb DHFR). 
The distances are 3.21 Å, 2.96 Å, and 3.12 Å, respectively.  
The methyl ester of the glutamic acid moieties have less interactions compared to 
2,4-diaminopyrimidnie ring, yet there are more interactions available compared to WT 
Pf DHFR:JCS-1187. The methoxy oxygen of one of the methyl ester has a hydrogen 
bond interaction with the nitrogen of Arg70 with the distance of 3.28 Å. The carbonyl 
groups of both methyl esters have hydrogen bonding interactions with the oxygen and 
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the nitrogen of Gln35 and the distances are 3.21 Å and 3.49 Å, respectively. The 4-
carbonyl group of the aniline ring also has hydrogen bonding interaction with the 
nitrogen of Asn64 with the distance of 2.50 Å. This carbonyl group is also in close 
proximity with Pro61 with the distance of 3.74 Å. The carbon atom of the methyl group 
on the aniline nitrogen is also in close proximity with Thr56 and Ser59 with the 
distances of 3.38 Å and 3.71 Å, respectively. Though these two interactions are not in 
hydrogen bonding interactions, they could be used as leverages for the further 
modification of SAR study.  
 
 
 
 
Figure 2-16. Superimposed structure of WT Pf DHFR:JCS-1187 (gray) and DM Pf 
DHFR:MTX. C59R and S108N mutations in double mutant (DM) Pf DHFR are 
labeled. Arg59 and Asn108 in DM Pf DHFR have closer contact with MTX or its 
ester analogs. 
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For some reason, there was difficulty acquiring crystal structure of Mtb 
DHFR:JCS-1187 or Mtb DHFR:JCS-1183 structure, so we sought crystal structures in Pf 
DHFR-TS instead, and the trial was successful. Though there is a possibility that the 
mode of interaction in Pf DHFR-TS with MTX analogs could be different in Mtb DHFR, 
these Pf DHFR-TS:JCS-1187 structures should be able to let us have a good idea of what 
interactions are involved in JCS-1187’s binding in DHFR and what differences there are 
compared to MTX. 
In the superimposed crystal structures of WT Pf DHFR:JCS-1187 and DM Pf 
DHFR:methotrexate (MTX, Figure 2-16), MTX and JCS-1187 have almost identical 
conformation in the active site. The two mutations in double mutant DHFR do not affect 
much on the binding, and Arg59 and Asn108 in DM Pf DHFR have slightly closer 
contact with the compounds compared to the wild type DHFR.  
In JCS-1187 bound WT Pf DHFR-TS structure, the main interactions between 
DHFR and the compound, and the corresponding distances are as following. 2-amino 
group:Asp54 (2.57 Å), N-1 nitrogen:Asp54 (2.78 Å), 4-amino group:Tyr170 (2.99 Å), 4-
amino group:Ile164 (main chain carbonyl, 3.03 Å), 4-amino group:Ile14 (main chain 
carbonyl, 2.71 Å), glutamate carbonyl:Cys59 (3.37 Å), and glutamate ester:Arg122 (2.74 
Å). Similar interactions were found in human DHFR:JCS-1187 structure, and the 
interactions and the corresponding distances are as following. 2-amino group:Glu30 
(2.71 Å), N-1 nitrogen:Glu30 (2.82 Å), 4-amino group:Tyr121 (3.12 Å), 4-amino 
group:Ile7 (main chain carbonyl, 3.21 Å), 4-amino group:Val115 (main chain carbonyl, 
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2.96 Å), benzoic acid carbonyl:Asn64 (2.50 Å), glutamate carbonyl:Gln35 (2.66 Å), and 
glutamate ester:Arg70 (3.28 Å).  
Due to the exceptional potency of JCS-1183 and JCS-1187 on H37Rv strain 
unlike their parent compound, MTX, a follow-up study is going on and more details 
such as pharmacokinetics and drug mechanism will be studied. So far a most probable 
reason for the discrepancy in whole cell assay result is that the ester groups help JCS-
1183 and JCS-1187 to pass through TB cell wall by simple diffusion and the ester 
groups are hydrolyzed in or in the middle of transferring to the active site. 
Unfortunately, however, there has not been any selectivity gain from MTX 
derivatization. It is not surprising when comparing pathogenic and human DHFR with 
JCS-1187 bound structures. The orientations that JCS-1187 has in both pathogenic and 
human DHFR are pretty similar and the interactions are almost identical. There were no 
noticeable difference between Pf DHFR:JCS-1187 and human DHFR:JCS-1187 
structure in terms of the interactions of JCS-1187 with DHFR. Therefore, we decided to 
try another DHFR inhibitor for selective inhibitor development. 
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CHAPTER III 
 
SAR STUDY OF C-8 NON BENZYL TMQ ANALOGS 
 
III.1. Structure Activity Relationship of TMQ Aniline Analogs and C-8 Non-Benzyl 
Analogs on M. tuberculosis DHFR and Human DHFR 
 
After learning that either boosting TMP’s potency against Mtb DHFR or 
decreasing MTX’s activity against human DHFR was not achievable, we turned our 
focus on to a new starting scaffold, trimetrexate (TMQ). TMQ is a well-known 2nd 
generation DHFR inhibitor and it has been used to treat various diseases including 
psoriasis, rheumatoid, and even some cancers. As its name indicates, TMQ is a structural 
hybrid of trimethoprim and methotrexate. It has 2,4-diaminoquinazoline ring instead of 
2,4-diaminopyrimidine as in TMP, yet it lacks di-glutamic acid moiety as in MTX which 
could hinder the diffusion through the pathogen’s cell wall or membrane including 
tuberculosis cell wall. 
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Figure 3-1. Mtb DHFR crystal structure bound with TMQ. The well-conserved hydrogen 
bonding interactions are shown. Instead of glycerol molecule found in the Mtb DHFR:TMP 
structure (1DG5), acetate (ACT) molecule is was found in our TMQ bound structure. Two 
important water molecules that mediate the hydrogen bonding interaction between TMQ and 
Mtb DHFR are shown in cyan. 
 
 
 
Similar to MTX, the 2,4-diaminoquinazoline ring of TMQ has well-conserved 
hydrogen bond interaction with Mtb DHFR (Figure 3-1). This Mtb DHFR structure 
bound with TMQ displayed the well-conserved hydrogen bonding interactions between 
Mtb DHFR and TMQ similar to MTX bound structure. Asp27 has two hydrogen 
bonding interactions with 2-amino group and N-1 nitrogen with the distances of 2.74 Å 
and 2.62 Å, respectively. Asp27 has potentially available hydrogen bonding interaction 
with the acetate molecule in the glycerol binding pocket with the distance of 2.96 Å. 
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Even though in the structure carbon atom is facing to Asp27, oxygen atoms could be in 
that direction instead of carbon. Asp27 further forms the hydrogen bonding network with 
Thr113 and the distance is 2.72 Å. Thr113 has another hydrogen bonding network via a 
water molecule with 2-amino group of the quinazoline ring of TMQ, and the distance 
between Thr113 and this water molecule is 2.81 Å and between the water molecule and 
the 2-amino group of TMQ is 2.76 Å. This water molecule forms another hydrogen 
bonding interaction with the main chain carbonyl group of Glu111 and the distance is 
3.12 Å.  
For 4-amino group of the 2,4-diaminoquinzaoline ring of TMQ has three hydrogen 
bonding interactions with the main chain carbonyl group of Ile5, with the main chain 
carbonyl group of Ile94, and with the carbonyl group of Tyr100. The distances are 2.86 
Å, 2.86 Å, and 3.40 Å, respectively.  
For the 3,4,5-trimethoxyaniline ring side, the aniline nitrogen has another 
hydrogen bonding network with Ser49 via a water molecule. The distance between the 
aniline nitrogen and the water is 2.71 Å and the distance between the water and the 
oxygen atom of Ser49 is 2.70 Å. The carbon atom of 3-methoxy group is close proximity 
with Arg23 and Pro51 with the distance of 3.17 Å and 3.24 Å, respectively. The carbon 
atom of 4-methoxy group is close proximity with Gln28 oxygen with the distance of 
2.87 Å. Although these methoxy groups are not in hydrogen bonding interactions, they 
represent a potential venue for enhancing the interactions with DHFR. 
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 Mtb:TMQ 
(4M2X) 
human:TMQ 
(4MBD) 
WT Pf:TMQ 
(4MAJ) 
QM Pf:TMQ 
(4M96) 
Space Group P1 P1 P212121 P212121 
Cell Dimension  
(Å) 
36.5, 65.7, 68.9  37.3, 39.6, 71.9 58.1, 156.7, 164.9 57.5, 156.6, 164.9 
(o) 93.6, 94.7, 100.9  78.0, 78.5, 67.4 90.0, 90.0, 90.0  90.0, 90.0, 90.0 
Resolution (Å) 20.22-1.93 
 (2.02-1.93) 
36.23-2.49 
(2.58-2.49) 
56.80-2.61 
(2.71-2.61) 
50.00-3.10 
(3.15-3.10) 
Rsym 0.069 (0.233) 0.045 (0.122) 0.159 (0.562) 0.138 (0.728) 
I/σ 7.2 (2.4) 9.7 (2.4) 7.0 (2.4) 7.8 (2.2) 
Completeness  94.4 (91.0) 96.1 (94.3) 99.5 (99.1) 94.9 (84.4) 
Redundancy 1.96 (1.95) 1.93 (1.94) 7.52 (7.27) 5.60 (3.40) 
# or reflections 44374 12392 46270 26569 
Rwork/Rfree 21.7/26.6 22.4/29.8 25.0/31.7 19.8/26.8 
# of Protein 
atoms 
4976 3004 9077 9046 
# of Ligand/Ion 300 174 150 97 
# of Water 462 27 161 16 
B factor – 
Protein 
30.1 62.9 56.8 80.4 
Ligand/Ion 30.4 64.4 52.1 74.4 
Water 36.1 57.4 45.5 63.8 
RMSD – 
length (A) 
0.004 0.006 0.005 0.007 
angles (o) 0.713 0.794 0.730 0.854 
Table 3-1. Crystallographic data and structure statistics of TMQ bound structures of Mtb, 
Pf (WT and QM), and human DHFR. 
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The crystallographic data and the statistics values from the structure refinement 
are in table 3-1. Even though they are in different space group with different coefficients, 
their active site composition and the TMQ binding, especially the 2,4-
diaminoquinazoline ring side, are very similar. 
 
 
 
 
Figure 3-2. Human DHFR structure bound with TMQ. Similar to Mtb DHFR:TMQ structure, 
2,4-diaminoquinazoline ring has conserved hydrogen bond interaction with DHFR. 3,4,5-
trimethoxyaniline ring also has similar interactions with Mtb DHFR, and Phe31 partially 
occupies the space where acetate molecule was found in the Mtb DHFR:TMQ structure. 
 
 
 
Similar to Mtb DHFR:TMQ structure, the 2,4-diaminoquinazoline ring of TMQ 
has well-conserved hydrogen bond interaction with human DHFR as well (Figure 3-2). 
This human DHFR structure bound with TMQ displayed the well-conserved hydrogen 
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bonding interactions between human DHFR and TMQ similar to Mtb DHFR:TMQ 
structure. Glu30, which is corresponding to Asp27 in Mtb DHFR, has two hydrogen 
bonding interactions with 2-amino group and N-1 nitrogen with the distances of 2.65 Å 
and 2.58 Å, respectively. Glu30 forms the hydrogen bonding network with Thr136 and 
the distance is 2.70 Å. Thr113 has another hydrogen bonding network with 2-amino 
group of the quinazoline ring of TMQ, and the distance between Thr113 and the 2-amino 
group of TMQ is 3.15 Å. 2-amino group of the 2,4-diaminoquinazoline further forms 
another hydrogen bond interaction with the main chain carbonyl group of Val8 and the 
distance between the two is 3.31 Å.  
For 4-amino group of the 2,4-diaminoquinzaoline ring of TMQ has three hydrogen 
bonding interactions with the main chain carbonyl group of Ile7, with the main chain 
carbonyl group of Val115, and with the carbonyl group of Tyr121. The distances are 
2.72 Å, 3.07 Å, and 2.96 Å, respectively.  
For the trimethoxyaniline ring side, the aniline nitrogen has a weak hydrogen 
bonding interaction with Ser59, and the distance between the aniline nitrogen and the 
oxygen atom of Ser49 is 3.93 Å . The carbon atom of 3-methoxy group is close proximity 
with Pro61 with the distance of 3.24 Å. The oxygen atom of 4-methoxy group is close 
proximity with the nitrogen atom of Asn64 and the distance between the two atoms are 
3.59 Å. The carbon atom of 5-methoxy group is in close contact with the nitrogen atom 
of Gln35 with the distance of 3.41 Å . Although these methoxy groups are not in 
hydrogen bonding interactions with human DHFR residues, they represent a potential 
venue for enhancing the interactions with DHFR. Phe31 occupies the space where an 
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acetate molecule in our Mtb DHFR:TMQ or a glycerol molecule in Mtb DHFR:MTX 
(1DF7) structures, and this difference gave us a revenue to take advantage of to develop 
selective inhibitors against pathogenic DHFRs. 
Since TMQ exhibited high potency on both Mtb and human DHFR with IC50 of 17 
nM and 16 nM, respectively, the main focus was naturally lowering the activity against 
human DHFR rather than enhancing the potency against Mtb DHFR. Based on the 
modelling on Mtb and human DHFR crystal structure bound with TMQ, both from 
quinazoline ring and 3,4,5-trimethoxybenzene ring were feasible to take advantage of the 
glycerol binding pocket. For the glycerol binding pocket in Mtb DHFR is surrounded by 
some hydrophilic residues such as Trp22 and Gln28, we first thought that there needs to 
be a hydrophilic group to gain selectivity, but this turned out to be not crucial.  
To improve the potency on Mtb DHFR, we turned our main focus from 
trimethoprim (TMP) analogs to trimetrexate (TMQ), whose IC50 on Mtb DHFR is 17 nM 
and IC50 on human DHFR is 16 nM, and its analogs. The converted Ki of TMQ on Mtb 
DHFR is only 1.8 nM, but the problem is IC50 on TMQ is 16 nM and Ki on human 
DHFR is 1.1 nM as well. Hence the main goal of TMQ modification is to increase the 
selectivity on Mtb DHFR over human DHFR. Two different modifications have been 
tried on trimetrexate (TMQ) to improve selectivity. 
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ID  Number 
Substitution 
R1 
Mtb IC50 
nM 
Human IC50 
nM 
Selectivity 
Index (SI) 
Human/Mtb 
TMQ 
3,4,5-trimethoxy w/ 
C5-methyl 
17 16 1 
1373 4-methoxy 540 120 0.4 
1376 3-methoxy 970 170 0.2 
1378 H 1120 62 0.05 
1379 2,4-dimethoxy 770 66 0.1 
1380 3,4-dimethoxy 590 30 0.05 
1381 3,5-dimethoxy 240 240 1 
1400 
3,5-dimethoxy, 
C8-bromo 
740 130 0.2 
1382 3-hydroxyl 1200 400 0.3 
1402 2-hydroxyl 2300 550 0.2 
1395 benzodioxane 1800 70 0.04 
1409 benzo[d][1,3]dioxole 200 200 1 
1410 
4-hydroxyl, 
C8-bromo 
460 170 0.4 
1441 2,5-diethoxy 5150 1850 0.4 
Table 3-2. IC50 values of TMQ aniline analogs. These analogs have no modification on 2,4-
diaminoquinazoine ring. No compound exceeded 1 of selectivity which means they are all more 
potent (some of them are the same) on human DHFR. 
 
 
 
The first modification we made was a modification of C-8 position of the 2,4-
diaminoquinazoline ring, and the second modification was on the trimethoxy benzene 
ring. To facilitate the synthesis of the compounds, we tried 2,4-dimethoxybenzene 
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analogs instead of 2,3,4-trimethylbenzene as in trimetrexate and removed C-5 methyl 
group from the quinazoline ring. Compared to the parent compound, TMQ, JCS-1381, 6-
((3,5-dimethoxyphenylamino)methyl)quinazoline-2,4-diamine, lost about 10 fold 
activity but retained the selectivity. The IC50 values are listed in Table 3-2. 
 
 
 
TMQ 
Asp27 (O):2-
amino (N) 
Asp27 (O):N-
1 
Ile5 (main 
chain O):4-
amino (N) 
Ile94 (main 
chain O):4-
amino (N) 
Tyr100 (O):4-
amino (N) 
Mtb DHFR 2.74 2.62 2.86 2.86 3.40 
WT Pf DHFR 2.93 (Asp54) 2.88 (Asp54) 2.63 (Ile14) 2.99 (Ile164) 2.99 (Tyr170) 
QM Pf DHFR 2.89 3.13 2.86 3.26 (Leu164) 3.22 
Human 2.65 (Glu30) 2.58 (Glu30) 2.72 (Ile7) 3.07 (Val115) 2.96 (Tyr121) 
Table 3-3. The conserved hydrogen bond interactions of TMQ in Mtb, Pf, and human 
DHFR, and the corresponding distances. The interacting residues are all specified 
in parentheses. 
 
 
 
As shown in the table 3-3, TMQ and DHFR from difference species have very 
well conserved hydrogen-bond interactions mainly through 2,4-diaminoquinazoline ring. 
Human DHFR has tighter interaction (shorter distances) with TMQ compared to the 
pathogenic DHFRs, and that illustrates how difficult it would be to gain selectivity on 
this TMQ compound.  
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A variety of C-8 functionalization have been synthesized and tested. In the initial 
designing step, we expected hydrophilic moiety from C-8 position would be more 
effective in approaching the pocket near the substrate binding site. However, this turned 
out that the flexibility of the bridging carbon chain and the suitable length of the 
functional group are more crucial factors for rendering selectivity. We will be using the 
selectivity index (SI) which is simply the ratio of IC50s of Mtb and human DHFR 
hereafter. The greater the value, the larger the selectivity goes. 
JCS-1373, which has 4-methoxyaniline ring, lost potency on both Mtb (IC50 = 540 
nM) and human DHFR (IC50 = 120 nM) compared to TMQ, which has 3,4,5-
trimethoxyaniline ring. JCS-1441, which has 2,5-diethoxyaniline ring, on the other 
hands, lost even greater potency on both Mtb (IC50 = 5150 nM) and human (IC50 = 1850 
nM) DHFR. In the superimposed crystal structures of Mtb DHFR:JCS-1373 and Mtb 
DHFR:JCS-1441, a probable reason for this drastic loss of potency could be explained. 
The interactions on the 2,4-diaminoquinazoline ring side are pretty much the same 
between the two structures. However, on the aniline ring side interactions, much bulkier 
2,5-diethoxy group pushed the DHFR loop region (Ser49-Arg55) away from JCS-1441. 
Compared to Mtb DHFR:JCS-1373, the residue-to-residue deviations in Mtb 
DHFR:JCS-1441 range from 0.89 Å to 1.78 Å. 
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Figure 3-3. Superimposed structure of Mtb DHFR:JCS-1373 (gray) and Mtb DHFR:JCS-
1441. Bulkier 2,5-diethoxy group in JCS-1441 pushed the loop region away from its 
normal position. 
 
 
 
Introducing functionalities on the aniline ring alone ended up hurting the 
selectivity. No compound has shown improved selectivity and some of the analogs in 
this category are significantly more potent on human DHFR with 0.04-0.05 folds 
selectivity. There were just two analogs with the equal potency on both DHFRs. JCS-
1409 (Benzo[d][1,3]dioxole group) and JCS-1381 (3,5-dimethoxy group) with low 
potency for both DHFRs (Figure 3-3). JCS-1381 (3,4-dimethoxyaniline group) exhibited 
240 nM of IC50 on both DHFRs and JCS-1409 (benzodioxoaniline group) exhibited 200 
nM of IC50 on both DHFRs.  
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Interestingly enough, other than benzyl substitution, most of the other C-8 
substitutions have shown diminished selectivity. For the compounds that gained 
selectivity, they displayed very low potencies. The analog with highest potency and 
selectivity in this category is phenethyl substitution (JCS-1439) with 160 nM of IC50 on 
Mtb DHFR and 1300 nM of IC50 on human DHFR (8 fold selectivity). JCS-1439 is just 
one carbon longer than its C-8 benzyl counterpart, JCS-1425. Compared to the analogs 
in TMQ-aniline category, non-benzyl C-8 substitution has increased IC50s more against 
human DHFR than Mtb DHFR and this result led us to successful trial on benzyl C-8 
derivatization. This trend is more noticeable with small functional groups such as methyl 
(JCS-1420) or ally (JCS-1426) group, as the smaller pocket in human DHFR was more 
severely affected by the bulkier groups. The IC50 values are listed in Table 3-4. 
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Table 3-4. IC50 values against Mtb DHFR and human DHFR of C-8 non-benzyl TMQ 
analogs. Some of the analogs with bulky group on C-8 position exhibited moderate 
selectivity with more than 2 fold of selectivity.  
 
ID Number 
Substitution 
R1 
Substitution 
R2 
Mtb IC50 
nM 
Human IC50 
nM 
Selectivity 
Index(SI)  
Human/Mtb 
1401 Ph  3,5-dimethoxy 5400 1700 0.3 
1420 CH3 3,5-dimethoxy 1100 150 0.1 
1426 allyl 3,5-dimethoxy 260 260 1 
1433 vinyl 3,5-dimethoxy 250 50 0.2 
1437 n-prOH 3,5-dimethoxy 240 120 0.5 
1438 CHOHEt 3,5-dimethoxy 440 110 0.2 
1439 phenethyl 3,5-dimethoxy 160 1300 8 
1450 styryl 3,5-dimethoxy 550 2700 4.9 
1452 cyclopropyl 3,5-dimethoxy 610 390 0.6 
1458 vinylcyclohexyl 3,5-dimethoxy 6200 5500 0.9 
1459 ethylcyclohexyl 3,5-dimethoxy 1400 2800 2 
1465 ethyl 3,5-dimethoxy 380 180 0.5 
1464 2-thiophene 3,5-dimethoxy 5600 11700 2.1 
1490 vinylcyclopropyl 3,5-dimethoxy 220 60 0.3 
1493 vinyl t-butyl 3,5-dimethoxy 1300 13200 10 
1498 ethyl t-butyl 3,5-dimethoxy 1100 5900 5.4 
1502 bromo 3,4,5-trimethoxy 3900 470 0.1 
1529 ethylcyclopropyl 3,5-dimethoxy 220 250 1.1 
1540 styryl 3,4,5-trimethoxy 900 5300 6.0 
1541 phenethyl 3,4,5-trimethoxy 380 980 2.6 
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Figure 3-4. The important conserved interactions between Mtb DHFR and JCS-1437. 2,4-
diaminoquinazoline ring retains most of the important hydrogen bonding interactions just as in 
TMQ or other TMQ analogs bound Mtb DHFR. The 4-butanol group is pushing the 3,5-
dimethoxybenzne ring toward the solvent access region. 
 
 
 
Similar to Mtb DHFR:TMQ structure, the 2,4-diaminoquinazoline ring of JCS-
1437 has well-conserved hydrogen bond interaction with Mtb DHFR (Figure 3-4). This 
Mtb DHFR structure bound with JCS-1437 displayed the well-conserved hydrogen 
bonding interactions between Mtb DHFR and JCS-1437 similar to Mtb DHFR:TMQ 
structure. Asp27 has two hydrogen bonding interactions with 2-amino group and N-1 
nitrogen with the distances of 2.58 Å and 2.79 Å, respectively. Asp27 also forms the 
hydrogen bonding network with Thr113 and the distance is 2.79 Å. This Thr113 has 
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another hydrogen bonding network with 2-amino group of the 2,4-diaminoquinazoline 
ring of TMQ, and the distance between Thr113 and the 2-amino group of TMQ is 3.51 Å.  
For 4-amino group of the 2,4-diaminoquinzaoline ring of TMQ has three hydrogen 
bonding interactions with the main chain carbonyl group of Ile5, with the main chain 
carbonyl group of Ile94, and with the carbonyl group of Tyr100. The distances are 2.55 
Å, 2.85 Å, and 3.10 Å, respectively.  
For the 3,5-dimethoxyaniline ring side, the carbon atom of 3-methoxy group is 
close proximity with Val54 with the distance of 3.56 Å . The 2-position carbon atom of 
the aniline ring is close proximity with the carbon atom of Leu50 and the distance 
between the two atoms are 3.22 Å. The carbon atom of 5-methoxy group is in close 
contact with the oxygen atom of Asp19 with the distance of 3.16 Å . Although these 
methoxy groups and the carbon atoms are not in hydrogen bonding interactions with Mtb 
DHFR residues, they represent a potential venue for enhancing the interactions with 
DHFR.  
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Figure 3-5. Superimposed structure of Mtb DHFR:JCS-1437 (plum) and Mtb DHFR:JCS-
1438. Both of the hydroxyl groups in C-8 propyl (JCS-1437) and isopropyl (JCS-
1438) face the same direction. Still JCS-1437 pushed the loop region close the 3,5-
dimethoxybenzyl group in the compound is located and gained more space 
compared to JCS-1438. 
 
 
 
JCS-1437 (C-8 propanol) and JCS-1438 (C-8 iso-propanol) make an interesting 
comparison in Figure 3-5. The IC50 for JCS-1437 on Mtb DHFR is 240 nM and that of 
JCS-1438 is 440 nM. In both structures, hydroxyl groups of the two propanol position in 
a way that they could form hydrogen bonding interaction with Gln28. The distance 
between the hydroxyl group of JCS-1437 and Gln28 is 3.31 Å, and the distance between 
the hydroxyl group of JCS-1438 and Gln28 is 3.42 Å. Other than slightly longer distance, 
due to the extra ethyl group that sits in the opposite direction of the hydroxyl group, 
JCS-1438 showed about 2 fold lower potency on Mtb DHFR.  
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Figure 3-6. Superimposed structure of Mtb DHFR:JCS-1425 (blue) and Mtb DHFR:JCS-
1529. JCS-1529 binding induces significant conformational changes of Mtb DHFR, 
especially for the major residues for inhibitor binding such as Asp27, Gln28 and 
Phe31. 
 
 
 
JCS-1529, 8-(2-cyclopropylethyl)-6-(((3,5-
dimethoxyphenyl)amino)methyl)quinazoline-2,4-diamine, offers another interesting 
comparison on Mtb and human DHFR (Figure 3-6). The ethylcyclopropyl group on C-8 
position is even longer than C-8 benzyl series, but this group has much smaller 
functional group (cyclopropane) compared to the benzene ring of C-8 benzyl derivatives. 
To be able to accommodate the longer substituent, ethylcyclopropyl group, Mtb DHFR 
compromised its optimal interaction with 2,4-diaminoquinazoline ring and its 2-amino 
group and N-1 nitrogen. The distance between Asp27 and the N-1 nitrogen is 2.74 Å 
which is pretty similar to the TMQ and Mtb DHFR interaction, but the distance between 
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Asp27 and 2-amino group is 3.64 Å which is far longer than in Mtb DHFR:TMQ or Mtb 
DHFR:JCS-1425 structures. Furthermore the orientation of the JCS-1529 in the substrate 
binding site is abnormally distorted compared to JCS-1425 or TMQ. 
 
 
 
 
Figure 3-7.  Mtb DHFR:JCS-1529 structure in the active site of Mtb DHFR. Due to C-8-(1-
cyclopyropl)propyl group, distortion of the compound from the optimal interaction with Asp27 
and Phe31 is clearly shown. Though cyclopropyl group is relatively smaller, the overall length of 
the C-8 substituent forced this unfavorable position and the overall orientation of the molecule is 
different than TMQ. Yet, all the major interactions are still retained on 2,4-diaminoquinazoline 
ring side. 
 
 
 
Similar to Mtb DHFR:TMQ structure, the 2,4-diaminoquinazoline ring of JCS-
1529 has well-conserved hydrogen bond interaction with Mtb DHFR (Figure 3-7), 
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despite the interactions with Asp27 distorted significantly. Still, this Mtb DHFR 
structure bound with JCS-1529 displayed the well-conserved hydrogen bonding 
interactions between Mtb DHFR and JCS-1529 similar to Mtb DHFR:TMQ or other 
TMQ analogs bound structures. Asp27 has two hydrogen bonding interactions with 2-
amino group and N-1 nitrogen with the distances of 3.64 Å and 2.74 Å, respectively. 
Asp27 also forms the hydrogen bonding network with Thr113 and the distance is 3.09 Å. 
This Thr113 has another hydrogen bonding network with 2-amino group of the 2,4-
diaminoquinazoline ring of JCS-1529 via a water molecule, and the distance between 
Thr113 and this water molecule is 2.74 Å, and the distance between the water molecule 
and the 2-amino group of JCS-1529 is 2.74 Å. This water molecule further forms 
another hydrogen bonding interaction with the main chain carbonyl group of Glu111 and 
the distance between the two is 3.32 Å. 
For 4-amino group of the 2,4-diaminoquinzaoline ring of JCS-1529 has three 
hydrogen bonding interactions with the main chain carbonyl group of Ile5, with the main 
chain carbonyl group of Ile94, and with the carbonyl group of Tyr100. The distances are 
2.73 Å, 2.27 Å, and 2.99 Å, respectively.  
For the 3,5-dimethoxyaniline ring side, the carbon atom of 3-methoxy group is 
close proximity with Arg32 with the distance of 3.30 Å . The oxygen atom of the same 
methoxy group is in close proximity with Leu57 and the distance is 3.32 Å. The 4-
position carbon atom of the aniline ring is close proximity with the carbon atom of 
Leu50 and the distance between the two atoms are 3.05 Å. The oxygen atom of 5-
methoxy group is in close contact with Pro51 with the distance of 3.86 Å . Although 
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these methoxy groups and the carbon atoms are not in hydrogen bonding interactions 
with Mtb DHFR residues, they represent a potential venue for enhancing the interactions 
with DHFR. The nitrogen atom of the aniline ring forms a hydrogen bonding network 
with the oxygen atom of Ser49 via a water molecule. The distance between the aniline 
nitrogen and this water molecule is 3.27 Å and the distance between the water molecule 
and the oxygen atom of Ser49 is 2.60 Å.  
To be able to accommodate this long C-8 substituent, JCS-1529 had an 
unfavorable position in the active site compared to other TMQ analogs. The distance 
between Asp27 and N-1 nitrogen is 2.74 Å. But the distance between Asp27 and 2-
amino group is 3.64 Å, due to the forced distortion. Also the angles of the two 
interactions are not the optimal angles compared to TMQ. Though the cyclopropyl group 
is relatively small group, due to the long bridge (2-carbon atoms excluding the 
cyclopropyl carbon), the optimal angle or distance could not be retained. Also this is 
why we decided to try the benzyl group as the main scaffold of our SAR study to 
develop selective inhibitors against Mtb/Pf DHFR over human counterpart. 
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CHAPTER IV 
 
SAR STUDY OF C-8 BENZYL TMQ ANALOGS 
 
IV.1. C-8 benzyl TMQ Analogs; Selective, Potent Inhibitors of M.tuberculosis DHFR 
and P. falciparum DHFR-TS and their SAR Study on Mtb DHFR, Wild Type (WT) and 
Quadruple Mutant (QM) Pf DHFR-TS, and Human DHFR. 
 
In this most important chapter, the detailed outcome of our C-8 benzyl TMQ 
analogs that displayed exceptional selectivity against both Mtb DHFR and Pf DHFR-TS 
(WT and QM) will be discussed. The results we earned from the previous two chapters 
helped us to develop the potent and selective C-8 benzyl TMQ analogs. Though the 
detailed structure of C-8 benzyl group in the M. tuberculosis and P. falciparum DHFR 
was different than our initial design and needs to be studied further, C-8 benzyl group 
itself was sufficient to exert great selectivity against pathogenic DHFRs over human 
counterpart. 
As previously stated in the introduction, Mtb DHFR and Pf DHFR-TS share 
common structural features that we were able to take advantage of. One is a pocket near 
the substrate binding site, which was dubbed the glycerol binding pocket in Mtb DHFR 
structure (1DF7), and a flexible residue near the acid residue (Asp27 in Mtb DHFR or 
Asp54 in Pf DHFR-TS). 
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Figure 4-1. Overall structure of Pf DHFR-TS. Pf DHFR-TS exists as homo dimer (Two 
DHFR-TS) in physiological condition and TS domains are connected to each other. There are 
missing densities between DHFR and TS domains (a junction region), and the detailed function 
of this ‘junction region’ is not known clearly yet. 
 
 
 
For Pf DHFR-TS (Figure 4-1), wild-type, double mutant (C59R/S108N), and 
quadruple mutant (N51I/C59R/S108N/I164L) were cloned, expressed, purified and 
crystallized. All three Pf DHFR-TS contained the pockets near the substrate binding site 
similar to the glycerol binding pocket, and the mutations other than I164L are distant 
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from the active site. I164L did not affect much on the active site binding of the inhibitors 
either.  
The similarity between DHFRs made it likely that trimetrexate (TMQ), a DHFR 
inhibitor used in human diseases, would also have high affinity for the pathogenic 
DHFR proteins. Our own enzyme assay results confirmed that TMQ strongly inhibited 
Mtb and wild type Pf DHFR-TS (IC50 of 17 nM and 5 nM, respectively). The structures 
of Mtb DHFR bound with TMQ showed that it binds in the substrate binding cleft with 
the 2,4-diaminoquinazoline end fitting into the inside of the substrate binding pocket and 
the trimethoxyaniline ring stretching toward the solvent opening. The Mtb DHFR 
structures bound with TMQ and its analogs show that TMQ and its analogs have 
conserved hydrogen bonding interactions with the Asp27 through the 2-amino group and 
the N-1 nitrogen of the 2,4-diaminoquinazoline ring, and with the main chain carbonyl 
groups of Ile94 and Ile5 through the 4-amino group of the 2,4-diaminoquinazoline ring. 
These interactions form a network of hydrogen bonds that is conserved in the DHFR 
crystal structures from human and pathogens. The comparison of pathogenic and human 
DHFR substrate binding sites using the TMQ bound DHFR structures revealed that the 
RMSD between Mtb DHFR and human DHFR is 1.28 Å over 144 Cα carbons, and 
between Pf DHFR and human DHFR the RMSD is 1.09 Å over 164 Cα carbons. The 
greatest deviation came from the loop region where the trimethoxyaniline ring is located 
(Leu50-Arg55 in Mtb DHFR). 
In Mtb DHFR, Asp27, corresponding to Glu30 in human DHFR and Asp54 in Pf 
DHFR-TS, plays a role as an acid that donates hydrogen atom to the substrate (DHF) to 
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produce tetrahydrofolate (THF). Right next to this acid residue of pathogenic DHFRs, 
there is a flexible residue (Gln28 in Mtb DHFR and Met55 in Pf DHFR) that could offer 
flexibility to the substrate binding site. These residues have 2 or more carbon bridging 
that could confer high degree of rotational freedom along with the smaller size of their 
side chains. On the other hand, Phe31 is located in the same position in human DHFR, 
and Phe31 cannot offer the similar flexibility due to the bulkier size of phenyl group and 
no rotational freedom from the one bridging carbon that the Phe31 has. Our aim was to 
exploit the increased space afforded by the smaller and more flexible amino acids in the 
Mtb and P. falciparum substrate binding sites to add functional groups to the existing 
TMQ framework, to increase the inhibitor’s selectivity and/or potency against the 
pathogenic DHFRs. 
The IC50 of TMQ against Mtb DHFR is 17 nM, nearly the same as against the 
human protein (IC50 = 16 nM). Potency in the P. falciparum wild-type and quadruple 
mutant (QM) DHFRs was also strong at 5 nM and 6 nM, respectively. The main 
interactions in the substrate binding pocket are preserved between species, the 
quinazoline ring itself maintains interactions in both the human and pathogenic DHFRs 
through the acidic residue (Asp27 in Mtb DHFR) and the aromatic residue (Phe31 in 
Mtb DHFR), so we focused our efforts on utilizing the glycerol binding pocket and the 
additional space available by the help of the flexible residues (Gln28 in Mtb DHFR and 
Met55 in Pf DHFR) that are exclusively available in the pathogenic DHFRs by 
modifying the C-8 position of the 2,4-diaminoquinazoline ring and the trimethoxyaniline 
ring.  
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Our initial designs all contain hydrophilic groups such as dihydroxyl group or 
imidazole to mimic the interaction of glycerol with Mtb DHFR residues in the glycerol 
binding pocket including Trp22 and Arg23 (Figure 4-2). However, the synthesis was 
challenging and those hydrophilic groups turned out to be not crucial for selectivity 
thanks to the existence of the flexible residue such as Gln28 in Mtb DHFR.  
Development of an inhibitor based on the Mtb DHFR:TMQ structure was directed 
at the interactions between the acetate molecule found in the glycerol binding pocket and 
the nearby residues including Trp22, Arg23, Asp27, and Gln28. Our initial additions to 
the TMQ rings were compounds that would fit into the substrate binding pocket and 
strengthen these interactions to the point where our inhibitors were more potent 
selectively against the pathogenic DHFRs. Carbon linkers of various lengths were added 
to C-8 of the 2,4-diaminoquinazoline ring to enable binding in both the substrate binding 
site and the glycerol binding pocket (Figure 4-2). Out of the 16 initial compounds, six 
compounds exhibited increased selectivity against Mtb DHFR over human DHFR, and 
the benzyl group (JCS-1425) showed the best potency and selectivity. All six 
compounds contained bulky groups (benzene ring, cyclohexyl, or t-butyl group) and 
their selectivity gain was mainly due to activity loss in the human DHFR compared to 
the Mtb counterpart. Most of them showed low potency on Mtb DHFR (400 – 1500 nM) 
except for the C-8 benzyl analog (JCS-1425 at 59 nM) and the C-8 phenethyl analog 
(JCS-1439 at 160 nM).  
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A) 
 B) 
Figure 4-2. Designing the initial C-8 benzyl compounds. Using the Mtb DHFR:TMQ showing 
the TMQ (blue) and acetate (cyan) molecules.  B) In the design, the C-8 benzyl compound 
retained the hydrogen bond interaction with Asp27, Ile5, Ile94, and Try100 (Top, Left) and the 
pi-stacking interaction with Phe31 (Top, Right). C-8 benzyl group sits well in the binding pocket 
where an acetate molecule was found in Mtb DHFR:TMQ structure. The C-8 benzyl group has 
possible interaction with Trp22, Arg23, Asp27, and Gln28 (Bottom). 
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Figure 4-3. Example of the initially designed compounds. We made derivatization attempts 
from C-7 or C-8 of quinazoline ring and C-2 of trimethoxybenzene ring targeting the glycerol 
binding pocket found in the Mtb DHFR structure, 1DF7. We tried to synthesize and evaluate 
hydrophilic group containing molecules first, but it turned out that hydrophilic group was not 
crucial part for gaining selectivity. 
 
 
 
Additionally, though the structure of the inhibitors in the initial test did not 
follow the predicted models, it did provide a new avenue of development of selective 
inhibitors (Figure 4-3). 
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DHFR’s role in DNA and amino acid synthesis makes it a universally present 
protein, but there is a low sequence identity between proteins, with Mtb and P. 
falciparum sharing only a 20% sequence identity. However, the overall fold of the 
protein is largely preserved requiring detailed understanding of the differences and 
similarities between species to create a specific inhibitor. Both the Mtb DHFR and P. 
falciparum DHFR-TS have eight central β-strands surrounded by four α-helices. The 
active site is divided into two main clefts: one cleft fits the cofactor (NADPH) and the 
other fits the substrate (DHF). P. falciparum DHFR differs from the Mtb protein in that 
it forms a complex with thymidylate synthase, but the overall fold and interactions in the 
active site remain the same. 
The similarities between Mtb and P. falciparum DHFR are only important to 
inhibitor development if they share features that are different in the human DHFR. The 
sequence identity between Mtb DHFR and the human counterpart is actually higher than 
between Mtb and P. falciparum; 26%, but the sequence identity is not indicative of the 
similarity in overall fold. The dihydrofolate binding site extends inward forming a deep 
hydrophobic pocket with the pterin portion of DHF binding deepest in the pocket and the 
glutamate pointing outwards to the solvent. While the exact residues are not conserved 
between all species, the network of four hydrogen bonds that interact with the pterin are 
highly conserved due to their importance in catalysis. But while the interior portion of 
the substrate binding site is largely unchanged between species, the outer portion of the 
substrate binding site displays interesting and potentially useful diversity. 
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Both the Mtb and P. falciparum DHFR share a commonality missing in the 
human counterpart; the glycerol binding pocket. In the pathogenic DHFRs just outside 
the substrate binding site is a small depression loosely surrounded by hydrophilic 
residues which is not present in human DHFR. These features are also present in the 
quadruple mutant (QM) Pf DHFR, whose mutations do not impact the overall fold of the 
protein much.  In the human DHFR this region is tightly crowded with hydrophobic 
residues. There are also a key difference in the human DHFR due to Phe31, 
corresponding to Gln28 in Mtb and Met55 in P. falciparum, which has reduced 
rotational freedom due to its bulky phenyl group creating a much smaller space in the 
substrate binding site compared to the pathogenic proteins. This represents a potential 
avenue for inhibitor development.  
DHFRs from M. tuberculosis, P. falciparum, and humans show little sequence 
identity between them. The sequence identity between Mtb and human DHFR is just 
29%, and between Mtb and Pf DHFR-TS is 20%, however, they exhibit a surprising 
similarity in their overall fold (Cody, Luft et al. 1992, Li, Sirawaraporn et al. 2000, 
Yuvaniyama, Chitnumsub et al. 2003). The general DHFR active site structure is 
characterized by two main clefts; one cleft fits the cofactor, while the other cleft fits the 
substrate (dihydrofolate). As in previously solved DHFR structures from E. coli and M. 
tuberculosis (Matthews, Alden et al. 1977, Li, Sirawaraporn et al. 2000), our DHFR 
structures from M. tuberculosis, P. falciparum, and human have eight central β-strands 
and four surrounding α-helices. In Mtb DHFR, the substrate binding site is surrounded 
by three β-sheets (Val2-Ala9, Thr39-Gly43, and Thr91-Gly95) and three α-helices 
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(Pro25-Thr35, Arg44-Trp47, and Ala52-Val54). There are also two loop regions (Thr10-
Leu24 and Asp48-Pro51) close to the substrate binding site. (Figure 4-4) 
 
 
 
 
Figure 4-4. Superimposed structure of Mtb DHFR:TMQ (gray) and wild-type Pf DHFR-
TS:TMQ. TMQ (yellow) and NADPH (green) are shown for the active site shape. 
They share the common structural scaffold, 8 beta-strands and 4 alpha-helices. In Pf 
DHFR-TS structures, depending on the inhibitors bound, showed some additional 
helices or strands. 
 
 
 
Unlike Mtb and human DHFR, the plasmodium DHFR forms a complex with 
thymidylate synthase (TS), and Pf DHFR-TS forms a dimer linked by the two TS 
regions. However, the overall folding and the core residues of the DHFR active site are 
similar to Mtb and human DHFR (Yuvaniyama, Chitnumsub et al. 2003). There are three 
extra α-helices in Pf DHFR-TS (Val5-Phe9, Glu67-Leu81, and Val146-Lys155). The 
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Val5-Phe9 helix is close to the N-terminus and the other two helices are on the surface, 
all distant from the active site. None of these helices affect the overall fold or binding 
interactions of the inhibitors.  
 
 
 
 
Figure 4-5. The important hydrogen bond interactions in wild type Pf DHFR-TS:TMQ 
structure. The interactions are very similar to Mtb DHFR, especially the 2,4-
diaminoquinazoline side. On the other hand, interactions on 3,4,5-
trimethoxybenzene ring side are not hydrogen bonds, yet they could be non-
hydrogen bonding interactions including hydrophobic interactions or van der Waals 
interactions and potential leverage for the further SAR study 
 
 
 
Similar to Mtb DHFR:TMQ structure, the 2,4-diaminoquinazoline ring of TMQ 
has well-conserved hydrogen bond interactions with WT Pf DHFR (Figure 4-5). This 
WT Pf DHFR structure bound with TMQ displayed the well-conserved hydrogen 
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bonding interactions between WT Pf DHFR and TMQ similar to Mtb DHFR:TMQ 
structure. Asp54 (corresponding to Asp27 in Mtb DHFR) has two hydrogen bonding 
interactions with 2-amino group and N-1 nitrogen of the quinazoline with the distances 
of 2.93 Å and 2.88 Å, respectively. Asp54 further forms the hydrogen bonding network 
with Thr185 and the distance is 2.69 Å. Thr185 has another hydrogen bonding network 
with 2-amino group of the quinazoline ring of TMQ, and the distance is 2.96 Å.  
For 4-amino group of the 2,4-diaminoquinzaoline ring of TMQ has three hydrogen 
bonding interactions with the main chain carbonyl group of Ile14, with the main chain 
carbonyl group of Ile164, and with the carbonyl group of Tyr170. The distances are 2.63 
Å, 2.99 Å, and 3.28 Å, respectively.  
For the trimethoxyaniline ring side, there are no actual hydrogen-bonding 
interactions. However, there are some noticeable residues that are within the close 
proximity. The 2-carbon atom of the trimethoxyaniline is close to Ile112 and the distance 
is 3.68 Å . The oxygen atom of 4-methoxy group is close proximity with Pro113 and 
Phe116 with the distances of 3.56 Å and 3.62 Å. Although these methoxy groups are not 
in hydrogen bonding interactions, they represent a potential venue for enhancing the 
interactions with DHFR. 
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Figure 4-6. The important conserved interaction between TMQ and QM Pf DHFR. Met55 
was labeled for the further discussion on its role. I164L mutation does not affect much on the 
interaction with 4-amino group of 2,4-diaminoquinzoline ring, but S108N mutation decrease the 
distance to TMQ. In TMQ, there is no available interaction with Asn108, but with proper 
modification, additional interaction with Asn108 could be introduced.  
 
 
 
Similar to WT Pf DHFR:TMQ structure, the 2,4-diaminoquinazoline ring of TMQ 
has well-conserved hydrogen bond interactions with QM Pf DHFR (Figure 4-6). This 
QM Pf DHFR structure bound with TMQ displayed the well-conserved hydrogen 
bonding interactions between QM Pf DHFR and TMQ similar to Mtb DHFR:TMQ or 
WT Pf DHFR:TMQ structure. Asp54 (corresponding to Asp27 in Mtb DHFR) has two 
hydrogen bonding interactions with 2-amino group and N-1 nitrogen of the quinazoline 
with the distances of 2.89 Å and 3.13 Å, respectively. Asp54 further forms a hydrogen 
bonding network with Thr185 and the distance is 3.32 Å. Thr185 has another hydrogen 
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bonding network with 2-amino group of the quinazoline ring of TMQ, and the distance 
is 3.36 Å. This hydrogen bonding network is much weaker compared to WT Pf DHFR or 
Mtb DHFR.  
For 4-amino group of the 2,4-diaminoquinzaoline ring of TMQ has three hydrogen 
bonding interactions with the main chain carbonyl group of Ile14, with the main chain 
carbonyl group of Leu164, and with the carbonyl group of Tyr170. The distances are 
2.85 Å, 3.26 Å, and 3.22 Å, respectively. One thing noticeable here is that I164L 
mutation caused the distance 0.27 Å  extended compared to the wild type.  
For the 3,4,5-trimethoxyaniline ring side, there are no actual hydrogen-bonding 
interactions just as WT Pf DHFR. However, there are some noticeable residues that are 
within the close proximity. The aniline nitrogen has hydrogen bond interaction with the 
oxygen of Ser111 with the distance of 3.97 Å. The oxygen atom of 3-methoxy group is 
in close proximity with Pro113 with the distance of 3.25 Å, and the oxygen atom of 4-
methoxy group is in close proximity with Phe116 with the distances of 3.46 Å . Although 
these methoxy groups are not in hydrogen bonding interactions, they represent a 
potential venue for enhancing the interactions with DHFR. It is intriguing to see that 
S108N mutation caused Asn108 comes into 3.50 Å away from TMQ. In WT Pf DHFR-
TS:TMQ structure, Ser108 was more than 4 Å away from TMQ. Even though there is no 
hydrogen bonding interaction available with Asn108 here, some modification on that 
position could develop a QM Pf DHFR-TS specific inhibitor.  
Since there is no apo or cofactor (NADPH) bound structures of Pf DHFR-TS 
available, the RMSD calculation was done using the wild-type Pf DHFR-TS structure 
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bound with the substrate, dihydrofolate (4DPD). The RMSD over 205 Cα carbons with 
96.4% sequence identity is 0.29 Å. The sequence difference comes from a missing loop 
(Ser22-Asn29) in the substrate bound structure. There also is a common missing loop 
region (Val86-Ser95) in both structures. 
As in the previously published Mtb DHFR structures (1DG5 or 1DF7), our Mtb 
DHFR substrate binding site is loosely surrounded by hydrophilic residues such as 
Trp22 or Gln28, while the analogous site in human DHFR is tightly crowded by 
hydrophobic residues. Pf DHFR’s substrate binding site is slightly larger than that of 
Mtb DHFR. One of the crucial differences is between Gln28 in Mtb DHFR (Met55 in Pf 
DHFR) and Phe31 in human DHFR. The bulky benzyl group of Phe31 and its reduced 
rotational freedom compared to Gln28 and Met55 prevent it from flipping away to 
provide more room for the C-8 functional groups of our modified TMQ inhibitors.   
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Figure 4-7. Graphical diagram of the interactions of TMQ with Mtb DHFR (left), and with 
wild-type Pf DHFR-TS. Both structures showed well conserved interactions with 
acidic residue (Aps27 in Mtb DHFR and Asp54 in Pf DHFR-TS), with isoleucines 
via 4-amino group of the quinazoline ring and pi stacking interaction with Phe31 in 
Mtb DHFR and Phe58 in Pf DHFR-TS. 
 
 
 
The substrate binding sites of the known structures of Mtb DHFR and Pf DHFR-
TS were closely examined (Figure 4-7). For the TMQ bound DHFR structures, the 
RMSD between Mtb DHFR and human DHFR is 1.28 Å over 144 Cα carbons with 33% 
sequence identity, and between Pf DHFR-TS and human DHFR the RMSD is 1.09 Å  
over 164 Cα carbons with 31% sequence identity. 
The Mtb DHFR structures show TMQ and its analogs interact with Asp27 through 
the 2-amino group and N-1 nitrogen of the quinazoline ring, and with the main chain 
carbonyl groups of Ile94 and Ile5 through the 4-amino group of the quinazoline ring 
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(Figure 3). In Mtb DHFR, Asp27, which corresponds to Glu30 in human DHFR and 
Asp54 in Pf DHFR-TS, is the acid that gives up a hydrogen atom to the substrate (DHF). 
In the Mtb DHFR:TMQ structure, the distances between Asp27 and N-1, and Asp27 and 
the 2-amino group are 2.62 Å and 2.74 Å. TMQ and the C-8 benzyl-2,4-
diaminoquinazoline TMQ analogs form hydrogen bonds with Ile5 and Ile94 in Mtb 
DHFR through the backbone carbonyl groups. In the Mtb DHFR:TMQ structure, the 
distance between Ile5 and the 4-amino group of the quinazoline is 2.86 Å and that of 
Ile94 and the same 4-amino group is 2.86 Å. These two isoleucines correspond to Ile14 
and Ile164 in Pf DHFR-TS. Tyr100 in Mtb DHFR, which is Tyr170 in Pf DHFR-TS, 
could form another hydrogen bond with the 4-amino group of the quinazoline ring at a 
distance of 3.40 Å between Tyr100 and the 4-amino group. However, in the Mtb 
DHFR:TMQ structure, Tyr100 is not at a favorable angle to the 4-amino group of the 
quinazoline ring for a hydrogen bond.  
When TMQ is bound to Mtb DHFR, it makes only slight conformational changes 
compared to the Mtb DHFR:NADPH structure (1DG8). The RMSD over 159 Cα 
carbons with 100% sequence identity is 0.69 Å. The biggest deviations are seen between 
Ser49-Val54 close to the substrate binding site, and Arg143-Arg150, which is a loop 
region close to the C-terminus. Specifically, Leu50 and Pro51 are closer to the substrate 
binding site in our TMQ bound structure strengthening their interaction with TMQ.  
Trimetrexate (TMQ) exhibited high potency against both Mtb and human DHFR 
with IC50s of 17 nM and 16 nM. In order to increase the potency of TMQ against the 
pathogenic DHFR in relation to the human DHFR, we made two major types of 
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modifications to the parent compound (Figure 4). We made changes to the C-8 position 
of the 2,4-diaminoquinazoline ring and to the aniline ring, and compared the activity and 
structure of each compound. To facilitate the synthesis of the compounds, 2,4-
dimethoxybenzene analogs were introduced instead of 2,3,4-trimethylbenzene as in 
TMQ. The C-5 methyl group was removed from the 2,4-diaminoquinazoline ring for the 
same reason. This compound, JCS-1381, lost 10 fold activity against both Mtb and the 
human DHFR.  
 
 
TMQ modifications 
 
TMQ also exhibited strong potency against both wild-type (WT) and quadruple-
mutant (QM) Pf DHFR-TS with IC50s of 5 nM and 6 nM. The RMSD for the TMQ 
bound structures of WT and QM Pf DHFR-TS was 0.43 Å for 217 residues with a 96.8% 
sequence identity, with the largest deviation arising from the loop region (residues 21-28) 
and residues near the missing region (residues 86-95). This missing region came from 
the model (1J3I and 4DP3), and the density was missing in our data as well. 
 
  
 
 
 
Figure 4-8. JCS-1474 in the active site of Mtb DHFR. Views from the front (top) and from the 
aniline ring side (bottom). JCS-1474 sits snugly in the active site thanks to the flexible Gln28 
residue in Mtb DHFR. 
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 JCS-1474, one of the C-8 benzyl TMQ analogs, exhibited an exceptional 
selectivity against Mtb DHFR over human counterpart (90 fold). According to the 
structure, Mtb DHFR:JCS-1474,  significant clues could be drawn (Figure 4-8, 4-9). 
 
 
 
    
 
Figure 4-9. TMQ (purple) and JSF-1474 in the active site of Mtb DHFR. Views from the 
front (left) and from the aniline ring side (right). JSF-1474 sit snugly in the active site by 
creating space that was not available in Mtb DHFR:TMQ structure due to Gln28’s orientation. 
The acetate (ACT) molecule that was found in the Mtb DHFR:TMQ structure is not found in the 
Mtb DHFR:JSF-1474 structure and C-8 benzyl group occupies that space partially. 
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 2,4-diaminoquinazoline ring occupies the similar space in both Mtb DHFR:TMQ 
and Mtb DHFR:JCS-1474 structures. C-8 benzyl group in JCS-1474 occupies the space 
where an acetate molecule was found in Mtb DHFR:TMQ structure. This space is not 
available in human DHFR due to the bulky Phe31 and its lack of rotational freedom and 
this caused the drastic potency loss of JCS-1474 in human DHFR with the IC50 of 18000 
nM. However, in Mtb DHFR, Gln28, with its smaller size and greater rotational 
freedom, allowed the enough space for C-8 benzyl group and lost just a little bit of 
potency with the IC50 of 200 nM. 
 
 
 
 
Figure 4-10. The important conserved interactions between JCS-1474 and Mtb DHFR. C-8 
benzyl group clearly pushed down Gln28 so that the bulky C-8 benzyl group can be 
accommodated in the pocket. The major hydrogen bond interactions on 2,4-diaminoquinazoline 
ring side are well conserved. On the other hand, there are a couple of new interactions were 
found on the 2,5-diethoxyaniline ring side. 
96 
 
 When we checked the Mtb DHFR:JCS-1474 crystal structure, which were grown 
from significantly different condition than Mtb DHFR:TMQ, has much similarity in the 
major interactions between the compound and the protein (Figure 4-10). Similar to Mtb 
DHFR:TMQ structure, the 2,4-diaminoquinazoline ring of JCS-1474 has well-conserved 
hydrogen bond interaction with Mtb DHFR. This Mtb DHFR structure bound with JCS-
1474 displayed the well-conserved hydrogen bonding interactions between Mtb DHFR 
and JCS-1474 similar to TMQ bound Mtb DHFR structure. Asp27 has two hydrogen 
bonding interactions with 2-amino group and N-1 nitrogen with the distances of 2.85 Å 
and 2.96 Å, respectively. Both distances are about 0.2 Å longer than in Mtb DHFR:TMQ 
structure. Asp27 further forms the hydrogen bonding network with Thr113 and the 
distance is 2.60 Å. Thr113 has another hydrogen bonding network via a water molecule 
with 2-amino group of the quinazoline ring of JCS-1474, and the distance between 
Thr113 and this water molecule is 2.76 Å and between the water molecule and the 2-
amino group of TMQ is 2.90 Å. This water molecule has an additional hydrogen bond 
interaction with the main chain carbonyl of Glu111 and the distance of this interaction is 
3.33 Å.  
For 4-amino group of the 2,4-diaminoquinzaoline ring of JCS-1474 has three 
hydrogen bonding interactions with the main chain carbonyl group of Ile5, with the main 
chain carbonyl group of Ile94, and with the carbonyl group of Tyr100. The distances are 
2.59 Å, 2.52 Å, and 2.99 Å, respectively. All of the three distances are shorter than the 
ones in Mtb DHFR:TMQ structure, yet JCS-1474 lost more than 10 fold of potency, and 
this could indicate that these three hydrogen bond interactions are either not in the 
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 favorable angles or not so significant to the overall interaction between DHFR and JCS-
1474. 
For the 2,5-dimethoxyaniline ring side, the carbon atom of 2-ethoxy group is in 
close proximity with Leu57 with the distance of 3.38 Å. The 4-carbon atom of the 
benzene ring is in close proximity with the carbon atom of Pro51 with the distance of 
4.15 Å. The carbon atom of 5-ethoxy group also is in close proximity with Arg23 with 
the distance of 3.25 Å. Although these ethoxy groups are not technically in hydrogen 
bonding interactions with DHFR residues, they represent a potential venue for enhancing 
the interactions with DHFR. 
Adding a benzyl group as in JCS-1474 (4-methylbenzyl) improved the selectivity 
considerably by significantly reducing the potency of this compound against human 
DHFR (IC50 = 18000 nM) versus the Mtb protein (IC50 = 200 nM) and the wild-type Pf 
DHFR-TS (IC50 = 20 nM). JCS-1474 did lose considerable activity against QM Pf 
DHFR-TS (IC50 = 70 nM) compared to the wild-type, but still retained sufficient activity 
to confer selectivity against the human DHFR. The modifications and their effect on IC50 
are illustrated in Tables 1 and 2. The size of the pocket near the substrate binding site of 
WT and QM Pf DHFR-TS is almost the same and the mutated residues of the mutant 
(N51I/C59R/ S108N/I164L) do not significantly alter the binding interactions of the C-8 
benzyl-2,4-diaminoquinazoline TMQ analogs. For instance, the closest contact comes 
from between the main chain carbonyl group of I164L of Pf DHFR-TS and the 4-amino 
group of the quinazoline ring. The distance of this contact is 2.8 Å in the WT Pf DHFR-
TS:JCS-1474 structure, and 2.9 Å in the QM Pf DHFR-TS:JCS-1474 structure (Figure 
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 4-12). The reduced potency of the C-8 benzyl group compounds in the quadruple-mutant 
Pf DHFR-TS compared to the wild-type can be explained by the longer distances 
between interacting residues. In the WT Pf DHFR-TS:JCS-1474 structure, the distances 
between the 4-amino group of the quinazoline ring and the three interacting residues, 
Ile14, Ile164, and Tyr170 are 2.6 Å, 2.8 Å, and 2.6 Å, respectively. These distances are 
increased in the QM Pf DHFR-TS:JCS-1474 structure to 2.8 Å, 2.9 Å, and 2.9 Å, 
reducing the strength of the interactions (Table 4-1). 
 
 
 
JCS-1474  
Asp27 (O) : 2-
amino (N) 
Asp27 (O) : N-1  
Ile5 main (O) : 
4-amino (N) 
Ile94 main (O) : 
4-amino (N) 
Tyr100 (O) : 4-
amino (N) 
Mtb DHFR 2.85 2.96 2.58 2.52 2.99 
WT Pf DHFR-
TS 
2.87 
(Asp54) 
2.99 
 
2.51 
(Ile14) 
2.79 
(Ile164) 
2.62 
(Tyr170) 
QM Pf DHFR-
TS 
2.94 3.22 2.81 
2.79 
(Leu164) 
2.89 
DM Pf DHFR-
TS (JCS-1552) 
2.65 2.86 2.49 2.99 2.61 
QM Pf DHFR-
TS (JCS-1552) 
2.48 3.21 2.85 2.83 3.07 
human DHFR 
(JCS-1502) 
2.80 
(Glu30) 
2.96 
2.67 
(Ile7) 
2.82 
(Val115) 
3.01 
(Tyr121) 
Table 4-1. The conserved hydrogen bond interactions in C-8 benzyl TMQ bound structures 
from various DHFRs. The major interactions on 2,4-diaminoquinazoline ring with 
the residues are well conserved, and the distances are consistent with the degree of 
potency in the corresponding DHFRs. JCS-1474 and JCS-1552 has different 
substituent on the aniline ring side, and it is not for the cross-comparison. 
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Figure 4-11. Superimposed structure of WT (khaki) and QM Pf DHFR:JCS-1569. The four 
mutations (N51I, C59R, S108N, and I164L) are shown with labels. Other than Ile164 (Leu164), 
all the other three positions are more than 3.5 Å away from the C-8 benzyl TMQ analogs, and 
I164L mutation does not have significant impact on the binding of C-8 benzyl TMQ on QM Pf 
DHFR-TS. The reasons for the activity loss on QM Pf DHFR-TS remain to be seen. 
 
  
Figure 4-12. The important conserved interactions between WT Pf DHFR and JCS-1474. 
The interactions on 2,4-diaminoquinazoline ring side are well conserved as in WT Pf 
DHFR:TMQ structure. The distances between Asp54 and 2-amino group and 1-nitrogen is 
significantly longer than WT Pf DHFR:TMQ structure. As Gln28 in Mtb DHFR, Met55 offered 
large enough space for C-8 benzyl group due to its rotational freedom and small side chain. 
 
 
 
When we checked the WT Pf DHFR:JCS-1474 crystal structure, which were 
grown from significantly different condition than Mtb DHFR:TMQ or WT Pf 
DHFR:TMQ structures, has much similarity in the major interactions between the 
compound and the protein (Figure 4-12). Similar to Mtb DHFR:TMQ or WT Pf 
DHFR:TMQ structures, the 2,4-diaminoquinazoline ring of JCS-1474 has well-
conserved hydrogen bond interactions with WT Pf DHFR. This WT Pf DHFR structure 
bound with JCS-1474 displayed the well-conserved hydrogen bonding interactions 
between WT Pf DHFR and JCS-1474 similar to TMQ bound WT Pf DHFR structure. 
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 Asp54, corresponding to Asp27 in Mtb DHFR, has two hydrogen bonding interactions 
with 2-amino group and N-1 nitrogen with the distances of 2.87 Å and 2.99 Å, 
respectively. Both distances are about 0.1 Å longer than in WT Pf DHFR:TMQ 
structure. Asp54 further forms the hydrogen bonding network with Thr185 and the 
distance is 2.89 Å. Thr185 has another hydrogen bonding network with 2-amino group 
of the quinazoline ring of JCS-1474, and the distance between Thr185 and the 2-amino 
group of JCS-1474 is 3.23 Å.  
For 4-amino group of the 2,4-diaminoquinzaoline ring of JCS-1474 has three 
hydrogen bonding interactions with the main chain carbonyl group of Ile14, with the 
main chain carbonyl group of Ile164, and with the carbonyl group of Tyr170. The 
distances between the 4-amino group and those residues are 2.51 Å, 2.79 Å, and 2.62 Å, 
respectively. All of the three distances are shorter than the ones in WT Pf DHFR:TMQ 
structure, yet JCS-1474 lost more than 4 fold of potency as in Mtb DHFR, and this could 
indicate that these three hydrogen bond interactions are either not in the favorable angles 
or not so significant to the overall interaction between WT Pf DHFR and JCS-1474. 
For the 2,5-diethoxyaniline ring side, the carbon atom of 5-ethoxy group is in 
close proximity with Ser111 with the distance of 3.82 Å. The 4-carbon atom of the 
benzene ring is in close proximity with the carbon atom of Pro113 with the distance of 
3.52 Å. The C-8 benzene ring has pi stacking interaction with Met55 with the distance of 
3.95 Å. Although these ethoxy groups are not technically in hydrogen bonding 
interactions with WT Pf DHFR residues, they represent a potential venue for enhancing 
the interactions with DHFR. 
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The mutations in the quadruple-mutant do not have a significant impact on 
inhibitor binding. Ile51 is far away from the active site, and the side chains of Asn108 
and Leu164 stretch in the opposite direction from the inhibitor. The main chain oxygen 
of Leu164 (or Ile164) can have the hydrogen bonding interaction with TMQ or its 
analogs, but the differences in distance are not crucially altered by the mutation (Figure 
4-13). Arg59, similar to Arg23 in Mtb DHFR, comes in closer contact with the aniline 
ring side of the compound but still not close enough to contribute a strong interaction. In 
the Pf DHFR-TS:JCS-1474 structure, the Arg59 in chain B is at a distance of 5.2 Å to 
JCS-1474.  
 
 
 
 
Figure 4-13. Superimposed structure of WT Pf DHFR:JCS-1474 (blue) and QM Pf 
DHFR:JCS-1474.  
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Figure 4-14. The important conserved interactions between QM Pf DHFR and JCS-1474. 
As other TMQ analogs, JCS-1474’s 2,4-diaminoquinazoline ring retains all the major hydrogen 
bonding interactions with QM Pf DHFR. Met55 flipped down as in the WT Pf DHFR:JCS-1474 
to be able to accommodate the C-8 benzyl group. Leu164 and Asn108 have better interactions 
than WT’s counterpart. 
 
 
 
When the QM Pf DHFR:JCS-1474 crystal structure was inspected, which were 
grown from a different condition than Mtb DHFR:TMQ or WT Pf DHFR structures, it 
has much similarity in the major interactions between the compound and the protein 
(Figure 4-14). Similar to Mtb DHFR:TMQ or WT Pf DHFR:TMQ structures, the 2,4-
diaminoquinazoline ring of JCS-1474 has well-conserved hydrogen bond interactions 
with QM Pf DHFR. This QM Pf DHFR structure bound with JCS-1474 displayed the 
well-conserved hydrogen bonding interactions between QM Pf DHFR and JCS-1474 
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similar to TMQ bound QM Pf DHFR structure. Asp54, corresponding to Asp27 in Mtb 
DHFR, has two hydrogen bonding interactions with 2-amino group and N-1 nitrogen 
with the distances of 2.94 Å and 3.22 Å, respectively. Both distances are about 0.1 Å 
longer than in QM Pf DHFR:TMQ structure. This increase in distances was also 
observed in WT Pf DHFR. Asp54 further forms the hydrogen bonding network with 
Thr185 and the distance is 3.30 Å. Thr185 has another hydrogen bonding network with 
2-amino group of the 2,4-diaminoquinazoline ring of JCS-1474, and the distance 
between Thr185 and the 2-amino group of JCS-1474 is 3.52 Å. These two interactions 
and their distances are about 0.3 Å longer than in WT Pf DHFR:JCS-1474 structure. 
For 4-amino group of the 2,4-diaminoquinzaoline ring of JCS-1474 has three 
hydrogen bonding interactions with the main chain carbonyl group of Ile14, with the 
main chain carbonyl group of Ile164, and with the carbonyl group of Tyr170. The 
distances between the 4-amino group and those residues are 2.81 Å, 2.79 Å, and 2.89 Å, 
respectively. The distance between the 4-amino group and the main chain carbonyl 
group of Ile14 is about 0.05 Å shorter than QM Pf DHFR:TMQ structure, and the other 
two distances are about 0.3 Å shorter than the ones in QM Pf DHFR:TMQ structure, yet 
JCS-1474 lost more than 4 fold of potency as in Mtb DHFR, and this could indicate that 
these three hydrogen bond interactions are either not in the favorable angles or not so 
significant to the overall interaction between QM Pf DHFR and JCS-1474. It is 
interesting to see that S108N mutation caused 0.42 Å increase in the distance from JCS-
1474, and I164L mutation caused 0.05 Å increase in the distance from the 4-amino 
group of the 2,4-diaminoquinazoline ring.  
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For the 2,5-diethoxyaniline ring side, the carbon atom of 5-ethoxy group is in 
close proximity with Lue119 with the distance of 3.81 Å . The 3-carbon atom of the 2,5-
diethoxyaniline ring is in close proximity with the carbon atom of Pro113 with the 
distance of 3.36 Å . The C-8 benzene ring has pi stacking interaction with Met55 with the 
distance of 3.93 Å. The carbon atom of the 4-methyl group of the C-8 benzyl group is in 
close proximity with Phe116 with the distance of 3.86 Å. Although these ethoxy groups 
are not in the hydrogen bonding interactions with QM Pf DHFR residues, they represent 
a potential venue for enhancing the interactions with DHFR. 
The closest contact among the 4 mutations in the quadruple mutant of Pf DHFR-
TS, comes from I164L mutation. The side chains are a bit far from the substrate binding 
site. However, the distance from the main chain carbonyl is close enough to have a 
hydrogen bond interaction with the 4 amino group of 2,4-diaminoquinazoline ring of 
TMQ and C-8 benzyl TMQ analogs.  
The distance between the man chain carbonyl of Ile164 and TMQ in WT Pf 
DHFR-TS is 2.99 Å. The same distance between Leu164 and TMQ became 3.26 Å in 
QM Pf DHFR-TS, and the I164L mutation caused the distance longer, and weaken the 
interaction of TMQ and the protein as a result. However, this difference in the distances 
between wild type and quadruple mutant DHFR is much smaller with C-8 benzyl TMQ 
analogs. For example, as previously seen, with JCS-1474 bound QM Pf DHFR the 
distance between Leu164 and the 4-amino group is 2.79 Å, and it is just 0.05 Å longer 
than the distance between Ile164 and the 4 amino group in WT Pf DHFR-TS (2.74 Å). 
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In the JCS-1569 bound structures, the distance is even 0.08 Å shorter in QM Pf DHFR-
TS (2.71 Å) than in WT Pf DHFR-TS (2.79 Å).  
 
 
 
 
Figure 4-15. Superimposed structure of DM Pf DHFR-TS:JCS-1552 (khaki) and QM Pf 
DHFR-TS:JCS-1552. The distance of the hydrogen bonding interaction between 
the main chain carbonyl of Ile164 and the 4-amino group of JCS-1552 in DM Pf 
DHFR is 2.99 Å, and the same distance of Leu164 and 4-amino group of JCS-1552 
in QM Pf DHFR is 0.16 Å shorter and 2.83 Å. This is an example of the inversed 
distance in the quadruple mutant.  
 
 
 
In the case of double mutant (DM) Pf DHFR-TS:JCS-1552 structure, the inversed 
distance was observed when compared to QM Pf DHFR-TS:JCS-1552 (Figure 4-15). 
This particular case might be an exception for the general trend of the increase of the 
distance with the quadruple mutant especially, I164L mutation. However, the decrease in 
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the distance of Leu164 main chain carbonyl group and the 4-amino group of JCS-1552 
in QM Pf DHFR-TS is 0.16 Å and this is significantly shorter, for there was about 0.05-
0.1 Å increase in the same distance found in other Pf DHFR-TS structures bound with 
TMQ or other C-8 benzyl TMQ analogs.  
 
 
 
 
Figure 4-16. The important conserved interactions between DM Pf DHFR-TS and TMQ. 
Double mutant (C59R/S108N) Pf DHFR displayed similar interactions with WT or QM Pf 
DHFR:TMQ structures, and the distances are pretty similar to them. Note that interactions with 
Asn108 are available which are not available in WT Pf DHFR. 
 
 
 
Similar to WT or QM Pf DHFR:TMQ structures, the 2,4-diaminoquinazoline ring 
of TMQ has well-conserved hydrogen bond interactions with DM Pf DHFR (Figure 4-
16). This DM Pf DHFR structure bound with TMQ displayed the well-conserved 
hydrogen bonding interactions between DM Pf DHFR and TMQ similar to Mtb 
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DHFR:TMQ or WT Pf DHFR:TMQ structure. Asp54 (corresponding to Asp27 in Mtb 
DHFR) has two hydrogen bonding interactions with 2-amino group and N-1 nitrogen of 
the quinazoline with the distances of 2.50 Å and 2.69 Å, respectively. Asp54 further 
forms a hydrogen bonding network with Thr185 and the distance is 2.93 Å. Thr185 has 
another hydrogen bonding network with 2-amino group of the 2,4-diaminoquinazoline 
ring of TMQ, and the distance is 2.81 Å.  
For 4-amino group of the 2,4-diaminoquinzaoline ring of TMQ has three hydrogen 
bonding interactions with the main chain carbonyl group of Ile14, with the main chain 
carbonyl group of Leu164, and with the carbonyl group of Tyr170. The distances are 
2.54 Å, 3.69 Å, and 3.20 Å, respectively. One thing noticeable here is that I164L 
mutation caused the distance 0.70 Å  extended compared to the wild type, this is even 
0.47 Å longer than the quadruple mutation and it could be the reason of the mediocre 
potency of DM Pf DHFR despite the shorter distances between TMQ and Asp54.  
For the 3,4,5-trimethoxyaniline ring side, there are no actual hydrogen-bonding 
interactions just as WT Pf DHFR. However, there are some noticeable residues that are 
within the close proximity. The aniline nitrogen has a possible hydrogen bond 
interaction with the oxygen of Asn108 with the distance of 3.69 Å . This Asn108 oxygen 
is in close proximity with the aniline carbon with the distance of 3.54 Å. The oxygen 
atom of 4-methoxy group is in close proximity with Phe116 with the distances of 3.13 Å . 
Although these methoxy groups are not in hydrogen bonding interactions, they represent 
a potential venue for enhancing the interactions with DHFR. It is intriguing to see that 
S108N mutation caused Asn108 comes into 3.54 Å away from TMQ. In WT Pf DHFR-
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TS:TMQ structure, Ser108 was more than 4 Å away from TMQ. Even though there is no 
hydrogen bonding interaction available with Asn108 here, some modification on that 
position could develop DM or QM Pf DHFR-TS specific inhibitor.  
 
 
 
 
Figure 4-17. The important conserved interactions between DM Pf DHFR-TS and JCS-
1552. Double mutant (C59R/S108N) Pf DHFR displayed similar interactions with 
WT or QM Pf DHFR:TMQ or JCS-1474 structures, and the distances are pretty 
similar to them. Note that interactions with Asn108 are available which are not 
available in WT Pf DHFR. 
 
 
 
When we checked the DM Pf DHFR:JCS-1552 crystal structure, which were 
grown from significantly different condition than Mtb DHFR:TMQ or WT Pf DHFR 
structures, has much similarity in the major interactions between the compound and the 
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DM Pf DHFR-TS protein (Figure 4-17). Similar to Mtb DHFR:TMQ or WT Pf 
DHFR:TMQ or DM Pf DHFR:TMQ structures, the 2,4-diaminoquinazoline ring of JCS-
1552 has well-conserved hydrogen bond interactions with DM Pf DHFR. This DM Pf 
DHFR structure bound with JCS-1552 displayed the well-conserved hydrogen bonding 
interactions between DM Pf DHFR and JCS-1552 similar to TMQ bound WT or DM Pf 
DHFR structure. Asp54, corresponding to Asp27 in Mtb DHFR, has two hydrogen 
bonding interactions with 2-amino group and N-1 nitrogen with the distances of 2.65 Å 
and 2.86 Å, respectively. Both distances are about 0.15 Å longer than in DM Pf 
DHFR:TMQ structure. Asp54 further forms the hydrogen bonding network with Thr185 
and the distance is 2.80 Å. Thr185 has another hydrogen bonding network with 2-amino 
group of the quinazoline ring of JCS-1552, and the distance between Thr185 and the 2-
amino group of JCS-1552 is 3.28 Å. This 2 amino group further forms another hydrogen 
bond interaction with the main chain carbonyl group of Cys15 with the distance of 3.24 
Å .  
For 4-amino group of the 2,4-diaminoquinzaoline ring of JCS-1552 has three 
hydrogen bonding interactions with the main chain carbonyl group of Ile14, with the 
main chain carbonyl group of Ile164, and with the carbonyl group of Tyr170. The 
distances between the 4-amino group and those residues are 2.49 Å, 2.99 Å, and 2.61 Å, 
respectively. All of the three distances are significantly shorter than the ones in DM Pf 
DHFR:TMQ structure, yet JCS-1552 lost more than 4 fold of potency compared to DM 
Pf DHFR:TMQ as in Mtb DHFR or WT Pf DHFR or QM Pf DHFR, and this could 
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indicate that these three hydrogen bond interactions are either not in the favorable angles 
or not so significant to the overall interaction between DM Pf DHFR and JCS-1552. 
For the 3,5-dimethoxyaniline ring side, there are no actual hydrogen-bonding 
interactions just as WT Pf DHFR. However, there are some noticeable residues that are 
within the close proximity. The aniline nitrogen has a possible hydrogen bond 
interaction with the oxygen of Asn108 with the distance of 3.34 Å . This Asn108 oxygen 
is in close proximity with the aniline carbon with the distance of 3.21 Å. The 2-carbon 
atom of the aniline ring is in close proximity with Ile112 with the distance of 3.60 Å. 
The oxygen atom of 3-methoxy group is in close proximity with Pro113 with the 
distances of 3.93 Å, and the carbon atom of 5-methoxy group is in close proximity with 
Phe116 with the distance of 3.69 Å. Although these methoxy groups do not have 
hydrogen bonding interactions with DM Pf DHFR-TS, they represent a potential venue 
for enhancing the interactions with DHFR. 
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Figure 4-18. The important conserved interactions between QM Pf DHFR and JCS-1552. 
As in other structures bound with C-8 benzyl TMQ analogs, 2,4-diaminoquinazoline ring retains 
all the major hydrogen bonding interactions. C-8 benzyl group has pi stacking interaction with 
Met55 and the 3,5-dimethoxyaniline ring, and the 3,5-dimethoxyaniline ring is in close 
proximity with some of the QM Pf DHFR residues. 
 
 
 
JCS-1552 bound structures were also elucidated on WT and QM Pf DHFR. When 
we checked the QM Pf DHFR:JCS-1552 crystal structure, which were grown from a 
different condition than Mtb DHFR:TMQ or DM Pf DHFR structures, has much 
similarity in the major interactions between the compound and QM Pf DHFR (Figure 4-
18). Similar to Mtb DHFR:TMQ or WT Pf DHFR:TMQ or DM Pf DHFR:TMQ or DM 
Pf DHFR:JCS-1552 structures, the 2,4-diaminoquinazoline ring of JCS-1552 has well-
conserved hydrogen bond interactions with QM Pf DHFR as well. This QM Pf DHFR 
structure bound with JCS-1552 displayed the well-conserved hydrogen bonding 
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interactions between QM Pf DHFR and JCS-1552 similar to TMQ bound WT or DM Pf 
DHFR structure. Asp54, corresponding to Asp27 in Mtb DHFR, has two hydrogen 
bonding interactions with 2-amino group and N-1 nitrogen with the distances of 2.48 Å 
and 3.21 Å, respectively. Asp54 further forms the hydrogen bonding network with 
Thr185 and the distance is 3.27 Å. Thr185 has another hydrogen bonding network with 
2-amino group of the 2,4-diaminoquinazoline ring of JCS-1552, and the distance 
between Thr185 and the 2-amino group of JCS-1552 is 3.82 Å. This 2-amino group 
further forms another hydrogen bond interaction with the main chain carbonyl group of 
Cys15 with the distance of 3.57 Å .  
For 4-amino group of the 2,4-diaminoquinzaoline ring of JCS-1552 has three 
hydrogen bonding interactions with the main chain carbonyl group of Ile14, with the 
main chain carbonyl group of Ile164, and with the carbonyl group of Tyr170. The 
distances between the 4-amino group and those residues are 2.85 Å, 2.83 Å, and 3.07 Å, 
respectively. All of the three distances are significantly shorter than the ones in QM Pf 
DHFR:TMQ structure, yet JCS-1552 lost potency compared to QM Pf DHFR:TMQ as in 
Mtb DHFR or WT Pf DHFR or DM Pf DHFR, and this could indicate that, due to C-8 
benzyl group in JCS-1552, these three hydrogen bond interactions are either not in the 
favorable angles or not so significant to the overall interaction between QM Pf DHFR 
and JCS-1552. 
For the 3,5-dimethoxyaniline ring side, there are no actual hydrogen-bonding 
interactions just as WT or DM Pf DHFR. However, there are some noticeable residues 
that are within the close proximity. The aniline nitrogen has a possible hydrogen bond 
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interaction with the oxygen of Asn108 with the distance of 3.63Å . This Asn108 oxygen 
is in close proximity with the aniline carbon with the distance of 3.14 Å. The oxygen 
atom of 3-methoxy group is in close proximity with Pro113 with the distances of 3.40 Å, 
and the carbon atom of 5-methoxy group is in close proximity with Leu119 with the 
distance of 3.90 Å . Although these methoxy groups do not have hydrogen bonding 
interactions with DM Pf DHFR-TS, they represent a potential venue for enhancing the 
interactions with DHFR.  
C-8 benzyl group of JCS-1552 has some additional interactions. 5-carbon atom of 
the C-8 benzyl group has probable pi stacking interaction with Met55 and the distance 
between the two is 3.61 Å. This C-8 benzyl group has another pi-pi stacking interaction 
with the aniline ring, and the distance between the two rings is 3.14 Å.  
Since the interaction between Ile164 (or Leu164) and the 4-amino group in 2,4-
diaminoquinazoline ring in TMQ and its C-8 benzyl analogs is not the only interaction 
nor the most important one among the all possible interactions, this distance alone could 
not be any indication for the strength of the overall interaction. Still, it could explain in 
part why there was a potency loss in QM Pf DHFR-TS compare to the wild type and 
why the available space in the substrate binding site in the quadruple mutant is slightly 
larger than that of the wild type counterpart. However, it remains to be seen what the 
exact reason(s) for the potency loss in the quadruple mutant Pf DHFR in general and the 
difference in the degree of the potency loss among the various analogs.  
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Table 4-2. IC50 values of C-8 benzyl TMQ analogs on Mtb DHFR and human DHFR. All of 
the C-8 benzyl analogs displayed more than 1 of selectivity and some of them are even more 
than 100 of selectivity.  
 
Number 
(JCS-) 
Substitution 
R1 
Substitution 
R2 
Mtb IC50 
nM 
Human IC50 
nM 
Selectivity 
Human/Mtb 
TMQ H, C5-CH3 3,4,5-trimethoxy 17  16 1 
1381 no C-8 substitution 3,5-dimethoxy 240 240 1 
1502 C-8 bromo 3,4,5-trimethoxy 3900 470 0.1 
1425 H 3,5-dimethoxy 58 1300 22 
1573 2-F 3,5-dimethoxy 82 1540 19 
1568 2-CH3 3,5-dimethoxy 61 1930 32 
1552 3-OCH3 3,5-dimethoxy 32 1230 38 
1585 3-CH3 3,5-dimethoxy 49 5100 104 
1595 3-CF3 3,5-dimethoxy 230 1080 4.7 
1569 4-F 3,5-dimethoxy 51 1700 33 
1453 4-CH3 3,5-dimethoxy 33 850 26 
1553 4-OCH3 3,5-dimethoxy 94 1530 16 
1513 4-OCF3 3,5-dimethoxy 240 2330 9.7 
1601 2-
methylnaphthalene 
3,5-dimethoxy 89 1570 18 
1443 H 2,5-diethoxy 170 >>20000 >117 
1474 4-CH3 2,5-diethoxy 200 18000 75 
1521 H 3,4,5-trimethoxy 45 6400 142 
1594 H, N-2 Bn 3,5-dimethoxy 2090 15400 7.4 
1596 H, N-2 isobutyl 3,5-dimethoxy 1640 2940 1.8 
1623 3,5-dimethoxy 3,5-dimethoxy 37 840 23 
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ID (JCS-) Pf WT Pf QM Mtb DHFR 
human 
DHFR 
EC50 on Pf 
3D7 
MIC99 on 
mc27000 
TMQ 5 nM 6 nM 17 nM 16 nM n/a 5 μM 
1474 20 nM 70 nM 200 nM 18000 nM 650 nM 6.3 μM 
1425 3 nM 30 nM 58 nM 1320 nM 425 nM 1.6 μM 
1552 5 nM 40 nM 32 nM 1230 nM 125 nM 1.6 μM 
1569 7 nM 35 nM 60 nM 1700 nM 600 nM 3.1 μM 
1585 13 nM 60 nM 48 nM 5140 nM n/a 3.1 μM 
Table 4-3. The major C-8 benzyl TMQ analogs and their selectivity 
 
 
 
ID (JCS-) 
Ki Mtb DHFR 
(μM) 
Ki WT Pf DHFR 
(μM) 
Ki QM Pf DHFR 
(μM) 
Ki Human DHFR 
(μM) 
TMQ 0.0018 0.0012 0.0016 0.0011 
1474 0.020 0.0049 0.0194 1.18 
1425 0.0059 0.0012 0.0091 0.086 
1552 0.0032 0.0012 0.0114 0.081 
1569 0.0061 0.0013 0.0100 0.11 
1585 0.0048 0.0029 0.0168 0.34 
Table 4-4. Converted Ki values from IC50 for selected C-8 benzyl TMQ analogs. The Ki 
values has been calculated using BotDB (Cer, Mudunuri et al. 2009). Km values for dihydrofolate 
(DHF) were found from the following articles. 1) Mtb DHFR (4.5 μM), human DHFR (2.8 μM) 
(White, Ross et al. 2004), and 2) WT (13 μM) and QM (14 μM) Pf DHFR-TS  (Sirawaraporn, 
Sathitkul et al. 1997). 
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While the activities of the major compounds were derived (Table 4-2, 4-3, 4-4), 
several compounds were co-crystallized to obtain comparative structures from each of 
the four DHFR proteins. Between wild-type Pf DHFR-TS:TMQ and WT Pf DHFR-
TS:JCS-1474 the RMSD over 220 Cα carbons with 100% sequence identity was 0.36 Å. 
The RMSD between Mtb DHFR:TMQ and Mtb DHFR:JCS-1474 over 159 Cα carbons 
with 100% sequence identity was 0.48 Å. In Mtb DHFR, the greatest deviation was seen 
in the active site near the aniline moiety of TMQ (Leu50-Arg55). 
All 6 α carbons showed more than 1 Å deviation and the Cα of Lys53 showed 
more than 2 Å deviation. This same region was found to be the most flexible when 
comparing the binary complex of Mtb DHFR:NADPH with the ternary complex of Mtb 
DHFR:TMQ. In Pf DHFR-TS, the corresponding region (Ser111-Phe116) exhibited 
much less deviation and only two Cα carbons (Ser111 and Pro 113) showed more than 1 
Å deviation. Considering the sheer size of 2,5-diethoxy group attached to the aniline ring 
of JCS-1474, it was clear that Pf DHFR-TS has a larger substrate binding site than Mtb 
DHFR. The crystallographic data and the structure statistics of Mtb DHFR, WT Pf 
DHFR-TS, and QM Pf DHFR-TS bound with JCS-1474 structures are shown in the table 
4-5. 
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 Mtb:1474 (4MAW) WT Pf:1474 (4M7Q) QM Pf:1474 (4M8F) 
Space group P1 P212121 P212121 
Unit cell dimension 36.68, 66.15, 69.63 (Å) 57.49, 156.42, 165.98 56.99, 156.09, 165.60 
 93.76, 94.48, 100.61 (o) 90.00, 90.00, 90.00 90.00, 90.00, 90.00 
Resolution (Å) 45.47-2.01  
(2.09-2.01) 
50.00-2.62  
(2.67-2.62)  
49.66-2.80 
(2.85-2.80) 
Rsym 0.069 (0.203) 0.208 (0.771) 0.142 (0.685) 
I/σ 6.7 (2.4) 11.9 (9.6) 6.4 (1.7) 
Completeness (%) 93.4 (89.8) 99.8 (99.2) 96.1 (82.3) 
Redundancy 2.15 (2.12) 7.1 (6.6) 5.5 (3.1) 
# of reflections 39516 43303 38282 
Rwork/Rfree 23.1/29.4 20.2/25.9 19.7/25.7 
# of atoms – Protein 4976 9076 9053 
  Ligand/Ion 328 204 186 
Water 439 291 14 
B factor – Protein 28.5 54.6 51.1 
Ligand/Ion 28.0 48.1 52.4 
Water 32.5 44.7 34.5 
RMSD – length 0.005 0.004 0.005 
angle 0.749 0.642 0.726 
Table 4-5. Crystallographic data and structure statistics for Mtb DHFR and WT Pf DHFR-
TS, and QM Pf DHFR-TS bound with JCS-1474 
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Figure 4-19. The important conserved interactions between JCS-1569 and WT Pf DHFR. 
As in other structures, 2,4-diaminoquinazoline ring has all the major interactions with WT Pf 
DHFR. One of the noticeable differences is that the fluoride atom is about 3 Å away from the 
oxygen atom of the methoxy group of the aniline ring. Met55 flipped down to accommodate the 
C-8 benzyl group of JCS-1569. 
 
 
 
Another C-8 benzyl TMQ analog we have structures in both WT and QM Pf 
DHFR is JCS-1569. When we checked the WT Pf DHFR:JCS-1569 crystal structure, it 
has much similarity in regard to the major interactions between the compound and the 
protein (Figure 4-19). Similar to Mtb DHFR:TMQ or WT Pf DHFR:TMQ structures, the 
2,4-diaminoquinazoline ring of JCS-1569 also has well-conserved hydrogen bond 
interactions with WT Pf DHFR. This WT Pf DHFR structure bound with JCS-1569 
displayed the well-conserved hydrogen bonding interactions between WT Pf DHFR and 
JCS-1569 similar to TMQ bound WT Pf DHFR structure. Asp54, corresponding to 
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Asp27 in Mtb DHFR, has two hydrogen bonding interactions with 2-amino group and N-
1 nitrogen with the distances of 2.77 Å and 2.80 Å, respectively. Both distances are 
significantly longer than in WT Pf DHFR:TMQ structure. Asp54 further forms the 
hydrogen bonding network with Thr185 and the distance is 2.95 Å. Thr185 has another 
hydrogen bonding network with 2-amino group of the quinazoline ring of JCS-1569 via 
a water molecule, and the distance between Thr185 and this water molecule is 2.73 Å 
and the distance between this water molecule and the 2-amino group of JCS-1569 is 3.36 
Å. This water molecule further forms additional hydrogen bonding interaction with the 
main chain carbonyl group of Tyr183, and the distance between the two is 2.87 Å.  
For 4-amino group of the 2,4-diaminoquinzaoline ring of JCS-1569 has three 
hydrogen bonding interactions with the main chain carbonyl group of Ile14, with the 
main chain carbonyl group of Ile164, and with the carbonyl group of Tyr170. The 
distances between the 4-amino group and those residues are 2.57 Å, 2.79 Å, and 2.69 Å, 
respectively. All of the three distances are shorter than the ones in WT Pf DHFR:TMQ 
structure, yet JCS-1569 lost more than 4 fold of potency as was seen in Mtb DHFR, and 
this could indicate that these three hydrogen bond interactions are either not in the 
favorable angles or not so significant to the overall interaction between WT Pf DHFR 
and JCS-1569 and other C-8 benzyl TMQ analogs. 
For the 3,5-dimethoxyaniline ring side, the carbon atom of 3-methoxy group is in 
close proximity with Leu119 with the distance of 3.55 Å . The oxygen atom of this 3-
methoxy group has potential hydrogen bonding interaction with the distance of 3.15 Å. 
The 1-carbon atom of the 3,5-dimethoxyaniline ring is in close proximity with the 
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carbon atom of Ile112 with the distance of 3.54 Å . The carbon atom of 5-methoxy group 
is in close proximity with Pro113, and the distance between the two is 3.43 Å. The C-8 
benzene ring has pi stacking interaction with Met55 with the distance of 3.74 Å. 
Although these methoxy groups are not technically in hydrogen bonding interactions 
with WT Pf DHFR residues, they represent a potential venue for enhancing the 
interactions with DHFR. Also, unlike some other structures, there is no available 
interaction on the nitrogen atom of the aniline ring. 
 
 
 
 
Figure 4-20. The important conserved interactions between JCS-1569 and QM Pf DHFR. 
As in other structures, 2,4-diaminoquinazoline ring has all the major interactions with QM Pf 
DHFR.  
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As previously stated, JCS-1569 bound structure was elucidated in QM Pf DHFR 
as well. When we checked the QM Pf DHFR:JCS-1569 crystal structure, which were 
grown from a different condition than Mtb DHFR or WT Pf DHFR structures, this 
structure has much similarity in the major interactions between the compound and the 
protein (Figure 4-20). Similar to Mtb DHFR:TMQ or WT Pf DHFR:TMQ structures, the 
2,4-diaminoquinazoline ring of JCS-1569 has well-conserved hydrogen bond 
interactions with QM Pf DHFR as well. This QM Pf DHFR structure bound with JCS-
1569 displayed the well-conserved hydrogen bonding interactions between QM Pf 
DHFR and JCS-1569 similar to TMQ bound WT or DM Pf DHFR structure. Asp54, 
corresponding to Asp27 in Mtb DHFR, has two hydrogen bonding interactions with 2-
amino group and N-1 nitrogen with the distances of 2.82 Å and 2.98 Å, respectively. 
Asp54 further forms the hydrogen bonding network with Thr185 and the distance is 3.04 
Å. Thr185 has another hydrogen bonding network with 2-amino group of the 2,4-
diaminoquinazoline ring of JCS-1569 via a water molecule, and the distance between 
Thr185 and this water molecule is 2.87 Å, and the distance between the water molecule 
and the 2-amino group of JCS-1569 is 3.53 Å. This water molecule further forms 
another hydrogen bond interaction with the main chain carbonyl group of Tyr183 with 
the distance of 2.80 Å .  
For 4-amino group of the 2,4-diaminoquinzaoline ring of JCS-1569 has three 
hydrogen bonding interactions with the main chain carbonyl group of Ile14, with the 
main chain carbonyl group of Ile164, and with the carbonyl group of Tyr170. The 
distances between the 4-amino group and those residues are 2.70 Å, 2.71 Å, and 2.81 Å, 
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respectively. All of the three distances are significantly shorter than the ones in QM Pf 
DHFR:TMQ structure and even shorter than QM Pf DHFR:JCS-1552 structure, yet JCS-
1569 lost potency compared to QM Pf DHFR:TMQ as in Mtb DHFR or WT Pf DHFR, 
and this could indicate that, due to C-8 benzyl group in JCS-1569, these three hydrogen 
bond interactions are either not in the favorable angles or not so significant to the overall 
interaction between QM Pf DHFR and JCS-1569. 
For the 3,5-dimethoxyaniline ring side, there are no actual hydrogen-bonding 
interactions just as WT or DM Pf DHFR. One possible interaction is the one between the 
oxygen atom of Asn108 and the nitrogen atom of the 3,5-dimethoxyaniline ring, and the 
distance between the two is 3.77 Å. However, there are some noticeable residues that are 
within the close proximity. The aniline nitrogen has a possible hydrogen bond 
interaction with the oxygen of Asn108 with the distance of 3.77 Å . The oxygen atom of 
3-methoxy group is in close proximity with Leu119 with the distances of 3.78 Å, and the 
carbon atom of the 3-methoxy group is in close proximity with Phe116 with the distance 
of 3.57 Å . The oxygen atom of 5-methoxy group is in close proximity with Pro113 and 
the distance between the two is 3.07 Å. Although these methoxy groups do not have 
hydrogen bonding interactions with QM Pf DHFR-TS, they represent a potential venue 
for enhancing the interactions with DHFR.  
C-8 benzyl group of JCS-1569 has some additional interactions. The C-8 benzyl 
group has probable pi stacking interaction with Met55 and the distance between the two 
is 3.65 Å. This C-8 benzyl group has another pi-pi stacking interaction with the aniline 
ring, and the distance between the two rings is 3.24 Å. The 4-fouride group on the C-8 
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benzene ring is 3.22 Å away from the 4-position of the aniline ring, and this potential 
interaction could be taken advantage of in the further development of selective inhibitors. 
Two of the most important residues to the potency of the C-8 benzyl-2,4-
diaminoquinazoline TMQ analogs are Asp27 and Phe31 in Mtb DHFR (Asp54 and 
Phe58 in Pf DHFR-TS). These two residues are conserved in many DHFRs as Asp27 is 
the acid for the last step of the DHFR enzymatic reaction, donating a hydrogen ion to the 
substrate to generate tetrahydrofolate (THF). Asp27 makes two hydrogen bonds with the 
nitrogen and the amino group in the 2,4-diaminoquinazoline ring of the TMQ analogs. 
Phe31 makes a pi-pi stacking interaction with the aromatic ring of the quinazoline. In 
human DHFR, these residues are Glu30 and Phe34, and they retain the same interactions. 
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Figure 4-21. Role of the flexibility of Gln28 (Mtb DHFR, top) and Met55 (Pf DHFR, 
bottom). The residues are shown in the JCS-1474 bound structures. DHFR:TMQ 
is in gray in both figures, Mtb DHFR:JCS-1474 is in blue, and QM Pf DHFR-
TS:JCS-1474 is shown in plum. Mtb DHFR exhibited more deviation when JCS-
1474 is bound compared to QM Pf DHFR-TS. Gln28 in Mtb DHFR and Met55 in 
Pf DHFR-TS displayed most dramatic changes of orientation, and Asp27 position 
is clearly different in Mtb DHFR unlike Pf DHFR-TS. 
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Our initial modification of the benzyl group resulted in surprisingly little 
conformational changes to the active site despite the differences in activity. According to 
the superimposed crystal structures of Mtb DHFR:1474 and human DHFR:1502, the 
selectivity gain is a result of the loss of potency on the human DHFR. The human DHFR 
Phe31 and the corresponding Mtb DHFR Gln28 and Pf DHFR-TS Met55 were the only 
real sites of change (Figure 4-21, 4-22).  
 
 
 
 
Figure 4-22. Superposed structures of human DHFR:JSF-1502 (blue) and QM Pf 
DHFR:JSF-1552. 3-methoxy group (3 position is at the arrow) of C-8 benzyl in 
JSF-1552 would have closer contact with human DHFR Phe31 compared to 4-
methoxy group. The in-depth study should be done on the positional effect of the 
substituent on C-8 benzyl group, yet it is at least clear that 3-postion of C-8 benzyl 
group is closer to the Phe31 or other residue at that position than 4-position of C-8 
benzyl group. 
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This might lead to the lower potency of the 3-methyl (JCS-1585) in human DHFR, 
compared to the 2-methyl (JCS-1568) or the 4-methyl group (JCS-1453). There should 
be a lot of more structure-activity relationship experiments on this before drawing any 
conclusion on the effect of the substitution on C-8 benzyl group, it still can be said 3-
position of the C-8 benzyl group could bring the closest contact with Phe31 in human 
DHFR.  
In the human DHFR the C-8 benzyl group is unable to maintain close contact with 
Phe31 and Leu22 because there is insufficient space for the residues to move and 
accommodate the C-8 benzyl moiety. In all the C-8 benzyl TMQ structures, Gln28 of 
Mtb DHFR lies lower and aligns almost parallel to the C-8 benzyl group allowing it 
ample space and effective interaction at the same time. Met55 in Pf DHFR-TS plays the 
same role in the C-8 benzyl-2,4-diaminoquinazoline TMQ bound structures. The side 
chain of Met55 rotates away from the C-8 benzyl group to allow enough room for the 
compound to sit in the pocket. The human DHFR Phe31 has a much lower degree of 
freedom than the Mtb DHFR Gln28 because of 1) the small pocket size of human DHFR 
compared to Mtb or Pf DHFR-TS, 2) Phe31 has only one virtual axis to rotate on 
compared to two in Pf Met55 and Mtb Gln28, and 3) the bulkier phenyl group in Phe31. 
The size of the C-8 benzyl group prevents Phe31 in the human DHFR from flipping 
because of the little rotational freedom and smaller space compared with Mtb or Pf 
DHFR. The restricted rotational freedom of Phe31 also comes in to play in the human 
DHFR:JCS-1502 structure. The phenylalanine ring positions between the C-8 bromo 
group and the aniline ring of TMQ analog. Phe31’s rotation is blocked by Arg28, Pro26, 
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and Gln35. Gln35 is also located in a more rigid and crowded area, leaving no room for 
Phe31 to rotate away from the C-8 benzyl group. In all the elucidated structure, C-8 
benzyl analogs have the similar orientation in the active site (Figure 4-22). The 
crystallographic data is also available in Table 4-6. 
 
 
 
 
Figure 4-23. Superimposed structure of three C-8 benzyl TMQ analogs. JCS-1474 (Gray), 
JCS-1569 (Gold), and JCS-1552 (Cyan) have the same conformation in the active site. Asp54 
and Met55 are shown together. 
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 WT Pf:1569 (4M6C) QM Pf:1552 (4MA2) QM Pf:1569 (4M8P) 
Space group P212121 P212121 P212121 
Unit cell dimension 
56.69, 155.78, 165.01 (Å) 58.75, 157.05, 166.39 56.81, 155.66, 165.11 
 90.00, 90.00, 90.00(o) 90.00, 90.00, 90.00 90.00, 90.00, 90.00 
Resolution (Å) 49.53-2.28 
(2.32-2.28) 
47.96-2.71 
(2.76-2.71) 
49.50-2.53 
(2.57-2.53) 
Rsym 0.091 (0.509) 0.116 (0.502) 0.140 (0.703) 
I/σ 10.3 (3.8) 11.0 (5.4) 9.5 (2.8) 
Completeness (%) 99.9 (100.0) 95.4 (87.9) 97.9 (90.7) 
Redundancy 7.4 (7.5) 5.3 (4.1) 6.4 (4.3) 
# of reflections 67011 58326 50972 
Rwork/Rfree 19.9/23.1 20.5/26.9 18.8/24.1 
# of atoms – Protein 9127 9053 9061 
Ligand/Ion 165 191 196 
Water 370 169 381 
B factor – Protein 56.4 66.2 54.2 
Ligand/Ion 47.2 67.4 49.9 
Water 49.3 48.4 45.2 
RMSD – length 0.005 0.005 0.005 
angle 0.694 0.672 0.678 
Table 4-6. Crystallographic data and structure statistics for WT Pf DHFR-TS and QM Pf 
DHFR-TS bound with C-8 benzyl TMQ analogs, JCS-1552 and JCS-1569. 
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The crystallographic data and the structure statistical values for WT and QM Pf 
DHFR-TS bound with two of the C-8 benzyl TMQ analogs, JCS-1552 and JCS-1569 are 
listed in the table 4-6. Introducing a methyl group to the C-8 benzene ring resulted in 
increased selectivity. The 2-methyl (JCS-1568) and 4-methyl (JCS-1453) groups 
modestly raised selectivity by 32 fold and 26 fold. The 3-methyl group (JCS-1585) 
drastically boosted selectivity by 104 fold in Mtb DHFR. According to the crystal 
structure, the 3-methyl group restricts the rotational freedom of the benzyl group 
compared to the 2-methyl group, contributing to the increased selectivity. However, the 
4-methyl group (IC50 = 33 nM) is more potent than the 3-methyl group (IC50 = 49 nM). 
The 4-methoxy group (JCS-1553) decreased the selectivity to 16 fold, whereas the 3-
methoxy group (JCS-1552) increased selectivity up to 38 fold. In the superimposed 
structure of human DHFR:JCS-1502 and QM Pf DHFR-TS:JCS-1552, it is clear that 
steric hindrance from Phe31 of the human DHFR interferes with the C-8 benzyl ring of 
Pf DHFR, and the closest contact is at the 3-position of the C-8 benzene ring (Figure 4-
23).  
Electronic effect could be seen in the –CH3 and –CF3 comparison. When the 
hydrogen molecules of the CH3 group in JCS-1585 were substituted with the fluoride 
molecules of JCS-1595, the potency against Mtb DHFR dropped five fold. To a lesser 
extent, this was also seen with JCS-1553 and JCS-1513. When the hydrogen of the 
methoxy group in JCS-1553 was substituted with the fluoride to make the 
trifluoromethoxy group in JCS-1513, the potency decreased two fold. This could be 
explained by the electronic effect of the fluoride group. The fluoride, which is an 
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electron-withdrawing group, lowered the electron density in the C-8 benzyl and the pi-pi 
stacking interaction with Gln28. The intensity of the pi-pi stacking interaction with the 
aniline ring in the same molecule decreased as well. When compared to hydrogen, the 
greater size of the fluoride could also contribute to the potency loss. 
When the DHFR crystal structures bound with TMQ and the C-8 benzyl-2,4-
diaminoquinazoline TMQ analogs are superimposed, the effect of the C-8 benzyl moiety 
on selectivity can be explained. In the Mtb DHFR structure with JCS-1474, which has a 
4-methylbenzyl group bound to C-8 position of quinazoline ring, the benzyl group 
occupies the same pocket as water or acetate molecule does in the TMQ bound structure. 
Gln28 (Met55 in Pf DHFR-TS) is pushed down to allow the C-8 benzyl group to sit near 
the pocket so that Gln28, the C-8 benzyl ring, and the aniline ring of TMQ align with 
each other so that the interaction with each other is available. Gln28 in Mtb DHFR and 
Met55 in Pf DHFR-TS align parallel to the C-8 benzyl group enabling the hydrophobic 
interaction.  
One of the driving forces stabilizing the C-8 benzyl compounds in the pocket of 
the pathogenic DHFRs is the pi-pi stacking interaction between the C-8 benzyl ring and 
the aniline ring. In the QM Pf DHFR-TS:JCS-1474 and Mtb DHFR:JCS-1474 structures, 
the distances between these two rings is 3.6 Å and this distance allows a favorable 
interaction between the two rings. Mtb DHFR Gln28 and Pf DHFR-TS Met55 offer 
additional van der Waals interactions with the C-8 benzyl ring. 
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It was found that there was about 20o of distortion of the 2,4-diaminoquinazoline 
ring of the C-8 benzyl TMQ analogs, compared to the same ring in the Mtb DHFR:TMQ 
structure or Pf DHFR-TS:TMQ structures (Figure 4-24). This distortion significantly 
forced the 2,4-diaminoquinazoline ring of the C-8 benzyl TMQ analogs to position in the 
non-optimal position compared to Mtb DHFR:TMQ and caused the compounds to 
interact with Asp27 and Phe31 (Asp54 and Phe58 in Pf DHFR-TS) unfavorably. 
However, this distortion gave more space to C-8 benzyl TMQ analogs and allowed a 
better arrangement of the C-8 benzyl moiety in the active site, subsequently allowed a 
much better interaction with Gln28 of Mtb DHFR (Met55 of Pf DHFR-TS) and with the 
aniline ring in the same molecule.  
The distortion angle ranged from 19o to 21o, and the distortion is observed in all 
C-8 benzyl-2,4-diaminoquinazoline analogs. From the crystal structures of QM Pf 
DHFR-TS:TMQ, the distances between Met55 and N1 and the nitrogen of the 2-amino 
group of the quinazoline ring are 2.84 Å and 2.87 Å, respectively. The same distances in 
QM Pf DHFR-TS:JCS-1474 are 3.04 Å and 2.94 Å. The loss of optimal interaction with 
DHFR is compensated by the extra interactions of the aniline:C-8 benzyl and the C-8 
benzyl:Met55 in Pf DHFR-TS (Gln28 in Mtb DHFR). In Pf DHFR-TS, the Met55 has an 
additional interaction with Cys50. 
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Figure 4-24. Distortion in C-8 benzyl TMQ analogs. 2,4-diaminoquinazoline ring distortion is 
shown in the superimposed structure of Mtb DHFR:TMQ (gray) and Mtb DHFR:JCS-1474 
(blue). From both front view (left) and top view (right), the quinazoline ring distortion is clearly 
observable. The distortion angle is about 20 degrees in Mtb DHFR, WT Pf DHFR-TS, and QM 
Pf DHFR-TS. Still, as seen in the picture Mtb DHFR displayed the greatest deviation from TMQ 
bound structure. 
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In Mtb DHFR, Arg23 is in close contact with the C-8 benzyl moiety and allowed 
extra interaction. In the Mtb DHFR:JCS-1474 structure, the distance between Arg23 and 
the ethyl group of the aniline moiety is 3.10 Å. In some structures, the density for Arg23 
is faint or missing, suggesting that Arg23 is flexible in the protein. Unlike Arg23 in Mtb 
DHFR, the corresponding Lys49 in Pf DHFR-TS stretches toward the surface, and 
instead, Cys50, whose counterpart residue is not present in Mtb DHFR, covers Arg23’s 
position. Cys50 has a hydrogen bond with Met55 at a distance of 3.28 Å. In addition to 
this interaction, Phe116 is in close contact with the aniline moiety of the compound in Pf 
DHFR-TS.  
It is necessary to mention the effect of different functionalities on the aniline ring, 
specifically the 2,5-ethoxy group. Da Cunha et al. pointed out in their 2,5-substituted 
aniline experiments that 2,5-diethoxy group exhibited much greater selectivity compared 
to 2,5-dimethoxy counterpart (da Cunha, Ramalho et al. 2008). In our C-8 benzyl TMQ 
compounds displayed the similar trends.  
Both JCS-1443 and JCS-1474, which have 2,5-diethoxybenzyl group instead of 
3,5-dimethoxybenzyl, exhibited greater selectivity when compared with their 3,5-
methoxy counterparts, JCS-1425 and JCS-1453. JCS-1443 lost about 3 fold potency on 
Mtb DHFR (IC50 = 170 nM) compared to its 3,5-dimethoxyaniline counterpart, JCS-
1425 (IC50 = 60 nM). However, JCS-1443 lost more than 15 fold potency on human 
DHFR (IC50 > 20,000 nM) compared to its 3,5-dimethoxyaniline counterpart, JCS-1425 
(IC50 = 1300 nM). In the superimposed structure of Mtb DHFR:JCS-1425 and Mtb 
DHFR:JCS-1443, bulkier 2,5-diethoxy substituent on the aniline ring pushes the loop 
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region (Pro51-Gly59) away from the active site. Also C-8 benzene ring position is 
different in those two structures.  
Due to the challenges of synthesis, there are only two compounds available to 
compare the effect of the 2,5-alkyloxy substitution on the aniline ring, and a conclusive 
effect remains to be seen. However, when compared with the 3,5-dimethoxyaniline, it is 
still apparent that the 2,5-ethoxy group has a positive effect on selectivity gain. 
According to the superimposed structures of human DHFR:JCS-1502 and Mtb 
DHFR:JCS-1474, the bulky 2,5-diethoxy groups of JCS-1474 could be affected more by 
Ile60 and Asn64 in human DHFR. These residues correspond to Leu50 and Val54 in 
Mtb DHFR, and these smaller residues could allow more space for the bulky 2,5-
diethoxy group. 
A couple of N-2 of quinazoline ring modification has been tried to evaluate the 
effect of substitution on the N-2 position.  For the TMP analogs, methyl- (JCS-1168) and 
ethyl- (JCS-1169) exhibited great selectivity. In TMQ analogs, the effect of N-2 
modification is smaller than TMP analogs. Also due to the difficulty of synthesis, not too 
many compounds can be synthesized.  
Two TMQ analogs with N-2 substitution were synthesized. JCS-1594 is 
containing N-2 benzyl group and JCS-1596 has N-2 isobutyl group. The IC50 values on 
Mtb DHFR and human DHFR of JCS-1594 are 2090 nM and 15400 nM, respectively, 
and the IC50 values on Mtb DHFR and human DHFR of JCS-1596 are 1640 nM and 
2940 nM, respectively. The selectivity of JCS-1594 is better than JCS-1596, but JCS-
1596’s potency on Mtb DHFR is slightly better than JCS-1594. Still, the potency in 
 137 
 
general was much too low compared other C-8 benzyl TMQ compounds and the detailed 
effects of N-2 substitution largely remain to be seen.  
Several C-8 benzyl-2,4-diaminoquinazoline TMQ analogs were tested on mc27000, 
a vaccine strain of M. tuberculosis. The minimal inhibitory concentration (MIC99) values 
ranged from 1.5 μM to 6 μM and show good potency compared to TMQ, whose MIC is 
5 μM (Figure 4-25).  
 
 
 
 
Figure 4-25. EC50 of C-8 benzyl TMQ on wild type P. falciparum (3D7) 
 
 
 
Four of the C-8 benzylquinazoline TMQ analogs, JCS-1425, JCS-1474, JCS-1552, 
and JCS-1569, were tested on the wild-type (WT) P. falciparum 3D7 strain thanks to the 
collaboration of Dr. Van Voorhis lab. The EC50 values ranged from 100 nM to 650 nM, 
and JCS-1552 exhibited the highest potency on the WT P. falciparum strain. 
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MIC values on mc27000 and EC50 values on the WT P. falciparum 3D7 strain 
agreed with the IC50 values from the enzyme assay. For example, JCS-1552, which has 
the strongest potency in the enzyme assay, exhibited the best MIC and EC50 values with 
1.6 μM and 125 nM, respectively. This JCS-1552 retained significant degree of the 
potency even on the low concentration of 1 uM unlike other compounds. On the other 
hand, JCS-1474, which has the lowest IC50 on the in-vitro enzyme assay, also displayed 
the lowest EC50 values on this test, yet the difference from the other compounds was not 
large compared to the enzyme assay. 
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CHAPTER V 
 
VALIDATION STUDY ON S. AUREUS DHFR 
 
V.1. Validation Study of C-8 Benzyl TMQ’s Potential for the Broad Spectrum Selective 
Antimicrobial on Staphylococcus aureus Dihydrofolate Reductase 
 
In this last chapter, we will discuss the effort we put in to broaden the application 
of our C-8 benzyl TMQ analogs toward the broad-spectrum selective 
antimicrobial/antibiotic. In fact, quite a few drugs are working on multiple species or 
diseases, yet it is not easy to find the ones that exclusively work on pathogens. Recent 
surge of infection rate or persistency that is drastically shown in the case of M. 
tuberculosis presses the urgency even greater.  
Staphylococcus aureus is one of the well-known pathogens and it causes 
infections mainly in the hospital in the past. However, there has been increasing number 
of reports of community-based infection of this pathogen and the emergence of 
methicillin-resistant mutant S. aureus made it more difficult to treat this infection. 
Therefore, just like tuberculosis or malaria, there is an urgent need for selective 
treatment for this pathogen. 
Staphylococcus aureus DHFR is similar to M. tuberculosis DHFR in many ways 
including the fact that they both have 159 residues and the active site, specifically 
substrate binding site, has similar conformation.  
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The important commonality for selectivity of M. tuberculosis DHFR and P. 
falciparum DHFR, a pocket like the glycerol binding pocket in Mtb DHFR and a flexible 
residue next to Aspartate, also partially present in S. aureus DHFR as well. This is 
partial because the flexible residue in Sa DHFR is Leu28, which has only one rotational 
axis yet much smaller than Phe31 in human DHFR. 
The overall structure of Mtb DHFR and Sa DHFR is very similar. In the 
superimposed structure of Mtb DHFR:TMQ and WT Sa DHFR:TMQ revealed that the 
two DHFRs have almost identical β-sheets and α-helices in the structure. The 
differences come mainly from the loop regions. Even though there was no water 
molecule or acetate or other molecule was found in Sa DHFR structure, there clearly is 
some space available corresponding to the glycerol binding pocket in Mtb DHFR 
structure. This similarity makes Sa DHFR a legitimate comparison for Mtb and Pf 
DHFR to evaluate the possibility for C-8 benzyl TMQ analogs’ use of broad-spectrum 
selective antimicrobial.  
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Figure 5-1. The important conserved interactions between TMQ and WT Sa DHFR. It is 
clear that 3,4,5-trimethoxyaniline ring is almost no interaction unlike Mtb DHFR or Pf DHFR-
TS. This solvent access area is much wider than Mtb DHFR or Pf DHFR-TS, and that is why Sa 
DHFR is more susceptible to the mutation and to the potency loss as a result. The hydrogen bond 
interactions on 2,4-diaminoquinazoline ring side are well conserved.  
 
 
 
Similar to Mtb DHFR:TMQ structure, the 2,4-diaminoquinazoline ring of TMQ 
has well-conserved hydrogen bond interactions with WT Sa DHFR (Figure 5-1). This 
WT Sa DHFR structure bound with TMQ displayed the well-conserved hydrogen 
bonding interactions between WT Sa DHFR and TMQ similar to Mtb DHFR:TMQ 
structure. Asp27 (corresponding to Asp27 in Mtb DHFR) has two hydrogen bonding 
interactions with 2-amino group and N-1 nitrogen of the quinazoline with the distances 
of 2.91 Å and 2.45 Å, respectively. Asp27 further forms the hydrogen bonding network 
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with Thr111 and the distance is 2.71 Å. Thr111 has another hydrogen bonding network 
with 2-amino group of the quinazoline ring of TMQ via water molecule and the distance 
between Thr111 and this water molecule is 2.95 Å and the distance between the water 
molecule and nitrogen of the 2-amino group is 2.83 Å.  
For 4-amino group of the 2,4-diaminoquinzaoline ring of TMQ has two hydrogen 
bonding interactions with the main chain carbonyl group of Leu5, and with the main 
chain carbonyl group of Phe92. The distances are 2.79 Å, and 2.79 Å, respectively. 
Unlike Mtb DHFR or Pf DHFR-TS, WT Sa DHFR has Phe98 and it is far apart from the 
4-amino group with the distance of 4.49 Å. 5-methyl group on the 2,4-
diaminoquinazoline ring is 3.83 A away from Thr46. Though there is no hydrogen bond 
interaction is available with Thr46, a proper modification on 5-methyl group, such as 
carbonyl, could bring additional hydrogen bond interaction with Thr46. 
For the 3,4,5-trimethoxyaniline ring side, there are no actual hydrogen-bonding 
interactions. It remains to be seen how this large and wobbly hole could sustain TMQ so 
tightly (IC50 = 2.5 nM), and one clue could come from Ser49. This Ser49 forms a 
hydrogen bond network with nitrogen atom of the 3,4,5-trimethoxyaniline ring via water 
molecule. The distance between Ser49 and the water molecule is 2.49 Å, and the 
distance between the water molecule and the nitrogen atom of the aniline ring is 2.82 Å. 
This additional hydrogen bond which is not observed in Mtb DHFR of Pf DHFR is the 
reason why TMQ has comparable, if not better, IC50 against Sa DHFR. 
A very important difference was found near the 3,4,5-trimethoxyaniline ring of 
TMQ is located in the active site (Figure 5-2). The two 3,4,5-trimethoxybenzene ring in 
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Mtb DHFR and WT Sa DHFR displayed significantly different position, and the extra 
interaction with Arg23 in Mtb DHFR is not feasible with the His23 in Sa DHFR in the 
same position. For Sa DHFR, the solvent access from the 3,4,5-trimethoxybenzene side 
is much wider and probably easier to lose activity with a conformational change. Even 
though Leu28 and Ile50 give hydrophobic interaction, they are more inside compared to 
Arg23 and Pro51 in Mtb DHFR, and it is more probable for Sa DHFR to be more 
sensitive to the conformational changes compared to Mtb DHFR or Pf DHFR-TS. That 
is one of the reasons why just a single mutation, F98Y, affect significantly on the 
potency loss compared to the quadruple mutant of P. falciparum DHFR-TS. 
 
 
 
 
Figure 5-2. Overview of the superimposed structure of Mtb DHFR:TMQ (blue) and WT Sa 
DHFR:TMQ. The zoomed view on the helix containing loop region (Ile50-Arg58 
in Sa DHFR) that is close the trimethoxybenzene side of TMQ. This region showed 
the only significant difference close to the active site from Mtb DHFR. 
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In Pf DHFR-TS, there was no noticeable IC50 decrease for TMQ in the QM Pf 
DHFR-TS (6 nM) compared to wild type (5 nM). Even for the C-8 benzyl TMQ analogs, 
10 fold loss of potency in JCS-1425 was the greatest among all the analogs. 
However, in Sa DHFR, there was a drastic potency (IC50) loss on TMQ itself from 
2.5 nM in WT Sa DHFR to 55 nM in F98Y SM Sa DHFR, and this is more than 20 fold 
loss of potency. For C-8 benzyl TMQ analogs, the potency loss in F98Y SM Sa DHFR 
was greater than QM Pf DHFR-TS. 
 
 
 
 
Figure 5-3. The important conserved interactions between F98Y Sa DHFR and TMQ. As in 
the wild type, 3,4,5-trimethoxyaniline ring has no significant interaction with the protein and 
stay loose. Compared to wild type, Tyr98 offers additional hydrogen bond, yet two water 
molecules that were formed hydrogen bond network in the wild type are missing in the mutant. 
Those two weakened interactions along with the unveiled reasons caused potency loss in F98Y 
Sa DHFR.  
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In the F98Y Sa DHFR, we could see the similar interactions between TMQ and 
the protein (Figure 5-3). Similar to WT Sa DHFR:TMQ structure, the 2,4-
diaminoquinazoline ring of TMQ has well-conserved hydrogen bond interactions with 
F98Y Sa DHFR. This F98Y Sa DHFR structure bound with TMQ displayed the well-
conserved hydrogen bonding interactions between F98Y Sa DHFR and TMQ similar to 
WT Sa DHFR:TMQ structure. Asp27 (corresponding to Asp27 in Mtb DHFR) has two 
hydrogen bonding interactions with 2-amino group and N-1 nitrogen of the quinazoline 
with the distances of 3.17 Å and 2.88 Å, respectively. Asp27 further forms the hydrogen 
bonding network with Thr111 and the distance is 2.89 Å. Thr111 has another hydrogen 
bonding network with 2-amino group of the quinazoline ring of TMQ and the distance 
between Thr111 and the nitrogen of the 2-amino group is 3.54 Å .  
For 4-amino group of the 2,4-diaminoquinzaoline ring of TMQ has three hydrogen 
bonding interactions with the main chain carbonyl group of Leu5, and with the main 
chain carbonyl group of Phe92, and with Tyr98. The distances between the protein and 
the main chain carbonyls of Leu5 and Phe92 are 2.88 Å, and 2.75 Å, respectively. 
Unlike WT Sa DHFR, F98Y Sa DHFR has Tyr98 and it is a little bit far apart from the 
4-amino group with the distance of 3.60 Å, but it is still much closer than the Phe98 in 
WT Sa DHFR whose distance from the 4-amino group is 4.49 Å. 5-methyl group on the 
2,4-diaminoquinazoline ring is 3.73 A away from Thr46. Though there is no hydrogen 
bond interaction is available with Thr46 similar to WT Sa DHFR, a proper modification 
on 5-methyl group, such as carbonyl, could bring additional hydrogen bond interaction 
with Thr46. 
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For the trimethoxyaniline ring side, there are no significant hydrogen-bonding 
interactions. The only probable hydrogen bond interaction came from Ser49. This Ser49 
forms a hydrogen bond with nitrogen atom of the 3,4,5-trimethoxyaniline ring with the 
distance of 3.91 Å. This interaction is much weaker compared to the hydrogen bond 
network via water molecule found in the WT Sa DHFR:TMQ structure. This weakened 
interaction might be the reason for TMQ’s drastic potency loss in F98Y Sa DHFR (IC50 
= 55 nM). 
Phe98 in Sa DHFR and Tyr100 in Mtb DHFR make an interesting comparison 
because the mutation arose in Phe98 to Tyrosine, and that mutation makes the position 
exactly the same as Mtb DHFR. Still, the drastic potency loss occurred. While the exact 
reason(s) for the drastic activity loss of TMQ and C-8 benzyl TMQ analogs in F98Y SM 
Sa DHFR remain to be seen, yet the probable reasons could be deduced from F98Y Sa 
DHFR:TMQ structure and WT Sa DHFR:JCS-1474 structure.  
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Figure 5-4. Superimposed structure of WT Sa DHFR:TMQ (Khaki) and F98Y SM Sa 
DHFR:TMQ. The two structures showed high similarity in the overall folding and 
the greatest deviation came from a loop region, Thr63-Gly72. The solvent accessible 
area of the substrate binding site where TMQ is bound is significantly larger than 
Mtb DHFR of Pf DHFR-TS. 
 
 
 
In the superimposed structure of WT Sa DHFR:TMQ and F98Y SM Sa 
DHFR:TMQ (Figure 5-4), it is not easy to figure out the reason for the drastic loss of 
TMQ’s activity on F98Y Sa DHFR. Other than a loop region of Thr63-Gly72, where the 
greatest deviation was observed, the two structures are almost identical. Furthermore the 
Thr63-Gly72 loop region is more than 10 Å away from TMQ in the active site. It was 
completely out of our expectation in the sense that there was about 20 fold loss of 
activity in terms of IC50 of C-8 benzyl TMQ analogs due to this seemingly small change 
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in F98Y Sa DHFR. Though more in depth study should be done for the reason for this 
significant loss of activity on F98Y Sa DHFR, yet they are still active compared to 
human DHFR counterparts (Table 5-1). 
 
 
 
 IC50 WT Sa DHFR 
(nM) 
IC50 F98Y Sa DHFR 
(nM) 
IC50 human DHFR 
(nM) 
TMQ 2.5 55 16 
JCS-1425 18 350 18000 
JCS-1474 95 760 1320 
JCS-1552 10 200 1230 
JCS-1569 17 340 1700 
JCS-1585 35 450 5140 
Table 5-1. IC50 values of the major C-8 benzyl TMQ analogs and TMQ on WT and F98Y 
Sa DHFR and human DHFR. Note that the IC50 values on F98Y Sa DHFR are 
much higher than the values against WT Sa DHFR. 
 
 
 
As stated in the beginning part of this chapter, Sa DHFR has the same acid residue 
(Asp27) and the residue next to Asp27 is Leu28. This could be very interesting 
comparison because leucine has much smaller side chain compared to phenyalanine, 
which is in human DHFR, but still has just one rotational axis, which is less than Mtb 
DHFR or Pf DHFR-TS.  
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Figure 5-5. Important conserved interactions between WT Sa DHFR and JCS-1474. As in 
WT Sa DHFR:TMQ structure, Phe98 has no available hydrogen bond interaction. For 2,4-
diaminoquinazoline ring side, all the conserved interactions were found including the 
interactions with Asp27 and the hydrogen bond network with Thr111 and the main chain 
carbonyls of Leu5 and Phe92.  
 
 
 
In the WT Sa DHFR:JCS-1474 structure, we could see the similar interactions 
between TMQ and the protein (Figure 5-5). Similar to WT Sa DHFR:TMQ structure, the 
2,4-diaminoquinazoline ring of JCS-1474 has well-conserved hydrogen bond 
interactions with WT Sa DHFR. This WT Sa DHFR structure bound with JCS-1474 
displayed the well-conserved hydrogen bonding interactions between WT Sa DHFR and 
JCS-1474 similar to WT Sa DHFR:TMQ structure. Asp27 (corresponding to Asp27 in 
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Mtb DHFR) has two hydrogen bonding interactions with 2-amino group and N-1 
nitrogen of the quinazoline with the distances of 3.00 Å and 2.57 Å, respectively. Asp27 
further forms the hydrogen bonding network with Thr111 and the distance is 2.83 Å. 
Thr111 has another hydrogen bonding network via a water molecule with 2-amino group 
of the quinazoline ring of JCS-1474 and the distance between Thr111 and the water 
molecule is 2.96 Å , and the distance between the water molecule and the nitrogen of the 
2-amino group is 2.96 Å . This water molecule further forms hydrogen bond interaction 
with the main chain carbonyl group of Tyr109 with the distance of 2.74 Å. 
For 4-amino group of the 2,4-diaminoquinzaoline ring of JCS-1474 has two 
hydrogen bonding interactions with the main chain carbonyl group of Leu5, and with the 
main chain carbonyl group of Phe92. The distances are 2.54 Å, and 2.69 Å, respectively. 
Unlike F98Y Sa DHFR and similar to WT Sa DHFR:TMQ structure, WT Sa DHFR has 
Phe98 and it is a little bit far apart from the 4-amino group with the distance of 4.27 Å.  
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Figure 5-6. Overview of superimposed structure of WT Sa DHFR:TMQ (blue) and WT Sa 
DHFR:JCS-1474. The red circled areas are the loop regions that showed large 
deviations. Gly139-Pro148 (left), Gly51-Arg58 (middle), and Thr63-Gly72 (right) 
displayed more than 1 A deviation. C-8 benzyl group and 2,5-diethoxybenzyl group 
of JCS-1474 caused large deviation. 
 
 
 
For the 2,5-diethoxyaniline ring side, there are no significant hydrogen-bonding 
interactions (Figure 5-6). The only probable hydrogen bond interaction came from Ser49. 
This Ser49 might form a hydrogen bond with oxygen atom of the 2-ethoxy group with 
the distance of 3.78 Å. This interaction is much weaker compared to the hydrogen bond 
network via water molecule found in the WT Sa DHFR:TMQ structure. 1-carbon atom 
of the 2,5-diethoxyaniline ring is in close proximity with Ile50 with the distance of 3.69 
Å, and the carbon atom of the 5-ethoxy group is in close proximity with Leu54 with the 
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distance of 3.42 Å, but both interactions are not hydrogen bond interaction. Still these 
residues could be used as another revenue for further development of more potent 
inhibitors. 
C-8 benzyl TMQ analogs showed great potency against WT Sa DHFR ranging 
from JCS-1552’s 10 nM to JCS-1474’s 95 nM. 3,5-dimethoxybenzyl containing 
compounds have great potency on WT Sa DHFR. 2,5-diethoxybenzyl containing JCS-
1474 displayed low potency of 95 nM, yet it is much better than F98Y SM Sa DHFR.  
Just like in Mtb DHFR and Pf DHFR-TS, the flexible residue (Leu28) exhibited 
drastically different position in WT Sa DHFR:JCS-1474 structure (Figure 5-7). Thanks 
to the flexibility and small size of Leu28, WT Sa DHFR could accommodate C-8 benzyl 
TMQ analog without causing too much loss of activity. The helix near 3,5-
dimethoxybenzene or 2,5-diethoxybenzene ring (Arg44-Ile50) also pushed back from the 
active site (about 1.4 Å) in WT Sa DHFR:JCS-1474 structure.  
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Figure 5-7. Superimposed structure of WT Sa DHFR:TMQ (blue) and WT Sa DHFR:JCS-
1474. The flexible residue next to the acid residue is Leu28 and it flipped down to 
allow more space to C-8 benzyl group. It proved that just one rotational axis is 
enough for any DHFR to interact well with C-8 benzyl TMQ if the side chain is not 
bulky like phenylalanine. 
 
 
 
Compared to WT Sa DHFR:TMQ, JCS-1474’s position in WT Sa DHFR was 
almost the same. Though a similar distortion with Mtb DHFR and Pf DHFR-TS was 
found, the degree was smaller with about 10-degree distortion. As anticipated, Leu28 
changed its orientation by flipping down in WT Sa DHFR:JCS-1474 structure and 
allowed the increased space to C-8 benzyl group of JCS-1474. Even though there is just 
one rotation axis that Leu28 could flipping on, the smaller side chain enabled Leu28 to 
change its orientation without causing any significant contact with other residues. All the 
crystallographic data is available in Table 5-2. 
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 WT Sa:TMQ (4MO6) F98Y Sa:TMQ 
(4MP1) 
WT Sa:JCS-1474 
Space group P61 P61 P61 
Unit cell dimension 86.76, 86.76, 96.42 (Å) 87.12, 87.12, 96.41 86.22, 86.22, 101.24 
 90.00, 90.00, 120.00 (o) 
90.00, 90.00, 
120.00 
90.00, 90.00, 120.00 
Resolution (Å) 50.00-2.15  
(2.19-2.15) 
50.00-2.65  
(2.70-2.65)  
50.00-2.84 
(2.89-2.84) 
Rsym 0.15 (0.41) 0.14 (0.80) 0.10 (0.71) 
I/σ 11.4 (7.1) 9.3 (4.1) 22.5 (4.1) 
Completeness (%) 98.8 (84.2) 99.8 (99.7) 99.7 (99.4) 
Redundancy 11.3 (9.0) 11.5 (11.5) 12.6 (12.5) 
# of reflections 22151 12126 10093 
Rwork/Rfree 18.2/23.1 21.5/25.9 18.2/22.7 
B factor 31.84 67.87 54.43 
RMSD length 0.005 0.009 0.009 
RMSD angle 0.747 0.982 0.951 
Table 5-2. Crystallographic data and structure statistics for WT and F98Y Sa DHFR 
bound with TMQ and JCS-1474 
 
 
 
As stated in the introduction of this chapter, Sa DHFR made really interesting 
comparison with Mtb DHFR and Pf DHFR in regard to the space induced by C-8 benzyl 
group in binding with C-8 benzyl TMQ analogs, and the key residue that is next to the 
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acid residue. In Sa DHFR’s case, it is Leu28 and Leu28 was able to allow enough space 
to the C-8 benzyl TMQ analogs including JCS-1474 in WT Sa DHFR. 
It is interesting to point out that F98Y Sa DHFR drastically reduced the activity of 
C-8 benzyl TMQ analogs and there has not been any crystal structure available for F98Y 
Sa DHFR bound with C-8 benzyl TMQ analogs. We were able to obtain some crystals 
from F98Y Sa DHFR:JCS-1474 and some other C-8 benzyl TMQ analogs, but there was 
no density for the compounds or very weak and partial density was observed. This 
indicates that the interaction between C-8 benzyl TMQ analogs and F98Y Sa DHFR is 
very weak, and it could be really intriguing future research point in that the mutation 
actually brings back the normal tyrosine on the position the same as Mtb DHFR or Pf 
DHFR. If this 98 position is really crucial for the interaction, F98Y Sa DHFR ought to 
have better potency with TMQ or C-8 benzyl TMQ analogs. Yet, the enzyme assay 
results say exactly opposite thing, and the detailed reason should be investigated further.  
However, one highly probable possibility could be drawn from the structures we 
have, and that is the 3,4,5-trimethoxyaninline ring side of TMQ interaction with the 
protein. This ring is 2,5-diethoxyaniline ring in JCS-1474 and in Sa DHFR (both WT 
and F98Y), the binding is much less and much weaker compared to Mtb DHFR or Pf 
DHFR. Therefore, the F98Y mutation could cause TMQ or C-8 benzyl TMQ to be 
pushed away from the optimal position in the active site. In fact, the F98Y Sa 
DHFR:TMQ structure revealed that there is only one interaction, which is with Ser49, is 
available for the 3,4,5-trimethoxyaniline ring. This effect could be more drastic in 
bulkier 2,5-diethoxyaniline ring containing JCS-1474. Even though more in-depth 
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research should be done to clarify the exact effect and reason for this drastic loss of 
activity in F98Y mutation Sa DHFR in binding with TMQ and its analogs, the structures 
we have now and the enzyme assay data would tell us much information as well in 
regard to the interactions between Sa DHFR and TMQ analogs. 
We tried to acquire the co-crystal structure of several C-8 benzyl TMQ analogs in 
F98Y Sa DHFR, and it was possible to get diffraction quality crystals. However, when 
we processed and refined the structure, there was no or very little density found in the 
substrate binding site. It was the same when we tried soaking the inhibitors before 
collecting the data. What this could indicate are 1) there was no binding (or any 
significant binding) between F98Y Sa DHFR and the C-8 benzyl TMQ analogs in the 
first place, and that is why we do not see any density in the active site, or 2) Somehow, 
the C-8 benzyl TMQ analogs became wobbly in the active site due to the extra carbonyl 
group in F98Y mutation on 98-position, and this flexible position of the compounds 
along with the wider solvent access point in Sa DHFR compared to Mtb DHFR caused 
the little or partial density of the compounds in the processed and refined crystal 
structures.  
Further in-depth study should be performed to be able to figure out the effect of 
F98Y mutation on the mode of action of C-8 benzyl TMQ analogs on Sa DHFR, and that 
study along with the results we presented here would give us a great opportunity to 
develop the broad spectrum selective inhibitors. 
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CHAPTER VI 
 
DISCUSSION AND CONCLUSION 
 
VI.1. Discussion 
 
The similarity of the overall fold between the pathogenic DHFR and human 
DHFR makes it difficult to design an inhibitor that does not interact with the human 
protein although some differences exist between the DHFRs from different species. An 
important difference is that the neighboring pocket of the substrate binding site in Mtb 
DHFR and Pf DHFR-TS is larger than the corresponding site in human DHFR. In 
addition, the large side chain of Phe31 in human DHFR and its low degree of rotational 
freedom in comparison with Gln28 of Mtb DHFR and Met55 of Pf DHFR-TS makes the 
available space in this pocket even smaller. We speculated that an improved selectivity 
could be achieved if a sufficiently large functional group were added to an inhibitor.  
Two major modifications were made to trimetrexate (TMQ) using a structure-
based design approach. One modification was on the C-8 position of the 2,4-
diaminoquinazoline ring side, and the other modification was on the 3,4,5-
trimethoxyaniline ring side. Modifications to the aniline side without a modification on 
C-8 position of the 2,4-diaminoquinazoline ring exhibited no gain in selectivity. Initially 
we thought the pocket near the substrate binding site could be reached from either the 
2,4-diaminoquinazoline or the aniline ring. However, only compounds with functional 
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groups on the C-8 of the 2,4-diaminoquinazoline were able to sit in the pocket. Without 
the C-8 benzyl group attached to the 2,4-diaminoquinazoline ring, no selectivity gain 
was observed. 
We expected to improve selectivity by placing only hydrophilic groups in the 
pocket because the pocket is surrounded by hydrophilic residues in Mtb DHFR. 
However, the hydrophobic groups, including the benzyl group, were enough to exhibit 
increased selectivity for Mtb DHFR and Pf DHFR-TS, and we discovered that the 
flexibility of the residues (Gln28) in the pocket of Mtb DHFR and the length of the 
bridging carbons were more important for rendering selectivity than the hydrophilicity of 
the moiety. Structure-based modeling for functionalities on C-8 of the 2,4-
diaminoquinazoline ring did not look promising initially because Gln28 of Mtb DHFR 
looked as if it would block functional groups from entering the pocket, but we found that 
a single carbon bridging from the C-8 position of the quinazoline ring was enough to 
allow a functional group to fit in the pocket including substituted benzene rings. The 
flexibility of the side chain of Gln28 of Mtb DHFR (Met55 of Pf DHFR-TS) played a 
crucial role in allowing a functional group to enter the pocket.  
There has been a successful and ongoing attempt to develop a potent and selective 
inhibitor against P. falciparum DHFR (Yuthavong, Tarnchompoo et al. 2012). A 2,4-
diaminopyrimidin derivative, P218, is the one and it is structurally similar to the potent 
DHFR inhibitor, WR99210 (Fig 2). In the paper published in 2012, the authors found out 
that a potent DHFR inhibitor, WR99210, which has 1,3,5-triazine ring instead of 2,4-
diaminopyriminie, showed poor absorption and bioavailability compared to its 2,4-
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diaminopyrimidine counterparts including P218 due to the extensive protonation 
occurred on 1,3,5-triazine ring in the acidic condition such as in some of the human 
intestines and that is why WR99210 is not being used for human disease now. However, 
2,4-diaminopyrimidine containing compounds including P218 was reported to have 
much better bioavailability. Beside the bioavailability issue, P218 was reported to 
improve the selectivity as well. Similar to MTX, WR99210 is potent on human DHFR as 
well and this lack of selectivity is a significant huddle to be used as antimicrobials. P218 
has proved this selectivity issue, and the Ki-ratio between wild type Pf DHFR-TS/human 
DHFR is about 200. For some reason, they did not report the IC50 value of P218 against 
human DHFR, still the Ki difference between Pf DHFR and human DHFR is large 
enough for P218 to be used as selective and potent Pf DHFR inhibitor.  
As for 2,4-diaminoquinazoline ring, there has not been any report in regard to 
selective and potent DHFR inhibitor. There should be follow-up study on the 
bioavailability on our C-8 benzyl TMQ analogs, but as in the case of 2,4-
diaminopyrimidine case, 2,4-diaminoquinazoline ring and its protonation would not be a 
serious issue for bioavailability or permeability when it comes to antimicrobials. There 
are a couple of reasons why there has not been any selective 2,4-diaminoquinazoline ring 
based DHFR inhibitors at least so far. First, the 2,4-diaminoquinazoline ring and its 
sheer size reduce the flexibility of the inhibitor and this flexibility was crucial for P218 
to have selectivity over human DHFR. Second, there was not much site in 2,4-
diaminoquinazoline containing compounds for modification to improve the selectivity, 
because most of the important and conserved interactions are on the 2,4-
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diaminoquinazoline ring not on the other side of the molecule except for the glutamic 
acid moiety in MTX.  
Our C-8 benzyl TMQ analogs exhibited the potential to be a potent inhibitor not 
only to the wild type Pf DHFR-TS but also to the quadruple mutant Pf DHFR-TS. The 
C-8 benzyl-2,4-diaminoquinazoline TMQ analogs exhibited great potency on both WT 
and QM Pf DHFR-TS with 3 to 10 fold greater potency against WT Pf DHFR-TS. This 
less than 10 fold potency loss was also observed in P218 case as well, and it is not a 
significant decrease considering the huge potency loss against human DHFR. The size of 
the pocket near the substrate binding site of WT and QM Pf DHFR-TS is almost the 
same and the mutated residues of QM (N51I/C59R/ S108N/I164L) do not directly affect 
the binding of the C-8 benzyl-2,4-diaminoquinazoline TMQ analogs. The potency loss in 
QM Pf DHFR-TS comes from effective slight loss in the intensity of the interactions 
between the compounds and proteins, compared to the wild-type.  
The effect of modifications to the 2-amino group of the 2,4-diaminoquinazoline 
ring also remains to be seen. Unlike the TMP series where methyl and ethyl groups were 
successfully introduced on the pyrimidine ring (JCS-1168 and 1169, unpublished data), 
putting an alkyl group on the quinazoline ring has been more challenging. Isobutyl (JCS-
1596) and benzyl (JCS-1594) groups have been attached to the N-2 position of 2,4-
diaminoquinazoline and they showed reduced potency and selectivity. This is not 
surprising considering the relatively small space available near N-2 of the 2,4-
diaminoquinazoline in both Mtb and human DHFR. Based on the crystal structures, N-2 
substitution could give potency gain rather than selectivity gain. The only difference 
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between Mtb and human DHFR at that site is His30 in Mtb DHFR, which is Tyr33 in the 
human DHFR. There are potential interactions with the main chain carboxyl group of 
Val8 and Glu111, and the side chain oxygen of Thr136.  
Mtb DHFR and both WT and QM Pf DHFR-TS share significant common 
structural features in the active site, specifically, the pocket near the substrate binding 
site. Based on our study on Mtb DHFR and Pf DHFR-TS, the C-8 benzyl-2,4-
diaminoquinazoline TMQ analogs can be used as selective and broad spectrum inhibitors 
for any pathogenic DHFR that has an acid (Asp27 in Mtb DHFR) and a residue with 
flexible side chain next to the residue working as an acid (Gln28 in Mtb DHFR). The 
acid residue (Asp or Glu) interacts with the 2,4-diaminoquinazoline ring and the 
neighboring residue should be flexible enough to allow space for the C-8 benzyl group 
by rotating away from the pocket.  
The confirmation study on S. aureus DHFR gave us a bigger insight on C-8 benzyl 
TMQ analogs and their application in the future. As stated in the results section, Sa 
DHFR was chosen because it has both similarity and difference with Mtb DHFR at the 
same time. Sa DHFR has the same number of residues with Mtb DHFR, the acid residue 
is Asp27 same as Mtb DHFR. The overall fold and the active site conformation are very 
similar as well. There also was a similar space with the glycerol binding pocket in Sa 
DHFR.  
However, there is a noticeable difference in Sa DHFR compared to Mtb DHFR. It 
is Val28 next to the acid residue, Asp27.  This valine is a very helpful control for our 
SAR study in two reasons. First is that it has just one rotational axis as in human 
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DHFR’s Phe31, and it could be much restricted rotational freedom compared to Gln28 in 
Mtb DHFR or Met55 in Pf DHFR-TS. But valine’s side chain is much smaller than 
human DHFR’s Phe31, and it could allow more space in the active site for the C-8 
benzyl group to position well in the substrate binding site and the pocket available.   
As expected the wild type Sa DHFR exhibited the similar potency and selectivity 
on C-8 benzyl TMQ analogs. However, when F98Y mutation was in place, this small 
change made a huge difference in potency. All the major C-8 benzyl TMQ analogs along 
with TMQ itself lost almost 20 fold of potency against F98Y Sa DHFR. Considering that 
quadruple mutant of Pf DHFR-TS did not affect much on the potency and that there is 
tyrosine from the beginning in Mtb and Pf DHFR, this potency loss is somewhat 
puzzling. The clue from the structure could be the wider solvent access area of Sa DHFR 
compared to Mtb and Pf DHFR, and when there is a push from F98Y mutation, there is 
nothing to hold the compounds on that side.  
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VI.2. Conclusion 
 
Trimetrexate analogs modified with the C-8 benzyl functionalities exhibited 
exceptional selectivity against Mtb and Pf DHFR-TS over human DHFR. The selectivity 
gain largely arose from the significantly reduced potency of these compounds against the 
human DHFR while retaining their potency against the pathogenic DHFRs. The crystal 
structures showed that a flexible residue (Gln28 of Mtb or Met55 of Pf) neighboring an 
acid residue (Asp or Glu) was crucial to accommodate our C-8 benzyl-2,4-
diaminoquinazoline TMQ analogs. The human DHFR Phe31, which has just one axis to 
rotate on and a considerably bulkier side chain, was unable to allow enough room for our 
C-8 benzyl-2,4-diaminoquinazoline TMQ analogs. 
This work has two important implications. First is that our C-8 benzyl-2,4-
diaminoquinazoline TMQ analogs have the potential for development into selective 
tuberculosis and malaria drugs. The other is that these compounds could provide a 
significant foundation for developing broad spectrum, selective antimicrobials because 
our C-8 benzyl-2,4-diaminoquinazoline TMQ analogs were successfully applied to the 
two different pathogenic DHFRs based on the similarities of their active site structures. 
The C-8 benzyl-2,4-diaminoquinazoline TMQ analogs could potentially be selective as a 
DHFR inhibitor against any pathogen that has a similar active site size and has a flexible 
residue next to the acid residue. Further work could explore the potential of this group of 
compounds against a broader selection of pathogenic organisms. 
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The confirmation study on WT and F98Y Sa DHFR displayed that C-8 benzyl 
TMQ analogs have enough potential to be used as broad-spectrum selective 
antimicrobials. However, the detailed reason for the loss of potency on F98Y Sa DHFR 
remains to be seen, and will be important next step for this research. 
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VI.3. Materials and Methods 
 
Cloning of M. tuberculosis DHFR into plasmid pET28a(+).   
cDNA of M. tuberculosis, H37Rv, was amplified by PCR to generate blunt-ended 
DNA with NdeI and HindIII restriction sites at the ends. Then the PCR product was 
purified using the gel purification kit from Qiagen. The purified DNA product and 
pET28a(+) vector were double digested with NdeI and HindIII restriction enzymes. The 
ligation of double digested PCR product and pET28a(+) followed, and the ligation 
product was then transformed into One Shot Top10 cells by the recommended method 
supplied by the manufacturer (Invitrogen). The sequence of the plasmid DNA isolated 
from these cells was confirmed by the Gene Technology Lab at Texas A&M University. 
 
Cloning of human DHFR and P. falciparum DHFR-TS into plasmid pET28b(+).   
cDNA of human DHFR purchased  from American Type Culture Collection 
(ATCC, Manassas, VA) was amplified by PCR to generate blunt-ended DNA with NdeI 
and XhoI restriction sites at the ends. Then the PCR product was purified using the gel 
purification kit from Qiagen. The purified DNA product and pET28b(+) vector were 
double digested with NdeI and XhoI restriction enzymes. The ligation of double digested 
PCR product and pET28b(+) followed, and the ligation product was then transformed 
into One Shot Top10 cells by the recommended method supplied by the manufacturer 
(Invitrogen). The sequence of the plasmid DNA isolated from these cells was confirmed 
by the Gene Technology Lab at Texas A&M University. Genomic DNA of P. 
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falciparum was used as a template for Pf DHFR-TS cloning, and it was cloned in a 
similar way using NheI and HindIII restriction sites at each end. The PCR product was 
then purified, double digested with NheI and HindIII, and ligated into pET28b(+) . One 
Shot Top10 competent cell was used for the plasmid extraction.  
 
Cloning of S. aureus  DHFR into plasmid pET28b(+).   
cDNA of S. aureus was amplified by PCR to generate blunt-ended DNA with 
NdeI and HindIII restriction sites at the ends. Then the PCR product was purified using 
the gel purification kit from Qiagen. The purified DNA product and pET28b(+) vector 
were double digested with NdeI and HindIII restriction enzymes. The ligation of double 
digested PCR product and pET28b(+) followed, and the ligation product was then 
transformed into One Shot Top10 cells by the recommended method supplied by the 
manufacturer (Invitrogen). The sequence of the plasmid DNA isolated from these cells 
was confirmed by the Gene Technology Lab at Texas A&M University. 
 
Site-directed mutagenesis of P. falciparum DHFR-TS.   
Stepwise mutagenesis was performed for quadruple mutant Pf DHFR-TS using 
QuikChange II Site-directed mutagenesis kit (Agilent Technologies). Double mutant 
(C59R and S108N) Pf DHFR-TS was generated first, and the further mutations gave 
quadruple mutant (N51I, C59R, S108N, and I164L) Pf DHFR-TS. The sequence of the 
mutated plasmid DNA was confirmed by the Gene Technology Lab in Texas A&M 
University. 
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 Site-directed mutagenesis of S. aureus DHFR.   
Single-step mutagenesis was performed for F98Y single mutant S. aureus DHFR 
using QuikChange II Site-directed mutagenesis kit (Agilent Technologies). The 
sequence of the mutated plasmid DNA was confirmed by the Gene Technology Lab in 
Texas A&M University. 
 
Expression and purification of M. tuberculosis DHFR and human DHFR.  
Competent E. coli BL21 (DE3) cells (Novagen) were transformed with the 
recombinant plasmids containing the Mtb DHFR gene and human DHFR gene and were 
grown at 37 oC to A600nm of 0.7 in LB medium containing 50 ug ml
-1 of kanamycin. The 
cells were cooled to 20 oC, equilibrated for an hour, and induced by the addition of 0.8 
mM IPTG for the protein expression. The purification procedures of both DHFRs were 
similar. The induced cell was allowed to proceed overnight at 20oC. The cells were spun 
down at 4000 rpm and the pellet was resuspended in the resuspension buffer (20 mM 
triethanolamine (TEA), 30 mM imidazole, 50 mM KCl, 5% glycerol, pH = 7.8) 
containing protease inhibitor cocktail (Novagen), 20 mg egg white lysozyme (Sigma), 5 
mg DNase I. The resuspended cells were disrupted by cell lysis machine and were spun 
down at 17,000 rpm for 45 min to remove the cell debris. The supernatant filtered 
through 0.22 um was applied to 15 ml column of High Performance HisTrap column 
(GE Healthcare) pre-equilibrated with the loading buffer (20 mM TEA, 30 mM 
imidazole, 300 mM KCl, 5% glycerol, pH = 7.8). The cell-loaded column was washed 
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with extensive amount of the loading buffer and then eluted with a linear gradient (350 
ml) from 0% to 100% of elution buffer (20 mM TEA, 500 mM imidazole, 300 mM KCl, 
5% glycerol, pH = 7.8). The pure-DHFR containing fractions were pooled and 
concentrated down to 4 ml and treated with 30 ul of thrombin (Novagen) at 16oC for 2 
days. The cleaved protein was passed through 5 ml HisTrap HP column (GE Healthcare) 
pre-equilibrated with the loading buffer. The unbound protein was collected, dialyzed 
against 4 L of dialysis buffer (25 mM potassium phosphate, 50 mM KCl, 0.1 mM EDTA, 
5% glycerol, pH 7.2) for 6 hrs and concentrated down to 15 mg ml-1for crystallization 
trial.  
 
Expression and purification of WT and QM P. falciparum DHFR-TS.   
Competent E. coli Rosetta 2 pLysS (DE3) cell (Novagen) was transformed with 
the recombinant plasmids containing the wild type (WT) or quadruple mutant (QM) Pf 
DHFR-TS gene and was grown at 37 oC to A600nm of 0.7 in LB medium containing 50 ug 
ml-1 of kanamycin and 34 ug ml-1 of chloramphenicol. The cell was induced with 0.75 
mM IPTG at 16 oC for 20 hrs. The same buffers were used and the remaining steps were 
similar to Mtb and human DHFR purification. Superdex-200 gel filtration column (GE 
Healthcare) was used for the further purification after Ni-column purification. Pure 
fractions were collected and dialyzed against 20 mM potassium phosphate buffer 
(pH=7.2) containing 2 mM dithiothreitol (DTT), 0.1 mM ethylenediaminetetraacetic 
acid (EDTA), 5% glycerol, and 50 mM potassium chloride for 20 hours at 4oC. The 
protein solution was concentrated down to 15 mg ml-1 for the crystallization trial. 
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Expression and purification of S. aureus DHFR.  
Competent E. coli BL21 (DE3) cells (Novagen) were transformed with the 
recombinant plasmids containing the S. aureus DHFR gene and were grown at 37 oC up 
to A600nm of 0.7 in LB medium containing 50 ug ml
-1 of kanamycin. The cells were 
cooled to 18 oC, equilibrated for an hour, and induced by the addition of 0.8 mM IPTG 
for the protein expression. The purification procedure was similar to Mtb DHFR. The 
induced cell was allowed to proceed overnight at 18oC. The cells were spun down at 
4000 rpm and the pellet was resuspended in the resuspension buffer (20 mM 
triethanolamine (TEA), 30 mM imidazole, 50 mM KCl, 5% glycerol, pH = 7.8) 
containing protease inhibitor cocktail (Novagen), 20 mg egg white lysozyme (Sigma), 5 
mg DNase I. The resuspended cells were disrupted by cell lysis machine and were spun 
down at 17,000 rpm for 50 min to remove the cell debris. The supernatant filtered 
through 0.22 um filter was applied to 15 ml to 20 ml column of High Performance 
HisTrap column (GE Healthcare) pre-equilibrated with the loading buffer (20 mM TEA, 
30 mM imidazole, 300 mM KCl, 5% glycerol, pH = 7.8). The cell-loaded column was 
washed with extensive amount of the loading buffer and then eluted with a linear 
gradient (350 ml) from 0% to 100% of elution buffer (20 mM TEA, 500 mM imidazole, 
300 mM KCl, 5% glycerol, pH = 7.8). The pure-DHFR containing fractions were pooled 
and concentrated down to 4 ml and treated with 30 ul of thrombin (Novagen) at room 
temperature for 3 hours. The cleaved protein was passed through 5 ml HisTrap HP 
column (GE Healthcare) pre-equilibrated with the loading buffer. Further purification 
via S200 or S75 size exclusion column did not make protein any purer. The unbound 
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protein was collected, dialyzed against 4 L of dialysis buffer (25 mM potassium 
phosphate, 50 mM KCl, 0.1 mM EDTA, 5% glycerol, pH 7.2) for 6 hrs and concentrated 
down to 15 mg ml-1for crystallization trial.  
 
Designing and validation of TMQ analogs including C-8 benzyl TMQ.   
TMQ bound crystal structure of Mtb DHFR was used for the designing the 
compounds that could take advantage of the glycerol binding pocket of Mtb DHFR and 
similar pocket in Pf DHFR-TS. We used the density of TMQ and the acetate molecule 
found in the glycerol binding pocket. First, TMQ and the acetate were removed from 
PDB file, and then the designed molecules were fit in the density one by one using 
COOT. The PDB files of the designed molecules were generated on PRODRG website. 
All the models that caused a close contact with the protein less than 2 Å were excluded 
from consideration.  
 
In vitro assay for M. tuberculosis, P. falciparum, S. aureus and human DHFR.   
The enzyme assays for M. tuberculosis, P. falciparum, and S. aureus DHFR were 
performed in 100 mM HEPES, 50 mM KCl, pH 7.0, and for human DHFR were in 100 
mM potassium phosphate buffer, 100 mM KCl, pH 7.5 at 25 oC. 20 nM of M. 
tuberculosis DHFR (5 nM of P. falciparum or S. aureus DHFR), 40 uM of NADPH, and 
the inhibitor of various concentrations were added to a 1 ml cuvette, and the reaction was 
initiated by the addition of 40 uM of dihydrofolate. The absorbance decrease at 340 nm 
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representing the oxidation of NAPDH was monitored for 2 minutes with a 
spectrophotometer, Cary 50.  
 
 
 
 
Fig E-1. Example of IC50 determination by the CDD program. IC50 curve, along with the 
chemical structure, of JCS-1425 on Mtb DHFR is shown. 
 
 
 
IC50 determination.   
5-20 nM of DHFRs were incubated with 40 uM of cofactor NADPH and 7 or 8 
different concentrations of the inhibitors (where applicable) for 1 minute. The reaction 
was initiated by the addition of 40 uM dihydrofolate. The reaction progress was 
measured for 2 minutes, and the linear region was used to determine the initial velocity 
parameters. Percent inhibition values from different concentration points were acquired 
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and fit into the IC50 curve by the curve fitting program supported by the Collaborative 
Drug Discovery website.  
 
Whole cell assay for MIC determination on mc
2
7000 strain.   
The vaccine strain of tuberculosis, mc27000, was given by Dr. Jacobs. 7H9 
medium containing pantothenate, OADC, tyloxapole and malachite green was used to 
grow mc27000. When the starter culture reaches A600 nm of 0.5-0.7, it was added into the 
testing media comprising dextrose, NaCl, tyloxapole, pantothenate and malachite green 
along with the inhibitors usually in 96 well plates and left to grow at 37oC for 5 days. 
After 5 days, all of the wells were stained with alamar blue, and the next day, the cell 
viability was checked according to the color of the well with blue representing 
successful inhibition.  
 
P. falciparum strains and culture.   
The P. falciparum strains used in this study were 3D7 (Netherlands, sensitive), 
obtained from the MR4 Unit of the American Type Culture Collection (ATCC, 
Manassas, VA). P. falciparum culture was maintained in RPMI-1640 (Sigma, St. Louis, 
MI) with L-Glutamine, 25 mM HEPES, 33mM NaHCO3, hypoxanthine, and 0.25% 
Ablumax (Gibco 11020-039). Type A+ erythrocytes were obtained from lab donors and 
washed three times with RPMI without Albumax and re-suspended in 50% RPMI and 
stored at 4 oC.   Parasites were grown in 10-ml of a 2% Hematocrit (hct)/RPMI (v/v) mix 
in 50-ml flasks under a 5% CO2, 5% O2, and balance N2 atmosphere.  Media and gas 
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were replenished daily and culture growth followed by microscopy.   When parasites 
reached 3-5%, cultures were adjusted to 0.5% parasites in fresh RPMI and erythrocytes.  
 
P. falciparum EC50 determination.   
Test compounds were diluted 6 times in RPMI 1640 media in serial 3 dilutions 
starting at 20 µM.  10µl of each dilution was distributed in duplicate wells of a 96-well 
plate.  190 µl of P. falciparum culture at 0.5% infected RBC (iRBC) and 0.5% hct was 
added to each well. Control wells with 0.5% iRBC in RPMI media, 0.5% uninfected 
RBCs in RPMI media, and 0.5% iRBC in RPMI media with 6.25 nM, 12.5 nM, and 25 
nM chloroquine were included.   Plates were flushed with 5% CO2, 5% O2, and balance 
N2 then incubated at 37
oC for 48h.  At 48h RMPI media containing 0.3 Ci of 3H-
hypoxanthine monohydrochloride was added to cultures and incubated for an additional 
24h.  Cells were harvested onto a filter mat using an Inotech Biosystems Cell Harvester 
System.  The filter mat was quenched with scintillation fluid and counted in a Perkin 
Elmer 2450 MicroBeta2. EC50 values were determined by linear regression analysis of 
the plots of growth inhibition vs. concentration of compound.  
 
Crystallization of M. tuberculosis, P. falciparum and human DHFRs.   
Crystallization screening of both DHFRs was performed using the sitting-drop and 
hanging-drop methods with Crystal Screen I and II, Index (Hampton Research), Wizard I 
and II (Emerald Biosystems), and previously successful conditions in our lab. Initial 
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crystallization screening was carried out with apo DHFR, DHFR with a trimethoprim 
analog bound (binary complex), and DHFR with NADPH and inhibitor bound (ternary 
complex). 50 ul of Mtb DHFR (12 mg/ml) was mixed with 9 ul of 10 mM NADPH and 
10 mM inhibitors and incubated in ice for 20 min. The initial condition contains 10% 
glycerol, 40% ammonium sulfate and 100 mM sodium acetate pH 4.6 at 4 oC, and gave 
diffraction quality crystals in 2 weeks. 50 ul of human DHFR (15 mg/ml) was mixed 
with 8 ul of 10 mM trimethoprim analogs and 8 ul of 10 mM NADPH, and was 
incubated on ice for 20 min.   
 
Data collection, Structure determination and Refinement.   
Crystals from a droplet were directly transferred to the cryo-protectant of 8% 
glycerol for a minute, and then transferred to 15% glycerol. The crystals were mounted 
on nylon loops and flash frozen in a liquid nitrogen stream at 120K before data 
collection. Most of the data were collected on the R-axis (Rigaku) and some of them 
were collected in APS in Chicago, IL, and were reduced using Crystal Clear software, 
and intensities were scaled with SCALEPACK in the CCP4 suite. Integrated and scaled 
data indicated that human DHFR belongs to P212121 space group. The binary complex of 
Mtb DHFR with trimethoprim analogs and the ternary complex of human DHFR with 
NADPH and inhibitors were crystallized in the same space group. The ternary complex 
of Mtb DHFR with C-8 benzylquinazoline TMQ was crystallized in P1 space group. The 
structures of the binary complex of Mtb DHFR with trimethoprim analogs were solved 
by molecular replacement method using previously solved structure (PDB ID: 1DG5) as 
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a search model. The structure was refined against the data using PHENIX whereas 
interactive model building was done by using COOT (Emsley and Cowtan 2004).  
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